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 Abstract 24 
The Homologous Recombination (HR) pathway is crucial for the repair of DNA 25 
double-strand breaks (DSBs) generated during DNA replication. Defects in HR repair have 26 
been linked to the initiation and development of a wide variety of human malignancies, and 27 
exploited in chemical, radiological and targeted therapies. In this study, we performed a 28 
personalised pathway analysis independently for four large sporadic breast cancer cohorts to 29 
investigate the status of HR pathway dysregulation in individual sporadic breast tumours, its 30 
association with HR repair deficiency and its impact on tumour characteristics. Specifically, 31 
we first manually curated a list of HR genes according to our recent review on this pathway 32 
(Liu et al., 2014), and then applied a personalised pathway analysis method named Pathifier 33 
(Drier et al., 2013) on the expression levels of the curated genes to obtain an HR score 34 
quantifying HR pathway dysregulation in individual tumours. Based on the score, we 35 
observed a great diversity in HR dysregulation between and within gene expression-based 36 
breast cancer subtypes, and by using two published HR-defect signatures, we found HR 37 
pathway dysregulation reflects HR repair deficiency. Furthermore, we identified a novel 38 
association between HR pathway dysregulation and chromosomal instability (CIN) in 39 
sporadic breast cancer. Although CIN has long been considered as a hallmark of most solid 40 
tumours, with recent extensive studies highlighting its importance in tumour evolution and 41 
drug resistance, the molecular basis of CIN in sporadic cancers remains poorly understood. 42 
Our results imply that HR pathway dysregulation might contribute to CIN in sporadic breast 43 
cancer. 44 
 45 
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 Introduction 49 
Chromosomal instability (CIN), defined as an increased rate of gain or loss of whole 50 
chromosomes or large chromosomal fragments, is a hallmark of most solid tumours. CIN is 51 
the primary form of genomic instability that is thought to be the major cause of genetic 52 
heterogeneity in cancer (Burrell et al., 2013b), and is thus strongly implicated in tumour 53 
evolution. CIN also has important clinical implications, as it has been linked to poor 54 
prognosis e.g. by conferring intrinsic multidrug resistance (Lee et al., 2011). The molecular 55 
basis of CIN in hereditary cancer is relatively clear, which has been attributed to mutations in 56 
DNA repair genes (Negrini et al., 2010); however, the underlying mechanisms of CIN in 57 
various sporadic cancers remain poorly understood. Carter and colleagues developed a gene 58 
expression-based CIN signature, termed CIN25, based on 25 genes that are most 59 
overexpressed in tumours with CIN (Carter et al., 2006). A considerable number of genes 60 
involved in replication and cell cycle contribute to this signature, suggesting an important 61 
link between these cellular processes and CIN. This was further corroborated by Negrini et 62 
al. (2010), who proposed a replication stress model to explain CIN in sporadic tumours; this 63 
model was recently validated in colorectal cancer (Burrell et al., 2013a).  64 
Highly proliferative cancer cells undergo considerable replication stress that results in 65 
the stalling of replication forks. These stalled forks are usually stabilised and restarted after 66 
the source of stress is removed via a complex replication stress response pathway (Zeman 67 
and Cimprich, 2014). Lack of stabilisation and/or the prolonged persistence of a stalled fork 68 
can generate DNA double-strand breaks (DSBs), which are subsequently repaired by DSB 69 
repair machinery to restart the forks. However, in the absence of such a DSB repair 70 
machinery the DSBs will develop into chromosomal breaks, resulting in CIN. Homologous 71 
recombination (HR) is a crucial pathway responsible for repairing DSBs during replication. 72 
Using homologous sister chromatid as templates, HR presents a high-fidelity repair 73 
mechanism that is crucial for error-free DNA replication.  74 
The core components of HR are fairly well established for their specific roles i.e. 75 
monitoring, signalling and repairing of DSBs (Liu et al., 2014), and HR defects can be 76 
detected by investigating the loss-of-function mutations in these genes. However, the 77 
dysfunction of HR can also be caused by numerous other mechanisms. For example, changes 78 
or defects in chromatin remodelling (Price and D'Andrea, 2013; van Attikum and Gasser, 79 
2009), microRNAs (Chowdhury et al., 2013; d'Adda di Fagagna, 2014; Sharma and Misteli, 80 














Jensen and Mailand, 2011; Dou et al., 2011; Ulrich, 2012),  and inappropriate expression of 82 
certain genes that are not directly involved in HR (Y. Peng et al., 2015; Watkins et al., 2015) 83 
can considerably affect HR components, thereby causing aberrant HR function. As a 84 
consequence, single-gene approaches or approaches focusing on one mechanism yield only 85 
an incomplete picture of abnormal HR in a given tumour. On the other hand, HR-deficient 86 
cells may compensate for the defect in a given HR gene by altering the expression level of 87 
other HR genes (Pitroda et al., 2014). The most notable example is the overexpression of 88 
DNA repair protein RAD51 homolog 1 (RAD51), which is observed when breast cancer 89 
susceptibility gene 1 (BRCA1) (Martin et al., 2007), breast cancer susceptibility gene 2 90 
(BRCA2) (Brown and Holt, 2009) or other key HR genes (Takata et al., 2001) are defective. 91 
It is therefore of interest to determine a measure of HR pathway dysregulation, aggregating 92 
the expression of all HR genes, which may reflect HR repair deficiency in tumours regardless 93 
of the mechanism that has led to the deficiency.  94 
The vast majority of breast tumours are sporadic, which accounts for 90%-95% of all 95 
diagnosed breast cancer cases (Davis, 2011) and are characterised by their great 96 
heterogeneity in biological property and patient outcome. To dissect this heterogeneity, 97 
estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 98 
receptor 2 (HER2) have been used as standardised diagnostic markers in clinical practice to 99 
guide the choice of treatment. Gene expression profiling has defined five intrinsic subtypes 100 
(also known as PAM50 subtypes) with clinical relevance: Luminal A, Luminal B, Basal-like, 101 
HER2 and Normal-like (Hu et al., 2006; Parker et al., 2009; Perou et al., 2000; Sørlie et al., 102 
2001). More-recent genomic studies, notably from the Cancer Genome Atlas (TCGA) and 103 
Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), have 104 
uncovered substantial heterogeneities within these receptor- or gene expression-based 105 
subtypes, resulting in the definition of up to ten subtypes (Ciriello et al., 2013; Curtis et al., 106 
2012; Koboldt et al., 2012; Lehmann et al., 2011; Yanagawa et al., 2012). However, it is 107 
likely that heterogeneity exists even within these newly established subtypes. In the coming 108 
age of personalised medicine, each tumour may be analysed individually. 109 
Pathway analysis has become the first choice to gain functional insights from 110 
expression data, beyond the detection of differential genes. Numerous pathway analysis tools 111 
have been developed, however, most of them are designed for providing pathway 112 
dysregulation information at population level instead of tumour level. Among the recently 113 
proposed methods for personalised pathways analysis (Ahn et al., 2014; Drier et al., 2013; 114 














particularly robust. It has been successfully applied to provide a pathway-based classification 116 
of breast cancer (Livshits et al., 2015), and when combined with Cox regression and L1 117 
penalised estimation, has achieved better prognosis prediction compared with gene-based 118 
models (Huang et al., 2014). 119 
In this study, we sought to perform a personalised pathway analysis to obtain a 120 
comprehensive understanding of the status of HR pathway dysregulation in individual 121 
sporadic breast tumours, its association with HR repair deficiency and its impact on tumour 122 
characteristics (CIN in this case). To this end, we calculated for each breast tumour an HR 123 
score that quantified the extent of HR pathway dysregulation in that tumour. Base on the 124 
score, we observed a great diversity in HR dysregulation between and within the PAM50 125 
subtypes, and by using two published HR-defect signatures, we found HR pathway 126 
dysregulation reflects HR repair deficiency. More importantly, we uncovered a novel 127 
association between HR dysregulation and CIN, which indicates that dysregulated HR might 128 
contribute to replication stress-induced CIN in breast cancer. This knowledge may help future 129 
studies to identify the causative factors of CIN in sporadic breast cancer as well as in other 130 
cancer types. 131 
Materials and Methods 132 
1. Genomic data 133 
Whole-genome gene expression data, DNA copy-number data, gene mutation data 134 
(only available for the TCGA samples) and related clinical data for four breast cancer cohorts 135 
(Table 1) were obtained from METABRIC (Curtis et al., 2012) and TCGA (Koboldt et al., 136 
2012). 137 
Table 1 Breast cancer cohorts analysed in this study 138 
Cohort 
No. of tumour samples No. of  
All Basal-like HER2 LumA LumB Normal-like normal breast tissues 
METABRIC Discovery 997 118 87 466 268 58 144 
METABRIC Validation 995 213 153 255 224 144 144 
TCGA RNA-seq 1068 188 80 549 213 38 113 
TCGA Microarray 522 98 58 231 127 8 22 
 139 
Gene-expression data and chromosomal-level DNA copy-number data from the 140 
METABRIC project (Genome-phenome Archive accession number EGAS00000000083) 141 














et al. (Curtis et al., 2012). Gene-expression data from this project were based on the Illumina 143 
HT-12 v3 Expression Beadchip (Illumina, San Diego, CA, USA). The probe-level 144 
transcription estimates were mapped to gene-level estimates using the HT-12 v3 annotation 145 
file downloaded from the Illumina website (http://www.illumina.com/). Where two or more 146 
probes represented the same gene, the probe with the largest variation was chosen as the gene 147 
representative. DNA copy-number data from METABRIC had been generated using 148 
Affymetrix SNP 6.0 arrays (Affymetrix, Santa Clara, CA, USA). The corresponding PAM50 149 
subtype assignment and clinical outcome were obtained from (Curtis et al., 2012).  150 
The preprocessed gene-expression and DNA copy-number data (both chromosome-151 
level and gene-level) for the TCGA RNA-seq cohort were downloaded via the UCSC Cancer 152 
Genomics Browser (https://genome-cancer.ucsc.edu/) on 13 October 2014. Gene-expression 153 
data for this cohort were measured using the Illumina HiSeq 2000 RNA Sequencing 154 
platform, and show the Expectation Maximization (RSEM)-normalised and percentile-ranked 155 
gene-level transcription estimates. DNA copy-number data for this cohort had been generated 156 
using Affymetrix SNA 6.0 arrays, with germline copy-number variation filtered out. PAM50 157 
classifications for this cohort were obtained through personal communication with the TCGA 158 
consortium. A subset of these 1068 cases also has gene expression data obtained from 159 
microarray. The Level 3 gene-expression data for this TCGA Microarray cohort and the 160 
corresponding PAM50 classifications were downloaded from the TCGA data portal 161 
publication site (https://tcga-data.nci.nih.gov/docs/publications/brca_2012/) on 3 June 2014. 162 
These gene-expression data were based on Agilent custom 244K whole-genome microarrays 163 
and had been preprocessed as described by Koboldt et al. (Koboldt et al., 2012). DNA copy-164 
number data for this cohort were obtained as a subset of the TCGA RNA-seq cohort, as the 165 
samples of the former cohort were covered by the later cohort. 166 
The preprocessed gene mutation data for 982 TCGA samples, generated on an 167 
IlluminaGA system, were downloaded via the UCSC Cancer Genomics Browser 168 
(https://genome-cancer.ucsc.edu/) on 06 July 2015. Each gene had been assigned a value of 1 169 
or 0, indicating whether a non-silent mutation was identified in the coding region of that gene 170 
(value=1) or not (value=0). These data were matched to the two TCGA cohorts respectively 171 
according to the sample ID.  172 
2. HR pathway curation and calculation of HR score 173 
Based on our recent review of the HR pathway (Liu et al., 2014), we manually 174 














applied Pathifier (Drier et al., 2013) to the mRNA expression level of the curated HR genes 176 
to calculate an HR score that quantifies HR pathway dysregulation in individual breast 177 
tumours. Based on gene-expression profiles for tumours and normal breast tissues, Pathifier 178 
transforms HR gene-expression measurements into a measure of HR pathway dysregulation 179 
by fitting a principal curve (see Supplementary Figure S1 for a visualisation of the curve) that 180 
captures the maximal variability of the expression levels of the HR genes in all samples, and 181 
then projects each sample onto that curve. A sample’s HR score is defined as its distance 182 
along the curve from the centroid of the normal tissues (Drier et al., 2013).  183 
Not all HR genes we curated were present in the gene expression data for each of the 184 
four cohorts. We therefore calculated the HR score for each cohort based only on HR genes 185 
that are available for that cohort (ranges from 67 to 72, see Supplementary Table S1). No 186 
other ways for selecting HR genes were examined to minimize retrospective optimization for 187 
the correlations with CIN (see below). 188 
3. CIN measurements calculation 189 
The numbers of chromosomal breakpoints and the proportions of the genome affected 190 
by copy-number change (Genomic Instability Index, GII) for samples in the two METABRIC 191 
cohorts were downloaded from a recent study (Vollan et al., 2015) in which the METABRIC 192 
Group was involved. According to this study, a few samples with mismatched DNA/RNA 193 
were identified and excluded, resulting in 985 samples remaining in the Discovery cohort and 194 
965 in the Validation cohort. To get the number of amplified/deleted genes for the same 195 
samples, we first calculated the copy number of each gene using the chromosomal-level 196 
DNA copy-number data available for the two cohorts, then applied cut-offs (≥ 0.10 for 197 
amplified genes and ≤ −0.15 for deleted genes) that are similar to those used by METABRIC 198 
to define chromosomal regions with amplifications or deletions. 199 
For the two TCGA cohorts, we used the chromosomal-level DNA copy-number data 200 
to calculate number of breaks by counting the total number of chromosomal segments at least 201 
1 kb in length. The calculation of GII was also based on the chromosomal-level DNA copy-202 
number data after filtering out segments shorter than 1kb, and the same cut-offs as mentioned 203 
above (≥ 0.10 for amplification and ≤ −0.15 for deletion) were used to identify chromosomal 204 
regions with copy-number change. The number of amplified/deleted genes for each of the 205 
two TCGA cohorts was obtained from the downloaded gene-level DNA copy-number data, 206 














4. Survival analysis 208 
Survival analysis for both of the METABRIC datasets was performed using the R 209 
package survival (http://cran.r-project.org/web/packages/survival/index.html). Patient follow-210 
up time was limited to 15 years, and only breast cancer-related deaths were counted.  211 
 Results  212 
1. An HR score for quantifying HR pathway dysregulation in individual breast 213 
tumours 214 
An HR score was developed for each breast tumour to quantify HR pathway 215 
dysregulation in that tumour; a high HR score means that the expression of the HR genes as a 216 
whole in an individual tumour is very different from the situation in normal breast tissues 217 
(see Supplementary Figure S2 for HR gene expression in tumours with low to high HR 218 
score). To calculate this score, we first manually curated a list of 82 HR genes 219 
(Supplementary Table S1) according to our recent review on the HR pathway (Liu et al., 220 
2014). This gene list provides more up-to-date knowledge about the content of HR compared 221 
to publicly available pathway databases; for instance, it catalogues 54 more genes than the 222 
HR pathway in the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (Kanehisa 223 
and Goto, 2000). The expression profiles of the curated HR genes were then employed as 224 
input to the Pathifier method (Drier et al., 2013) to compute the score. To ensure 225 
reproducibility of the results, we performed this pathway analysis independently for four 226 
large breast cancer cohorts that also include data on normal breast tissues (Table 1). 227 
Depending on data availability, the number of HR genes for calculating the score is slightly 228 
different across the cohorts (Supplementary Table S1).  229 
The boxplots in Figure 1 display the HR score distribution in each cohort with regard 230 
to the PAM50 molecular subtypes, and in normal breast tissues. We observed a consistent 231 
pattern across the four cohorts: basal-like tumours generally have the highest HR score, 232 
followed by HER2 and Luminal B tumours, and then Luminal A and Normal-like tumours; 233 
the normal breast tissues always have the lowest HR score as a consequence of being the 234 
benchmark. Similar results can be seen in Supplementary Figure S3 showing HR score versus 235 
the HR score-based rank of the tumours of different subtypes. The consistent distribution of 236 
the HR score by tumour subtype across the different cohorts and gene-expression profiling 237 














and reproducible. Interestingly, we observed some variability in HR score within tumours of 239 
the same subtype, as highlighted by some outliers in the boxplots, suggesting some 240 
heterogeneity in HR pathway dysregulation within the subtypes. 241 
2. The HR score is reflective of HR repair deficiency.   242 
The HR score is gene expression-based, and measures the extent to which the HR 243 
pathway is dysregulated. To test whether there exists an association between HR pathway 244 
dysregulation and HR repair deficiency, we next asked whether the HR score is reflective of 245 
HR repair deficiency (i.e., whether a tumour with high HR score is likely to be HR-defective). 246 
We used two published HR-defect signatures, homologous recombination defect (HRD) (G. 247 
Peng et al., 2014) and Large-scale transitions (LSTs) (Popova et al., 2012), to test this 248 
hypothesis. 249 
2.1. Comparison with the HRD signature 250 
The HRD signature encompasses 230 genes that are differentially expressed between 251 
HR-intact and HR-deficient cells, and is intended to represent the global impact of HR defect 252 
on the transcriptome of a tumour cell (G. Peng et al., 2014). To identify tumours (or cell 253 
lines) with HR deficiency, Peng et al. performed a hierarchical clustering analysis based on 254 
the expression level of the 230 genes to divide samples into two clusters, one considered as 255 
HR-intact and the other HR-deficient (G. Peng et al., 2014).  256 
In this study, we performed the same clustering analysis for each of the four cohorts 257 
(Figure 2A for the METABRIC discovery cohort and Supplementary Figures S4, S5 and S6 258 
for the three remaining cohorts). As shown in Figure 2A, tumours with low HR score (upper 259 
horizontal bar, green) are mostly tumours belonging to the HR-intact cluster, whereas 260 
tumours with high HR score (upper horizontal bar, red) are mostly tumours belonging to the 261 
HR-deficient cluster. To be more precise, Figure 2B shows the distribution of the HR score in 262 
the two HRD-based clusters for each of the four cohorts, demonstrating that tumours in the 263 
HR-deficient cluster in general have significantly higher HR score compared with tumours in 264 
the HR-intact cluster (p-values ≤ 9.1e-63, Wilcoxon Signed-rank test). These observations 265 
indicate that tumours with high HR scores are likely to be HR-defective, as predicted by the 266 
HRD signature. 267 
2.2. Comparison with the LST signature 268 
LST refers to a chromosomal break whose flanking regions are at least 10 Mb in size. 269 














measure of chromosomal instability (Popova et al., 2012). In this study, we estimated the 271 
number of LSTs for each tumour using the DNA copy number data, and divided each cohort 272 
into two groups according to the method and cut-offs described in (Popova et al., 2012): 273 
LST+ (≥ 20 LSTs) and LST- (< 20 LSTs). The numbers of LST+ and LST- tumours identified 274 
in each cohort are summarised in Supplementary Table S2. As in the comparison with the 275 
HRD signature, we found that LST+ tumours generally have higher HR scores compared with 276 
LST- tumours, even in the case of the METABRIC Discovery cohort where only nine LST+ 277 
tumours were identified (Figure 3).  This observation also supports the idea that the HR score 278 
is indicative of HR defect.  279 
Taken together, the results based on HRD and on LST demonstrate an association 280 
between HR pathway dysregulation, as represented by the HR score, and HR repair 281 
deficiency. In addition, in the two TCGA cohorts for which gene mutation data were 282 
available, we also observe that tumours with at least one non-synonymous mutation in one of 283 
six key HR genes have significantly higher HR score than do the tumours with no mutation in 284 
any of these genes (see Supplementary Figure S7 for more details). All these results support 285 
the existence of a compensatory mechanism through which HR-deficient cells respond to 286 
their HR defect by altering the expression level of HR genes. Interestingly, it has been 287 
proposed that melanoma cells exploit the overexpression of DNA repair genes, particular 288 
those involved in DSB repair, to increase their DNA repair capacity that is necessary for 289 
them to invade and give rise to distant metastases (Sarasin and Kauffmann, 2008). Consistent 290 
with this, overexpression of certain DNA repair genes is utilised by polyploid cells to 291 
overcome replication stress-induced senescence barriers (Zheng et al., 2012). All these results 292 
indicate that altering the expression of DNA repair genes or pathways may be a 293 
compensatory mechanism commonly exploited by tumour cells. 294 
3. Association with CIN 295 
Because replication stress has emerged as a common source of CIN in caner, and HR 296 
is the crucial pathway for the repair of replication stress-induced DSBs, we hypothesised that 297 
there might be a link between HR pathway dysregulation, which is indicative of HR repair 298 
deficiency as described above, and the degree of CIN in breast carcinomas. To test this 299 
hypothesis, we first examined the correlation between the HR score and the widely used CIN 300 
signature CIN25 (Carter et al., 2006). We then investigated the association between the HR 301 














breakpoints, fraction of the genome with copy-number alterations (genomic instability index, 303 
GII), and number of amplified/deleted genes. In particular, as data pre-processing and 304 
segregation algorithm can significantly affect the actual value of the CIN measurements, we 305 
downloaded the numbers of chromosomal breaks and GII for the two METABRIC cohorts 306 
from a recent publication (Vollan et al., 2015). We believe these measures from a third-party 307 
study provide more-objective results for our analysis. 308 
3.1. Association with CIN25 309 
Figure 4 displays a scatter plot between the CIN25 score, defined as the mean 310 
expression value of the CIN25 genes (Carter et al., 2006), and the HR score for tumours from 311 
each of the four cohorts. Each cohort showed a high correlation between the CIN25 score and 312 
the HR score (Spearman correlation coefficient r = 0.94 and r = 0.93 for the two METABRIC 313 
cohorts, and r = 0.85 and r = 0.96 for the two TCGA cohorts), indicating that the HR score is 314 
also correlated with CIN level. Moreover we found ten of the CIN25 genes (40%) to be 315 
present among the 230 genes of the HRD signature mentioned in Section 2.1, which indicates 316 
that HR defects might be one of the underlying biological mechanisms responsible for the 317 
expression change of the CIN25 genes.  318 
Overall, these results revealed that the HR score correlates with the CIN25 score, and 319 
support the hypothesis that there exists an association between HR pathway dysregulation, as 320 
represented by the HR score, and CIN level in tumours, as predicted by the CIN25 score.   321 
3.2. Association with three common CIN measurements 322 
Because the CIN25 score only indirectly estimates CIN level in tumours, we also 323 
directly assessed the relationship between the HR score and each of the three common CIN 324 
measures (breakpoints, GII and number of amplified/deleted genes). We asked whether 325 
tumours with higher HR score tend to have a higher CIN level. To address this, we divided 326 
tumours into four equal-sized groups based on the HR score quartiles, and statistically 327 
examined the differences between adjacent groups for each of the three CIN measurements. 328 
The boxplots in Figure 5 (METABRIC discovery cohort) show a high variability in each HR 329 
score quartile group for each CIN measurement, indicating that other mechanisms can also 330 
affect CIN. However, we observed a clear pattern that tumours with higher HR score indeed 331 
tend to have higher CIN level (Wilcoxon Signed-rank test, one sided FDR p-value < 0.05), 332 
with the exception of tumours in the third and fourth quartile groups in GII. Similar results 333 














Overall, these results suggest an association between the extent of HR pathway dysregulation 335 
and the degree of CIN level in breast carcinomas. 336 
As the HR score is based on gene expression, to ascertain whether the association 337 
observed above is due to the gene expression-based PAM50 subtypes, we performed the 338 
same analysis independently on tumours within each PAM50 subtype. In each analysis, the 339 
samples were divided into high and low HR score groups according to the median. The 340 
results for the METABRIC discovery cohort are summarised in Figure 6. For this cohort we 341 
consistently observed that tumours in the high HR score group have more breakpoints than do 342 
tumours in the low HR score group within the subtypes, despite the wide range of the 343 
breakpoint numbers observed for each subtype. The difference in GII between the low and 344 
high HR score groups was significant in Basal-like, Luminal A and Normal-like tumours, but 345 
not in HER2 and Luminal B tumours, while the difference in number of amplified/deleted 346 
genes between the two groups was significant in all subtypes except HER2. For the other 347 
cohorts (Supplementary Figures S11, S12 and S13) we observed some differences between 348 
cohorts. For example, in the METABRIC Validation cohort, all three CIN measurements are 349 
significantly different between the two HR score groups for all subtypes, whereas the 350 
difference is significant in fewer subtypes in the TCGA Microarray cohort. These 351 
discrepancies might be due to low sample size in the TCGA Microarray cohort (e.g. there are 352 
only eight samples in its Normal-like subtype). Apart from these possible exceptions, the 353 
above results support the hypothesis that tumours with more-deregulated HR pathway are 354 
likely to have a higher degree of CIN, and this relationship can still be detected within the 355 
gene expression-based PAM50 subtypes. 356 
3.3. Association between the CIN measurements and other pathways 357 
The scatter plots in Figure 5 (METABRIC discovery cohort) show that the HR score 358 
is moderately correlated with each of the three CIN measurements (breakpoints r = 0.60, GII 359 
r=0.39 and number of amplified/deleted genes r = 0.48). These moderate correlations are not 360 
surprising, given that we do not consider aberrant HR as the only mechanism that contributes 361 
to CIN. In this section we investigated whether there are other pathways whose dysregulation 362 
also correlates with CIN, and whether these moderate correlations are far from random. 363 
We computed a score for each of the 186 KEGG pathways (Kanehisa and Goto, 2000) 364 
and for 674 Reactome pathways (Croft et al., 2010), using the same approach as for the HR 365 
score. Spearman correlation coefficients between these scores and each of the three CIN 366 














score and the three CIN measurements. Figure 7 shows the results for the METABRIC 368 
Discovery cohort (KEGG pathways are in green and Reactome pathways in blue; similar 369 
results for the other three cohorts are in Supplementary Figures S14, S15 and S16). We found 370 
only a few KEGG or Reactome pathways whose dysregulation showed a similar level of 371 
correlation with CIN as did the HR pathway. For example, only four (2.2%) KEGG pathways 372 
(cell cycle, oocyte meiosis, progesterone-mediated oocyte maturation and p53 signalling) 373 
were more strongly associated with number of breakpoints than with the HR pathway (r = 374 
0.61- 0.63 compared to r = 0.60 for the HR pathway in Figure 7). Moreover, the strong 375 
associations of the oocyte meiosis, progesterone-mediated oocyte maturation and p53 376 
signalling pathways with number of breakpoints is mainly due to their considerable overlap 377 
in gene content with the KEGG cell cycle pathway: 37%, 34% and 36% genes from each of 378 
these three pathways are also present in the cell cycle pathway (Supplementary Table S3). In 379 
contrast, only two HR genes are present in the cell cycle pathway. After removing the 380 
overlapping genes, association levels between each of these three pathways with number of 381 
breakpoints significantly decreased (results not shown). Similarly, although there were 24 382 
(3.6%) Reactome pathways whose dysregulation showed a similar level of correlation with 383 
CIN as did the HR pathway, 18 of these are either the cell cycle pathway or its sub-pathways 384 
(Supplementary Table S4).  385 
As the KEGG and Reactome pathways do not cover all genes measured in the whole-386 
genome gene expression profiling data analysed in this study, we also constructed 1000 387 
“Random” pathways for each cohort to calculate an empirical p-value for the association 388 
between the HR score and each of the three CIN measurements. Each Random pathway is of 389 
the same length as HR but is composed of genes randomly selected from the gene-expression 390 
profiling data, excluding those from HR and cell cycle pathways. Similar to the KEGG 391 
pathways analysed above, we computed a score for each Random pathway, and compared the 392 
correlation coefficients with the three CIN measures against those for the HR score. As 393 
shown in Figure 7, only a few Random pathways (in pink) showed a level of association with 394 
CIN similar to that of the HR pathway, as indicated by the empirical p-values. Similar results 395 
for the other three cohorts were obtained (Supplementary Figures S14, S15 and S16).  396 
Overall, these results indicate that the CIN level in tumours is associated with the 397 
dysregulation of only a limited number of pathways (e.g., the cell cycle pathway), and that 398 














4. Association with survival in ER
+
 tumours 400 
The two METABRIC cohorts are annotated with disease-specific survival data that 401 
are lacking for the two TCGA cohorts. We thus tested whether the HR score can predict 402 
patient survival in the two METABRIC cohorts. Figure 8 shows Kaplan-Maier plots for 403 
patients with ER+ tumours from the METABRIC discovery (n=699; follow-up time ≤ 15 404 
years) and validation cohorts (n=582; follow-up time ≤ 15 years). For each cohort, patients 405 
were divided into high and low HR score groups based on the median HR score. For both 406 
cohorts, we observed a significant difference in patient survival between the two HR score 407 
groups with ER+ tumours (Figure 8; Cox proportional hazards regression test p-value = 8.4e-408 
04 and 3.9e-09 for the two cohorts, respectively). However, we observed no significant 409 
difference in survival between the two HR score groups for patients with ER- tumours (data 410 
not shown). As an association between CIN and prognosis in ER+ tumours has already been 411 
documented (Przybytkowski et al., 2014; Smid et al., 2011), and after control for the number 412 
of chromosomal breaks there is no significant difference in survival between the two HR 413 
score-based groups (result not shown), we infer that the prognostic value of the HR score in 414 
ER+ tumours is due to the association between the HR score and CIN. 415 
 Discussion 416 
Multiple molecular mechanisms have been associated with the origin of CIN in 417 
cancer, including replication stress, telomere dysfunction, aberrant DNA repair and various 418 
defects in chromosome segregation (reviewed in (Abbas et al., 2013; Aguilera and García-419 
Muse, 2013; Negrini et al., 2010; Thompson et al., 2010). Although CIN can be 420 
experimentally induced by exploiting any of these mechanisms, replication stress has been 421 
recently identified as the first recurrent genetic defect associated with CIN in colorectal 422 
cancer (Burrell et al., 2013a). In this scenario, CIN is induced during DNA replication in fast-423 
dividing tumour cells, giving rise to frequent stalling of replication forks. Consequently, HR 424 
as the primary pathway for repair of the resultant DSBs during replication becomes 425 
overworked, and if HR is dysfunctional the frequency of replication stress-induced CIN is 426 
likely to increase dramatically. Here we have shown that HR dysregulation as measured by 427 
the HR score, which is indicative of aberrant HR repair, is prevalent in sporadic breast cancer 428 
and correlates with the level of CIN. We thus propose that HR dysregulation might contribute 429 














overexpression of the key HR gene RAD51, which is commonly seen in breast cancer as well 431 
as other cancer types, promotes chromosomal instability (Richardson et al., 2004), and two 432 
other critical HR genes, BRCA1 and BRCA2, were recently proposed as chromosome 433 
custodians mainly due to their role in HR (Venkitaraman, 2014a; 2014b). 434 
Dysfunction of the HR pathway, although not the primary cause, may increase the 435 
level of replication stress-induced CIN in several ways. Firstly, it can cause inefficient repair 436 
of DSBs, resulting in an accumulation of chromosomal breaks. Secondly, by triggering error-437 
prone repair pathways including canonical non-homologous end-joining (C-NHEJ) and 438 
alternative non-homologous end-joining (Alt-NHEJ, also called microhomology-mediated 439 
end joining (MMEJ)), HR dysfunction can lead to translocations, translocation-related 440 
chromosomal breaks and DNA copy-number changes. Specifically, in contrast to HR that 441 
requires homologous sequence to guide repair, C-NHEJ and Alt-NHEJ mediate the repair by 442 
a direct ligation of the break ends after more-or-less end processing, and so do not ensure that 443 
the broken DNA strands are re-joined in the correct position. These two low-fidelity 444 
pathways come to repair DSBs generated during DNA replication when HR is deficient, 445 
resulting in translocation as well as translocation-related chromosomal breaks (Alexandrov et 446 
al., 2013; Bunting and Nussenzweig, 2013; Ottaviani et al., 2014; Villarreal et al., 2012). 447 
Moreover, gene copy number changes also arise when the repair of broken replication forks 448 
switched from HR to the two NHEJs, especially Alt-NHEJ (Hastings et al., 2009); 449 
A third way in which HR pathway dysfunction can increase replication stress-induced 450 
CIN is by affecting mitosis and the proper functioning of telomeres. HR defects and the 451 
consequent slow progression of replication forks can elicit alterations of mitosis, which 452 
highlights the importance of HR at the interface of these two processes for protection against 453 
CIN (Wilhelm et al., 2014). In addition, DSB repair is shut down during the M phase to avoid 454 
telomere fusion and as a consequence, mitosis will continue even in the presence of DSBs or 455 
fragmented chromosomes, giving rise to CIN (Orthwein et al., 2014). This emphasises the 456 
importance of DSB repair during DNA replication, especially given the presence of DSBs 457 
that result from replication stress. HR defects caused by BRCA2 mutations could also lead to 458 
telomere dysfunction, a mechanism that has been proposed to explain, in part, the 459 
chromosomal instability observed in BRCA2-deficient tumours (Badie et al., 2010). Taken 460 
together, HR dysfunction can increase CIN via diverse mechanisms, and the association 461 
revealed in this study between HR dysregulation and CIN (Figures 4, 5 and 6) indicates that 462 














The study of CIN in breast cancer has attracted immense interest in recent years 464 
following the recognition of its clinical relevance in disease heterogeneity, drug resistance 465 
and patient response (A'Hern et al., 2013; Birkbak et al., 2011; Endesfelder et al., 2014; 466 
Habermann et al., 2009; Roylance et al., 2011; Sansregret and Nepveu, 2011; Swanton et al., 467 
2009; Vincent-Salomon et al., 2013); reviewed by (Wiechec, 2011). CIN induces evolution in 468 
tumours, providing the heterogeneity from which aggressive and/or drug-resistant tumour 469 
clones are selectively established. CIN aids tumour development by amplifying genomic 470 
regions containing oncogenes and deleting regions containing tumour-suppressor genes, 471 
thereby significantly influencing treatment response and survival in patients. Our results 472 
further strengthen this connection by associating dysregulated HR with the extent of 473 
amplified/deleted genes and regions of the chromosome, and by showing that ER+ tumours 474 
with high HR score or CIN levels display significantly poorer prognosis (Figure 8). 475 
A measure of HR dysregulation such as the one adopted here can be extremely 476 
valuable to guide therapeutic options. The observation that cancer cells deficient in HR are 477 
profoundly sensitive to PARP inhibitors (Bryant et al., 2005; Farmer et al., 2005) has already 478 
led to the development of targeted PARP therapies for sporadic breast and ovarian cancers 479 
with defects in core HR genes such as BRCA1 and BRCA2, a condition termed as 480 
“BRCAness” (Turner et al., 2004). PARP is an important protein family whose members 481 
function in restarting stalled replication forks and diverting DSBs to HR-mediated repair. It 482 
has been proposed that accumulated chromosomal instability arising from the continued 483 
stalling of replication forks, accompanied by deficiency in repairing DSBs and thereby 484 
triggering a genomic catastrophe, may explain how PARP inhibition kills HR-deficient 485 
cancer cells (Bryant et al., 2005; Farmer et al., 2005). Although focusing on a mechanistic 486 
explanation for PARP-based cancer therapy, these models indirectly suggest an underlying 487 
relationship among replicative stress, dysfunctional HR and the accumulation of 488 
chromosomal instability.  489 
In conclusion, we performed a personalised pathway analysis by calculating an HR 490 
score that quantifies HR pathway dysregulation in individual breast tumours, with the 491 
behaviour of HR in normal breast tissues serving as a benchmark. Our results are 492 
reproducible across four large breast cancer cohorts (~ 3000 tumours in total). We found HR 493 
is dysregulated to various extents between and within the gene expression-based PAM50 494 
subtypes, which may reflects their HR repair deficiency. More importantly, we uncovered a 495 














maintaining genomic integrity, this work is the first large-scale study to assess the correlation 497 
between HR dysregulation and CIN in sporadic breast cancer. As such our results will be 498 
useful for future studies that aim to identify causative factors of CIN in sporadic breast cancer 499 
as well as in other cancer types. 500 
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Figure 1 - Distribution of the HR score across the PAM50 subtypes and normal 
breast tissues (in green) for the four cohorts. 
Figure 2 – Comparison of the HR score with the HRD signature. A: HRD-based 
hierarchical clustering of tumours from the METABRIC Discovery cohort. B: 
Distribution of the HR score in the two HRD-based clusters for each of the four 
cohorts. Colour represents the HRD-based cluster. P-values were obtained using a 
Wilcoxon signed-rank test. 
Figure 3 - Distribution of the HR score in LST+ tumours and LST- tumours for 
each of the four cohorts. Colour represents LST status. P-values were obtained using 
a Wilcoxon signed-rank test. 
Figure 4 - Correlations between the CIN25 score and the HR score for each of 
the four cohorts. 
Figure 5 - HR score versus the three CIN measurements for the METABRIC 
Discovery cohort. Left: Boxplots of the three CIN measurements versus the four HR 
score quartile groups; stars indicate statistical significance according to a Wilcoxon 
signed-rank test: ns means not significant, * means 0.01< p-value < 0.05, ** means 
0.001 < p-value <0.01, and *** means p-value < 0.001. Right: Scatter plots of the HR 
score versus each of the three CIN measurements; r represents Pearson Correlation 
Coefficient.  
Figure 6 - HR score versus the three CIN measurements within PAM50 subtypes 
(METABRIC Discovery cohort). For each plot, the two HR score groups were 
divided according to the median HR score in each subtype; stars indicate the 
significance according to a Wilcoxon signed-rank test for each pair of groups: ns 
means not significant, * means 0.01< p < 0.05, ** means 0.001 < p <0.01, and *** 
means p < 0.001. 
Figure 7 - Distributions of the correlations between pathway scores and the three 
CIN measurements (METABRIC Discovery cohort). Results for KEGG pathways 
are in green, Reactome pathways in blue and Random pathways in pink. Spearman 
correlation coefficients (r) are represented on the x-axis. Pathway score were 
calculated with Pathifier. The vertical dashed line in each histogram indicates the 
value of r between the HR score and each of the three CIN measurements, and p 
represents an empirical p-value for that value of r. 
Figure 8 - Kaplan-Maier plot for disease specific survival in the METABRIC 
Discovery cohort (left) and Validation cohort (right). Patients with ER+ tumour 
were divided into two equal-sized groups based on the median HR score in each 
cohort. 
Figure S1 – Principal curve of the HR pathway for each of the four cohorts. For 
each cohort, the black points represent samples in that cohort. The samples are 
projected onto the principal curve and are coloured according to their PAM50 
assignment. The data points and the principal curve are projected on the three leading 













Figure S2 – The expression of the HR genes in tumours from the METABRIC 
Discovery cohort. The HR genes are ranked in decreasing importance according to 
their contribution to the first principal component. 
Figure S3 – Scatter plots of the HR score versus the rank of tumours according 
to their HR score, colour by the PAM50 assignment. 
Figure S4 - Hierarchical clustering of tumours from the METABRIC Validation 
cohort based on the HRD signature.  
Figure S5 - Hierarchical clustering of tumours from the TCGA RNA-seq cohort 
based on the HRD signature.  
Figure S6 - Hierarchical clustering of tumours from the TCGA Microarray 
cohort based on the HRD signature.  
Figure S7 - HR score versus HR gene mutation for the two TCGA cohorts. 
Mutant refers to tumours with at least one nonsynonymous mutation in any of the six 
key HR genes (BRCA1, BRCA2, RAD51, PALB2, DNA2 and EXO1). Wild type refers 
to tumours with no mutations in these six genes. Normal refers to normal breast 
tissues. P-values were obtained using a Wilcoxon signed-rank test, for the comparison 
between wild type and mutant tumours.   
Figure S8 - HR score versus the three CIN measurements for the METABRIC 
Validation cohort. Left: Boxplots of the three CIN measurements versus the four HR 
score quartile groups; stars indicate statistical significance according to a Wilcoxon 
signed-rank test: ns means not significant, * means 0.01< p-value < 0.05, ** means 
0.001 < p-value <0.01, and *** means p-value < 0.001. Right: Scatter plots of the HR 
score versus each of the three CIN measurements; r represents Pearson Correlation 
Coefficient. 
Figure S9 - HR score versus the three CIN measurements for the TCGA RNA-
seq cohort. Left: Boxplots of the three CIN measurements versus the four HR score 
quartile groups; stars indicate statistical significance according to a Wilcoxon signed-
rank test: ns means not significant, * means 0.01< p-value < 0.05, ** means 0.001 < 
p-value <0.01, and *** means p-value < 0.001. Right: Scatter plots of the HR score 
versus each of the three CIN measurements; r represents Pearson Correlation 
Coefficient. 
Figure S10 - HR score versus the three CIN measurements for the TCGA 
Microarray cohort. Left: Boxplots of the three CIN measurements versus the four 
HR score quartile groups; stars indicate statistical significance according to a 
Wilcoxon signed-rank test: ns means not significant, * means 0.01< p-value < 0.05, 
** means 0.001 < p-value <0.01, and *** means p-value < 0.001. Right: Scatter plots 
of the HR score versus each of the three CIN measurements; r represents Pearson 
Correlation Coefficient. 
Figure S11 - HR score versus the three CIN measurements within PAM50 
subtypes (METABRIC Validation cohort). For each plot, the two HR score groups 
were divided according to the median HR score in each subtype; stars indicate the 
significance according to a Wilcoxon signed-rank test for each pair of groups: ns 
means not significant, * means 0.01< p < 0.05, ** means 0.001 < p <0.01, and *** 













Figure S12 - HR score versus the three CIN measurements within PAM50 
subtypes (TCGA RNA-seq cohort). For each plot, the two HR score groups were 
divided according to the median HR score in each subtype; stars indicate the 
significance according to a Wilcoxon signed-rank test for each pair of groups: ns 
means not significant, * means 0.01< p < 0.05, ** means 0.001 < p <0.01, and *** 
means p < 0.001. 
Figure S13 - HR score versus the three CIN measurements within PAM50 
subtypes (TCGA Microarray cohort). For each plot, the two HR score groups were 
divided according to the median HR score in each subtype; stars indicate the 
significance according to a Wilcoxon signed-rank test for each pair of groups: ns 
means not significant, * means 0.01< p < 0.05, ** means 0.001 < p <0.01, and *** 
means p < 0.001. 
Figure S14 - Distributions of the correlations between pathway scores and the 
three CIN measurements (METABRIC Validation cohort). Results for KEGG 
pathways are in green, Reactome pathways in blue and Random pathways in pink. 
Spearman correlation coefficients (r) are represented on the x-axis. Pathway score 
were calculated with Pathifier. The vertical dashed line in each histogram indicates 
the value of r between the HR score and each of the three CIN measurements, and p 
represents an empirical p-value for that value of r. 
Figure S15 - Distributions of the correlations between pathway scores and the 
three CIN measurements (TCGA RNA-seq cohort). Results for KEGG pathways 
are in green, Reactome pathways in blue and Random pathways in pink. Spearman 
correlation coefficients (r) are represented on the x-axis. Pathway score were 
calculated with Pathifier. The vertical dashed line in each histogram indicates the 
value of r between the HR score and each of the three CIN measurements, and p 
represents an empirical p-value for that value of r. 
Figure S16 - Distributions of the correlations between pathway scores and the 
three CIN measurements (TCGA Microarray cohort). Results for KEGG 
pathways are in green, Reactome pathways in blue and Random pathways in pink. An 
additional 100 CIN-related genes were excluded prior to the construction of the 
Random pathways as the Pathifer method was sensitive to the addition or removal of 
a small number of genes in this cohort. Spearman correlation coefficients (r) are 
represented on the x-axis. Pathway score were calculated with Pathifier. The vertical 
dashed line in each histogram indicates the value of r between the HR score and each 
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• Homologous recombination (HR) pathway dysregulation is quantified at 
tumour level. 
• HR dysregulation is indicative of HR repair deficiency. 
• An association between HR dysregulation and chromosomal instability is 
uncovered. 













































































































Total = 82 69 present 69 present 72 present 67 present 2 present 7 present













METABRIC Discovery 9 976
METABRIC Validation 25 940
TCGA RNA-seq 77 820














No. of breaks GII No. of amplified/deleted genes No. of breaks GII No. of amplified/deleted genes No. of breaks GII No. of amplified/deleted genes No. of breaks GII No. of amplified/deleted genes
OOCYTE MEIOSIS 114 42 36.84% 0.63 0.29 0.43 0.61 0.32 0.48 0.52 0.47 0.50 0.57 0.50 0.52
CELL CYCLE 128 128 100.00% 0.62 0.30 0.42 0.60 0.35 0.48 0.61 0.57 0.59 0.56 0.52 0.52
PROGESTERONE MEDIATED OOCYTE MATURATION 86 29 33.72% 0.61 0.32 0.44 0.59 0.34 0.48 0.56 0.51 0.54 0.54 0.47 0.48
P53 SIGNALING PATHWAY 69 25 36.23% 0.61 0.28 0.42 0.56 0.29 0.45 0.51 0.48 0.49 0.55 0.48 0.49
PYRIMIDINE METABOLISM 98 0 0.00% 0.58 0.30 0.43 -0.05 0.19 0.04 0.38 0.36 0.36 0.52 0.48 0.48
SMALL CELL LUNG CANCER 84 15 17.86% 0.57 0.23 0.39 0.50 0.22 0.37 0.45 0.45 0.44 0.50 0.44 0.49
BASE EXCISION REPAIR 35 1 2.86% 0.56 0.35 0.44 0.56 0.43 0.52 0.57 0.53 0.53 0.51 0.52 0.50
UBIQUITIN MEDIATED PROTEOLYSIS 138 21 15.22% 0.55 0.41 0.42 0.30 0.23 0.23 0.30 0.30 0.32 0.53 0.40 0.47
PATHWAYS IN CANCER 328 32 9.76% 0.54 0.23 0.36 0.48 0.35 0.40 0.25 0.31 0.22 0.49 0.39 0.44
DNA REPLICATION 36 7 19.44% 0.54 0.31 0.38 0.52 0.35 0.45 0.53 0.53 0.52 0.49 0.54 0.52
HOMOLOGOUS RECOMBINATION 28 0 0.00% 0.52 0.25 0.37 0.45 0.30 0.38 0.41 0.37 0.38 0.53 0.51 0.49
PROSTATE CANCER 89 15 16.85% 0.52 0.20 0.33 0.45 0.24 0.30 0.25 0.29 0.22 0.25 0.27 0.21
CYSTEINE AND METHIONINE METABOLISM 34 0 0.00% 0.51 0.12 0.34 0.46 0.15 0.32 0.44 0.37 0.39 0.54 0.49 0.52
MISMATCH REPAIR 23 1 4.35% 0.51 0.27 0.40 0.43 0.30 0.45 0.48 0.50 0.50 0.48 0.53 0.52
BLADDER CANCER 42 11 26.19% 0.51 0.16 0.31 0.47 0.23 0.34 0.31 0.33 0.32 0.32 0.23 0.30
PROPANOATE METABOLISM 33 0 0.00% 0.50 0.13 0.29 0.28 0.04 0.13 0.44 0.38 0.42 0.27 0.18 0.21
FATTY ACID METABOLISM 42 0 0.00% 0.49 0.32 0.38 0.20 0.35 0.27 0.22 0.27 0.18 0.18 0.22 0.16
PEROXISOME 78 0 0.00% 0.49 0.15 0.39 -0.05 0.21 0.07 0.10 0.10 0.07 0.15 0.16 0.16
PURINE METABOLISM 159 0 0.00% 0.49 0.20 0.37 0.47 0.23 0.41 0.42 0.39 0.41 0.55 0.47 0.48
ONE CARBON POOL BY FOLATE 17 0 0.00% 0.49 0.14 0.33 0.47 0.18 0.36 0.52 0.49 0.51 0.41 0.39 0.39
TYROSINE METABOLISM 42 0 0.00% 0.48 0.14 0.30 0.36 0.12 0.24 0.41 0.36 0.33 0.42 0.36 0.37
STEROID BIOSYNTHESIS 17 0 0.00% 0.48 0.19 0.30 0.47 0.26 0.35 0.46 0.40 0.41 0.53 0.43 0.45
GLUTATHIONE METABOLISM 50 0 0.00% 0.48 0.11 0.30 0.30 0.00 0.18 0.47 0.45 0.45 0.36 0.31 0.29
GLYCINE SERINE AND THREONINE METABOLISM 31 0 0.00% 0.47 0.09 0.30 0.44 0.17 0.32 0.54 0.46 0.50 0.47 0.40 0.40
LYSINE DEGRADATION 44 0 0.00% 0.47 0.15 0.27 0.36 0.18 0.24 0.47 0.41 0.43 0.53 0.50 0.51
VALINE LEUCINE AND ISOLEUCINE DEGRADATION 44 0 0.00% 0.47 0.07 0.25 0.35 0.08 0.20 0.47 0.41 0.48 0.36 0.21 0.26
AMINOACYL TRNA BIOSYNTHESIS 41 0 0.00% 0.47 0.15 0.31 0.47 0.26 0.34 0.52 0.47 0.50 0.42 0.44 0.50
REGULATION OF ACTIN CYTOSKELETON 216 0 0.00% 0.47 0.11 0.26 0.31 0.05 0.16 0.18 0.24 0.17 0.21 0.27 0.19
PANCREATIC CANCER 70 15 21.43% 0.46 0.30 0.35 0.40 0.43 0.40 0.18 0.23 0.16 0.07 0.14 0.06
NEUROTROPHIN SIGNALING PATHWAY 126 9 7.14% 0.46 0.09 0.25 0.32 0.07 0.17 0.38 0.38 0.39 0.20 0.10 0.20
PPAR SIGNALING PATHWAY 69 0 0.00% 0.45 0.28 0.36 0.50 0.22 0.39 0.13 0.17 0.11 0.34 0.25 0.31
COLORECTAL CANCER 62 10 16.13% 0.45 0.16 0.27 0.41 0.23 0.31 0.38 0.39 0.37 0.57 0.52 0.52
HISTIDINE METABOLISM 29 0 0.00% 0.45 0.08 0.25 0.38 0.14 0.24 0.39 0.32 0.31 0.33 0.22 0.20
TRYPTOPHAN METABOLISM 40 0 0.00% 0.45 0.03 0.23 0.37 -0.01 0.17 0.41 0.32 0.32 0.38 0.19 0.28
PYRUVATE METABOLISM 40 0 0.00% 0.44 0.13 0.31 0.33 0.13 0.27 0.40 0.39 0.38 0.06 -0.02 0.04
NON HOMOLOGOUS END JOINING 14 2 14.29% 0.44 0.29 0.35 0.45 0.31 0.37 0.36 0.32 0.36 0.46 0.48 0.49
NUCLEOTIDE EXCISION REPAIR 44 4 9.09% 0.44 0.30 0.42 0.34 0.25 0.36 0.38 0.38 0.38 0.45 0.54 0.49
SELENOAMINO ACID METABOLISM 26 0 0.00% 0.44 0.25 0.34 0.41 0.29 0.35 0.21 0.25 0.24 0.48 0.44 0.46
PARKINSONS DISEASE 133 0 0.00% 0.42 0.17 0.22 0.17 0.15 0.24 0.28 0.25 0.24 0.43 0.36 0.39
CHRONIC MYELOID LEUKEMIA 73 21 28.77% 0.42 0.16 0.23 0.28 0.23 0.22 0.20 0.21 0.17 0.51 0.49 0.49
PROTEASOME 48 0 0.00% 0.41 0.02 0.24 0.20 0.22 0.15 0.47 0.35 0.43 0.28 0.19 0.25
RNA POLYMERASE 29 0 0.00% 0.41 0.24 0.39 0.45 0.36 0.51 0.31 0.32 0.33 0.40 0.42 0.42
TERPENOID BACKBONE BIOSYNTHESIS 15 0 0.00% 0.41 0.15 0.30 0.42 0.28 0.37 0.07 0.04 0.06 0.08 0.14 0.18
GLIOMA 65 11 16.92% 0.40 0.14 0.21 0.46 0.29 0.35 0.05 0.13 0.02 -0.04 0.01 -0.09
MELANOMA 71 11 15.49% 0.39 0.18 0.21 0.41 0.27 0.31 0.24 0.31 0.22 0.12 0.18 0.10
CIRCADIAN RHYTHM MAMMAL 13 0 0.00% 0.39 0.17 0.35 0.19 0.07 0.12 0.32 0.35 0.33 0.13 0.16 0.20
LYSOSOME 121 0 0.00% 0.39 -0.05 0.17 0.21 -0.03 0.03 0.13 0.12 0.15 -0.10 -0.04 -0.07
GLYOXYLATE AND DICARBOXYLATE METABOLISM 16 0 0.00% 0.39 0.13 0.27 0.44 0.23 0.35 0.51 0.47 0.51 0.45 0.38 0.44
SPLICEOSOME 128 0 0.00% 0.39 0.12 0.33 0.17 0.02 0.19 0.43 0.39 0.42 0.56 0.58 0.58
ARGININE AND PROLINE METABOLISM 54 0 0.00% 0.39 0.11 0.21 0.28 0.19 0.21 0.37 0.32 0.30 -0.27 -0.19 -0.19
FOLATE BIOSYNTHESIS 11 0 0.00% 0.39 0.15 0.30 0.33 0.09 0.28 0.46 0.43 0.48 0.37 0.35 0.42
GLYCOLYSIS GLUCONEOGENESIS 62 0 0.00% 0.39 0.03 0.27 0.29 0.23 0.26 0.45 0.45 0.46 0.43 0.38 0.39
ARACHIDONIC ACID METABOLISM 58 0 0.00% 0.38 0.32 0.34 0.16 0.01 0.14 0.24 0.27 0.20 -0.04 -0.02 -0.08
APOPTOSIS 88 3 3.41% 0.38 0.01 0.23 0.14 -0.13 -0.03 0.23 0.25 0.16 0.02 0.04 -0.02
AMYOTROPHIC LATERAL SCLEROSIS ALS 53 1 1.89% 0.37 -0.02 0.18 0.35 0.34 0.32 0.46 0.43 0.45 0.39 0.42 0.35
PENTOSE PHOSPHATE PATHWAY 27 0 0.00% 0.37 0.07 0.23 0.27 0.05 0.21 0.42 0.42 0.44 0.29 0.24 0.30
VIBRIO CHOLERAE INFECTION 56 0 0.00% 0.37 0.09 0.22 0.05 0.04 0.07 0.17 0.21 0.15 -0.11 -0.16 -0.18
METABRIC Validation Cohort TCGA RNA-seq Cohort TCGA Microarray Cohort
Pathway Name Length Overlap Percentage
Note: 
Correlations between the Pathifier score of each KEGG pathway and three CIN measurements in the four breast cancer cohorts
METABRIC Discovery Cohort
1. Overlap = length of the overlap with the CELL CYCLE pathway in KEGG













PHENYLALANINE METABOLISM 18 0 0.00% 0.36 0.06 0.20 0.35 0.09 0.23 0.33 0.25 0.24 0.30 0.20 0.19
FRUCTOSE AND MANNOSE METABOLISM 34 0 0.00% 0.35 0.11 0.25 0.34 0.14 0.23 0.05 0.02 0.02 0.19 0.19 0.19
TYPE II DIABETES MELLITUS 47 0 0.00% 0.35 0.00 0.15 0.25 0.03 0.09 0.38 0.36 0.39 0.33 0.22 0.29
ALDOSTERONE REGULATED SODIUM REABSORPTION 42 1 2.38% 0.34 0.14 0.24 0.32 0.12 0.24 0.33 0.37 0.34 0.11 0.19 0.10
PATHOGENIC ESCHERICHIA COLI INFECTION 59 3 5.08% 0.33 -0.09 0.17 0.23 -0.06 0.12 0.23 0.22 0.18 -0.21 -0.17 -0.24
JAK STAT SIGNALING PATHWAY 155 6 3.87% 0.33 0.07 0.14 0.24 -0.03 0.06 0.23 0.29 0.20 0.19 0.21 0.13
CITRATE CYCLE TCA CYCLE 32 0 0.00% 0.33 0.10 0.20 0.14 0.04 0.01 0.33 0.37 0.37 0.37 0.31 0.34
RENIN ANGIOTENSIN SYSTEM 17 0 0.00% 0.30 0.16 0.20 0.33 0.24 0.25 0.25 0.29 0.23 0.41 0.34 0.40
AMINO SUGAR AND NUCLEOTIDE SUGAR METABOLISM 44 0 0.00% 0.30 0.02 0.18 0.26 0.09 0.15 0.26 0.28 0.33 0.30 0.30 0.32
N GLYCAN BIOSYNTHESIS 46 0 0.00% 0.30 0.28 0.32 0.05 0.05 0.11 0.34 0.34 0.37 0.25 0.24 0.23
LIMONENE AND PINENE DEGRADATION 10 0 0.00% 0.30 0.01 0.11 0.06 -0.05 -0.03 0.01 -0.02 -0.04 0.11 0.02 0.08
NON SMALL CELL LUNG CANCER 54 9 16.67% 0.30 0.10 0.11 0.29 0.20 0.19 0.00 0.06 -0.03 0.06 -0.01 -0.04
NOTCH SIGNALING PATHWAY 47 4 8.51% 0.29 0.07 0.22 0.34 0.15 0.33 0.34 0.35 0.33 0.38 0.37 0.32
GALACTOSE METABOLISM 26 0 0.00% 0.28 -0.03 0.18 0.24 0.02 0.12 0.12 0.06 0.08 0.16 0.12 0.19
GAP JUNCTION 90 1 1.11% 0.28 0.00 0.15 0.43 0.29 0.35 0.25 0.32 0.25 -0.07 0.02 -0.04
RIBOFLAVIN METABOLISM 16 0 0.00% 0.27 0.04 0.21 0.27 0.14 0.21 0.18 0.20 0.22 -0.07 0.04 0.05
ALZHEIMERS DISEASE 169 1 0.59% 0.27 0.01 0.13 0.23 0.19 0.28 0.23 0.21 0.18 0.51 0.48 0.50
TOLL LIKE RECEPTOR SIGNALING PATHWAY 102 0 0.00% 0.27 -0.12 0.04 0.22 -0.15 0.03 0.22 0.15 0.20 0.25 0.12 0.22
ALPHA LINOLENIC ACID METABOLISM 19 0 0.00% 0.26 0.14 0.23 0.21 0.06 0.20 -0.16 -0.10 -0.17 -0.14 -0.13 -0.15
HEDGEHOG SIGNALING PATHWAY 56 1 1.79% 0.26 -0.03 0.13 0.38 0.16 0.26 0.08 0.12 0.03 -0.13 -0.05 -0.15
CARDIAC MUSCLE CONTRACTION 80 0 0.00% 0.25 0.34 0.28 0.35 0.14 0.31 -0.06 -0.03 -0.10 -0.18 -0.13 -0.21
NITROGEN METABOLISM 23 0 0.00% 0.25 0.22 0.28 0.35 0.07 0.27 0.41 0.39 0.43 0.33 0.41 0.34
FOCAL ADHESION 201 4 1.99% 0.25 0.35 0.23 0.28 0.34 0.29 0.26 0.34 0.26 0.00 -0.09 -0.05
RETINOL METABOLISM 64 0 0.00% 0.25 0.35 0.28 0.21 0.26 0.21 0.15 0.26 0.21 0.38 0.40 0.39
CYTOKINE CYTOKINE RECEPTOR INTERACTION 267 3 1.12% 0.25 -0.15 0.01 0.19 -0.16 0.02 0.17 0.23 0.13 0.18 0.23 0.12
CHEMOKINE SIGNALING PATHWAY 190 1 0.53% 0.25 -0.18 0.02 0.20 -0.16 0.01 0.13 0.21 0.11 0.18 0.06 0.14
SNARE INTERACTIONS IN VESICULAR TRANSPORT 38 0 0.00% 0.24 0.29 0.21 0.16 0.22 0.19 0.42 0.36 0.38 0.33 0.28 0.28
SYSTEMIC LUPUS ERYTHEMATOSUS 140 0 0.00% 0.22 0.10 0.20 0.14 0.06 0.11 0.38 0.32 0.31 0.14 0.12 0.13
LINOLEIC ACID METABOLISM 29 0 0.00% 0.22 -0.02 0.16 0.12 -0.02 0.11 0.04 0.08 0.03 -0.12 -0.14 -0.17
LONG TERM DEPRESSION 70 0 0.00% 0.20 0.07 0.07 -0.06 0.17 0.02 0.02 0.10 0.03 0.01 0.03 -0.03
OXIDATIVE PHOSPHORYLATION 135 0 0.00% 0.20 0.23 0.25 0.18 0.16 0.24 0.20 0.18 0.16 0.03 0.05 -0.02
DRUG METABOLISM OTHER ENZYMES 51 0 0.00% 0.20 0.19 0.24 0.37 0.21 0.28 0.48 0.43 0.42 0.48 0.43 0.44
B CELL RECEPTOR SIGNALING PATHWAY 75 1 1.33% 0.19 -0.13 -0.04 0.14 -0.14 -0.04 0.06 0.12 0.03 -0.10 -0.14 -0.13
TIGHT JUNCTION 134 1 0.75% 0.19 0.40 0.26 0.28 0.36 0.30 0.24 0.29 0.23 0.18 0.10 0.08
LEUKOCYTE TRANSENDOTHELIAL MIGRATION 118 0 0.00% 0.19 0.23 0.13 0.23 0.02 0.08 0.16 0.25 0.16 0.36 0.45 0.34
T CELL RECEPTOR SIGNALING PATHWAY 108 2 1.85% 0.19 -0.18 -0.06 0.13 -0.19 -0.06 0.02 0.08 0.00 0.04 -0.07 0.02
TGF BETA SIGNALING PATHWAY 86 19 22.09% 0.18 0.29 0.16 0.21 0.31 0.21 0.26 0.29 0.27 -0.04 -0.11 -0.11
GLYCOSAMINOGLYCAN DEGRADATION 21 0 0.00% 0.17 -0.13 0.11 0.11 -0.11 0.05 0.14 0.03 0.07 0.28 0.12 0.19
FC GAMMA R MEDIATED PHAGOCYTOSIS 97 0 0.00% 0.17 -0.22 -0.01 0.18 0.10 0.08 0.05 0.12 0.01 -0.12 -0.06 -0.16
ASCORBATE AND ALDARATE METABOLISM 25 0 0.00% 0.16 0.12 0.12 0.20 0.12 0.15 0.22 0.20 0.22 -0.13 -0.10 -0.12
MATURITY ONSET DIABETES OF THE YOUNG 25 0 0.00% 0.15 0.07 0.11 0.20 0.09 0.12 0.09 0.02 0.04 0.27 0.25 0.28
NICOTINATE AND NICOTINAMIDE METABOLISM 24 0 0.00% 0.14 -0.04 -0.03 0.15 -0.06 0.05 0.40 0.33 0.39 0.13 0.14 0.11
ADIPOCYTOKINE SIGNALING PATHWAY 67 0 0.00% 0.14 0.35 0.26 0.37 0.32 0.31 0.19 0.22 0.16 0.05 0.15 0.05
ERBB SIGNALING PATHWAY 87 5 5.75% 0.14 0.20 0.10 0.11 0.28 0.16 -0.04 0.00 -0.06 0.09 0.04 -0.01
MTOR SIGNALING PATHWAY 52 0 0.00% 0.14 0.27 0.12 0.16 0.29 0.15 0.16 0.23 0.18 0.44 0.48 0.44
RIG I LIKE RECEPTOR SIGNALING PATHWAY 71 0 0.00% 0.14 0.05 0.05 0.17 0.07 0.05 0.01 -0.01 0.04 -0.07 -0.11 -0.04
RIBOSOME 88 0 0.00% 0.13 0.10 0.18 -0.04 -0.07 0.01 0.08 0.13 0.09 0.18 0.23 0.20
NATURAL KILLER CELL MEDIATED CYTOTOXICITY 137 0 0.00% 0.12 -0.27 -0.10 0.07 -0.26 -0.10 0.01 0.10 -0.02 0.47 0.34 0.36
PORPHYRIN AND CHLOROPHYLL METABOLISM 41 0 0.00% 0.12 0.09 0.18 0.23 0.19 0.26 0.18 0.18 0.23 -0.02 0.04 0.03
MAPK SIGNALING PATHWAY 267 9 3.37% 0.11 0.27 0.08 0.38 0.17 0.24 0.27 0.33 0.25 0.50 0.52 0.48
ACUTE MYELOID LEUKEMIA 60 3 5.00% 0.11 0.29 0.12 0.06 0.21 0.09 0.09 0.06 -0.01 0.24 0.23 0.15
PRIMARY IMMUNODEFICIENCY 35 0 0.00% 0.11 -0.27 -0.11 0.02 -0.31 -0.15 0.00 -0.06 0.06 0.04 -0.06 0.08
PROTEIN EXPORT 24 0 0.00% 0.10 0.07 0.09 0.19 0.03 0.16 0.33 0.24 0.27 0.39 0.32 0.35
EPITHELIAL CELL SIGNALING IN HELICOBACTER PYLORI INFECTION 68 0 0.00% 0.10 0.38 0.23 0.17 0.17 0.12 0.00 0.06 -0.02 -0.16 -0.10 -0.18
BIOSYNTHESIS OF UNSATURATED FATTY ACIDS 22 0 0.00% 0.10 0.14 0.07 0.03 0.05 -0.02 -0.22 -0.17 -0.25 0.08 0.00 -0.01
PENTOSE AND GLUCURONATE INTERCONVERSIONS 28 0 0.00% 0.10 0.23 0.19 0.28 0.32 0.29 0.31 0.30 0.30 0.27 0.27 0.27
GLYCOSPHINGOLIPID BIOSYNTHESIS GANGLIO SERIES 15 0 0.00% 0.09 0.04 0.11 0.09 0.04 0.12 0.35 0.33 0.33 -0.07 -0.07 -0.09
ANTIGEN PROCESSING AND PRESENTATION 89 0 0.00% 0.09 -0.26 -0.09 0.01 -0.30 -0.15 0.28 0.21 0.29 -0.06 -0.13 -0.03
CYTOSOLIC DNA SENSING PATHWAY 56 0 0.00% 0.09 -0.17 -0.03 0.09 -0.06 0.00 0.38 0.35 0.40 0.22 0.18 0.22
CELL ADHESION MOLECULES CAMS 134 0 0.00% 0.08 -0.26 -0.10 0.05 -0.26 -0.10 0.19 0.24 0.14 -0.01 -0.07 -0.02
ALANINE ASPARTATE AND GLUTAMATE METABOLISM 32 0 0.00% 0.08 -0.03 0.06 0.23 0.06 0.13 0.49 0.43 0.47 0.26 0.24 0.30
DORSO VENTRAL AXIS FORMATION 25 0 0.00% 0.08 0.36 0.16 0.09 0.31 0.19 0.03 0.08 0.01 -0.06 0.00 -0.08
GLYCOSPHINGOLIPID BIOSYNTHESIS LACTO AND NEOLACTO SERIES 26 0 0.00% 0.08 0.01 0.10 0.14 0.03 0.12 -0.08 -0.04 -0.14 -0.07 -0.03 -0.11













AXON GUIDANCE 129 2 1.55% 0.08 0.37 0.15 0.11 0.32 0.20 0.21 0.27 0.19 0.13 0.19 0.11
INOSITOL PHOSPHATE METABOLISM 54 0 0.00% 0.08 0.37 0.21 0.06 0.32 0.19 0.04 0.08 0.01 0.00 0.07 -0.04
GLYCOSAMINOGLYCAN BIOSYNTHESIS CHONDROITIN SULFATE 22 0 0.00% 0.07 0.21 0.08 0.07 0.17 0.06 -0.14 -0.15 -0.12 0.01 0.04 -0.04
HYPERTROPHIC CARDIOMYOPATHY HCM 85 3 3.53% 0.07 0.36 0.14 0.30 0.30 0.29 0.30 0.34 0.30 -0.03 0.01 -0.05
GLYCEROLIPID METABOLISM 49 0 0.00% 0.07 0.35 0.14 0.15 0.31 0.18 0.09 0.14 0.07 0.01 0.07 0.00
BUTANOATE METABOLISM 34 0 0.00% 0.06 -0.04 0.04 -0.10 0.05 -0.05 0.42 0.34 0.35 0.46 0.36 0.40
ABC TRANSPORTERS 44 0 0.00% 0.06 0.23 0.16 0.19 0.18 0.11 0.47 0.48 0.49 0.19 0.20 0.17
METABOLISM OF XENOBIOTICS BY CYTOCHROME P450 70 0 0.00% 0.06 0.28 0.17 -0.14 0.09 -0.05 0.20 0.26 0.20 -0.10 -0.07 -0.15
GRAFT VERSUS HOST DISEASE 42 0 0.00% 0.05 -0.28 -0.12 0.00 -0.32 -0.16 0.10 0.14 0.11 0.30 0.29 0.24
SULFUR METABOLISM 13 0 0.00% 0.05 0.19 0.24 0.08 0.07 0.17 0.25 0.18 0.23 0.21 0.20 0.29
HEMATOPOIETIC CELL LINEAGE 88 0 0.00% 0.05 -0.31 -0.15 0.03 -0.29 -0.14 0.19 0.23 0.12 0.20 0.22 0.13
ALLOGRAFT REJECTION 38 0 0.00% 0.04 -0.28 -0.13 -0.02 -0.33 -0.17 0.12 0.17 0.15 0.03 0.11 -0.02
ETHER LIPID METABOLISM 33 0 0.00% 0.04 0.28 0.10 0.13 0.28 0.20 0.03 0.10 0.02 -0.06 -0.03 -0.08
VIRAL MYOCARDITIS 73 2 2.74% 0.04 -0.30 -0.13 0.00 -0.30 -0.14 0.23 0.26 0.16 0.13 0.05 0.14
GLYCOSAMINOGLYCAN BIOSYNTHESIS KERATAN SULFATE 15 0 0.00% 0.03 0.02 0.04 0.15 0.07 0.14 0.02 0.02 0.01 -0.29 -0.21 -0.26
ADHERENS JUNCTION 75 5 6.67% 0.03 0.38 0.16 0.14 0.34 0.20 0.33 0.38 0.36 0.07 -0.01 -0.04
INTESTINAL IMMUNE NETWORK FOR IGA PRODUCTION 48 1 2.08% 0.03 -0.29 -0.13 -0.03 -0.34 -0.18 0.41 0.38 0.37 0.13 0.22 0.08
GLYCOSAMINOGLYCAN BIOSYNTHESIS HEPARAN SULFATE 26 0 0.00% 0.03 0.12 0.03 0.19 -0.08 0.09 0.02 -0.01 -0.04 0.15 0.02 0.05
TYPE I DIABETES MELLITUS 44 0 0.00% 0.02 -0.27 -0.13 0.01 -0.32 -0.15 -0.02 -0.07 0.04 0.11 0.09 0.18
ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY ARVC 76 0 0.00% 0.01 0.17 0.01 0.10 0.21 0.11 0.20 0.24 0.28 -0.06 -0.01 -0.08
ENDOMETRIAL CANCER 52 4 7.69% 0.01 0.14 -0.01 0.02 0.15 0.04 0.00 0.00 -0.08 -0.03 0.00 -0.07
OTHER GLYCAN DEGRADATION 16 0 0.00% 0.01 0.00 0.04 0.04 0.16 0.13 -0.15 -0.15 -0.14 0.00 0.05 0.08
TASTE TRANSDUCTION 52 0 0.00% 0.00 0.21 0.10 0.12 0.19 0.17 0.09 0.12 0.08 -0.20 -0.13 -0.16
VEGF SIGNALING PATHWAY 76 0 0.00% 0.00 0.24 0.07 0.05 0.31 0.17 -0.12 -0.04 -0.13 -0.03 0.02 -0.08
DRUG METABOLISM CYTOCHROME P450 72 0 0.00% 0.00 0.28 0.14 0.08 0.27 0.15 0.34 0.35 0.29 0.06 0.08 0.01
LEISHMANIA INFECTION 72 3 4.17% 0.00 -0.30 -0.13 -0.03 -0.29 -0.15 0.18 0.19 0.20 0.25 0.24 0.29
VASCULAR SMOOTH MUSCLE CONTRACTION 115 0 0.00% 0.00 0.29 0.09 0.11 0.31 0.18 0.25 0.31 0.24 -0.13 -0.05 -0.15
THYROID CANCER 29 3 10.34% -0.02 0.23 0.02 -0.02 0.16 0.01 0.05 0.01 -0.04 0.10 0.06 -0.02
REGULATION OF AUTOPHAGY 35 0 0.00% -0.03 0.05 -0.04 0.03 0.10 0.02 0.06 0.06 0.06 -0.06 -0.06 -0.06
NEUROACTIVE LIGAND RECEPTOR INTERACTION 272 0 0.00% -0.03 0.35 0.13 0.18 0.37 0.26 0.56 0.55 0.54 0.02 0.09 -0.01
BASAL CELL CARCINOMA 55 2 3.64% -0.03 0.29 0.09 0.03 0.20 0.06 0.04 0.05 -0.02 -0.02 0.00 -0.05
OLFACTORY TRANSDUCTION 389 0 0.00% -0.03 -0.01 0.04 -0.09 -0.08 -0.08 0.31 0.27 0.25 0.43 0.35 0.38
STARCH AND SUCROSE METABOLISM 52 0 0.00% -0.03 0.04 0.02 -0.01 0.10 0.07 -0.07 -0.13 -0.13 -0.01 -0.09 -0.08
LONG TERM POTENTIATION 70 2 2.86% -0.04 0.28 0.08 0.06 0.27 0.15 0.06 0.14 0.06 0.35 0.40 0.39
PHOSPHATIDYLINOSITOL SIGNALING SYSTEM 76 0 0.00% -0.04 0.31 0.11 0.08 0.33 0.19 0.09 0.14 0.07 0.01 0.08 -0.05
INSULIN SIGNALING PATHWAY 137 1 0.73% -0.04 0.18 0.00 0.07 0.24 0.12 0.04 0.11 0.07 0.13 0.23 0.15
GLYCEROPHOSPHOLIPID METABOLISM 77 0 0.00% -0.04 0.23 0.12 0.04 0.21 0.17 -0.05 0.01 -0.06 -0.14 -0.12 -0.18
GLYCOSPHINGOLIPID BIOSYNTHESIS GLOBO SERIES 14 0 0.00% -0.05 0.10 0.03 0.03 0.10 0.07 0.12 0.07 0.07 0.10 0.04 0.02
ECM RECEPTOR INTERACTION 84 0 0.00% -0.05 -0.04 0.04 0.05 0.02 0.06 0.30 0.30 0.25 -0.06 -0.15 -0.09
FC EPSILON RI SIGNALING PATHWAY 79 0 0.00% -0.05 0.34 0.14 0.34 0.23 0.36 0.12 0.11 0.16 -0.03 -0.03 -0.11
PRION DISEASES 35 0 0.00% -0.05 0.29 0.08 0.08 0.29 0.15 0.12 0.21 0.11 0.07 0.11 0.05
RENAL CELL CARCINOMA 70 6 8.57% -0.06 0.28 0.03 0.05 0.29 0.14 0.11 0.16 0.11 -0.02 0.07 -0.02
STEROID HORMONE BIOSYNTHESIS 55 0 0.00% -0.06 0.07 0.08 0.02 0.09 0.08 -0.10 0.00 -0.09 -0.01 0.01 0.03
ASTHMA 30 0 0.00% -0.06 -0.33 -0.18 -0.12 -0.38 -0.24 -0.16 -0.20 -0.08 0.08 0.17 0.03
TAURINE AND HYPOTAURINE METABOLISM 10 0 0.00% -0.07 -0.07 -0.01 0.04 -0.02 0.01 0.09 0.13 0.15 0.19 0.18 0.13
PANTOTHENATE AND COA BIOSYNTHESIS 16 0 0.00% -0.08 0.23 0.04 -0.04 0.22 0.03 0.12 0.15 0.05 -0.20 -0.10 -0.13
PROXIMAL TUBULE BICARBONATE RECLAMATION 23 0 0.00% -0.08 0.17 0.09 0.34 0.09 0.23 0.43 0.41 0.44 0.20 0.28 0.22
SPHINGOLIPID METABOLISM 40 0 0.00% -0.08 0.26 0.05 -0.05 0.20 0.05 0.29 0.30 0.27 0.04 0.18 0.19
ENDOCYTOSIS 183 1 0.55% -0.09 0.32 0.09 0.03 0.27 0.13 -0.03 0.04 -0.03 -0.13 -0.08 -0.16
GNRH SIGNALING PATHWAY 101 0 0.00% -0.09 0.30 0.06 -0.03 0.18 0.08 -0.04 0.01 -0.08 -0.10 -0.07 -0.13
NOD LIKE RECEPTOR SIGNALING PATHWAY 62 0 0.00% -0.12 -0.14 -0.07 -0.07 -0.16 -0.07 0.04 0.11 0.02 0.12 0.18 0.05
PRIMARY BILE ACID BIOSYNTHESIS 16 0 0.00% -0.13 0.08 -0.01 0.34 0.26 0.30 -0.18 -0.16 -0.20 -0.03 -0.03 -0.06
BASAL TRANSCRIPTION FACTORS 36 0 0.00% -0.13 0.08 -0.08 -0.06 0.09 -0.01 0.31 0.28 0.32 0.12 0.16 0.12
GLYCOSYLPHOSPHATIDYLINOSITOL GPI ANCHOR BIOSYNTHESIS 25 0 0.00% -0.13 0.20 0.07 -0.10 -0.01 0.00 -0.12 -0.03 -0.09 -0.21 -0.03 -0.13
CALCIUM SIGNALING PATHWAY 178 0 0.00% -0.13 0.30 0.04 0.01 0.27 0.13 0.19 0.25 0.16 -0.14 -0.02 -0.13
COMPLEMENT AND COAGULATION CASCADES 69 0 0.00% -0.14 0.24 0.06 0.05 0.30 0.19 0.30 0.37 0.28 0.19 0.28 0.20
HUNTINGTONS DISEASE 185 5 2.70% -0.14 0.17 -0.04 0.28 0.15 0.30 0.27 0.25 0.24 -0.15 -0.15 -0.18
DILATED CARDIOMYOPATHY 92 3 3.26% -0.15 0.20 0.01 0.22 0.00 0.11 0.29 0.33 0.28 -0.05 0.01 -0.05
VASOPRESSIN REGULATED WATER REABSORPTION 44 0 0.00% -0.15 0.00 0.00 -0.13 0.15 -0.02 -0.27 -0.13 -0.18 -0.20 -0.13 -0.11
WNT SIGNALING PATHWAY 151 15 9.93% -0.16 0.03 0.00 0.11 0.31 0.17 -0.06 0.00 -0.08 0.05 0.04 -0.01
BETA ALANINE METABOLISM 22 0 0.00% -0.18 0.00 -0.04 0.09 0.03 0.03 0.42 0.39 0.36 0.14 0.18 0.17
MELANOGENESIS 102 3 2.94% -0.18 0.18 -0.01 -0.04 0.22 0.06 -0.03 0.02 -0.08 -0.15 -0.08 -0.11
VALINE LEUCINE AND ISOLEUCINE BIOSYNTHESIS 11 0 0.00% -0.19 0.14 -0.02 0.00 0.17 0.05 0.21 0.24 0.22 -0.15 0.00 0.00


























No. of breaks GII No. of amplified/deleted genes No. of breaks GII No. of amplified/deleted genes No. of breaks GII No. of amplified/deleted genes No. of breaks GII No. of amplified/deleted genes
CELL CYCLE 421 421 100.00% 0.65 0.32 0.45 0.59 0.36 0.50 0.63 0.57 0.59 0.57 0.52 0.52
CELL CYCLE MITOTIC 325 325 100.00% 0.64 0.32 0.45 0.62 0.36 0.51 0.65 0.59 0.61 0.57 0.52 0.52
MITOTIC G2 G2 M PHASES 81 81 100.00% 0.64 0.33 0.44 0.56 0.36 0.48 0.59 0.50 0.53 0.57 0.52 0.53
LOSS OF NLP FROM MITOTIC CENTROSOMES 59 59 100.00% 0.64 0.33 0.46 0.33 0.28 0.26 0.64 0.57 0.59 0.55 0.48 0.54
DNA REPLICATION 192 192 100.00% 0.64 0.31 0.44 0.62 0.36 0.51 0.65 0.59 0.61 0.57 0.52 0.52
MITOTIC M M G1 PHASES 172 172 100.00% 0.64 0.31 0.44 0.62 0.35 0.50 0.65 0.58 0.60 0.57 0.51 0.51
MITOTIC PROMETAPHASE 87 87 100.00% 0.64 0.33 0.44 0.60 0.36 0.50 0.63 0.58 0.59 0.55 0.50 0.50
RECRUITMENT OF MITOTIC CENTROSOME PROTEINS AND COMPLEXES 66 66 100.00% 0.63 0.32 0.47 0.27 0.10 0.27 0.43 0.38 0.41 0.54 0.51 0.53
CELL CYCLE CHECKPOINTS 124 124 100.00% 0.63 0.29 0.44 0.49 0.24 0.41 0.52 0.45 0.50 0.58 0.53 0.53
MHC CLASS II ANTIGEN PRESENTATION 91 14 15.38% 0.63 0.26 0.43 0.41 0.13 0.30 0.39 0.35 0.40 0.55 0.49 0.49
SIGNALING BY SCF KIT 78 5 6.41% 0.62 0.35 0.48 0.31 0.08 0.16 0.09 0.12 0.06 0.46 0.38 0.41
FACTORS INVOLVED IN MEGAKARYOCYTE DEVELOPMENT AND PLATELET PRODUCTION 132 13 9.85% 0.62 0.32 0.44 0.62 0.38 0.51 0.32 0.34 0.34 0.56 0.51 0.50
INHIBITION OF THE PROTEOLYTIC ACTIVITY OF APC C REQUIRED FOR THE ONSET OF ANAPHASE BY MITOTIC SPINDLE CHECKPOINT COMPONENTS 24 24 100.00% 0.62 0.31 0.46 0.53 0.27 0.45 0.46 0.42 0.40 0.57 0.49 0.50
REGULATION OF MITOTIC CELL CYCLE 85 85 100.00% 0.62 0.25 0.44 0.48 0.20 0.38 0.51 0.41 0.47 0.59 0.50 0.52
APC CDC20 MEDIATED DEGRADATION OF NEK2A 28 28 100.00% 0.62 0.35 0.48 0.56 0.34 0.49 0.37 0.31 0.32 0.56 0.49 0.51
MITOTIC G1 G1 S PHASES 137 137 100.00% 0.62 0.29 0.43 0.61 0.33 0.49 0.59 0.54 0.57 0.56 0.52 0.53
KINESINS 24 6 25.00% 0.62 0.34 0.43 0.60 0.39 0.51 0.56 0.53 0.51 0.54 0.49 0.47
CYCLIN A B1 ASSOCIATED EVENTS DURING G2 M TRANSITION 15 15 100.00% 0.61 0.33 0.42 0.60 0.38 0.50 0.59 0.54 0.57 0.56 0.50 0.50
G0 AND EARLY G1 25 25 100.00% 0.61 0.30 0.42 0.60 0.34 0.49 0.60 0.55 0.56 0.56 0.51 0.53
METABOLISM OF NUCLEOTIDES 72 3 4.17% 0.61 0.29 0.44 0.46 0.23 0.38 0.41 0.34 0.36 0.53 0.47 0.47
HIV LIFE CYCLE 125 17 13.60% 0.61 0.32 0.44 -0.08 0.03 0.03 0.36 0.33 0.34 0.57 0.54 0.54
G2 M CHECKPOINTS 45 45 100.00% 0.60 0.32 0.41 0.57 0.38 0.49 0.58 0.56 0.56 0.56 0.53 0.52
SYNTHESIS OF DNA 92 92 100.00% 0.60 0.28 0.43 0.57 0.30 0.46 0.60 0.53 0.56 0.57 0.55 0.55
E2F MEDIATED REGULATION OF DNA REPLICATION 35 35 100.00% 0.60 0.28 0.41 0.55 0.33 0.45 0.59 0.56 0.56 0.52 0.49 0.47
APC C CDH1 MEDIATED DEGRADATION OF CDC20 AND OTHER APC C CDH1 TARGETED PROTEINS IN LATE MITOSIS EARLY G1 72 72 100.00% 0.60 0.22 0.42 0.44 0.16 0.35 0.48 0.38 0.44 0.60 0.49 0.53
G1 S SPECIFIC TRANSCRIPTION 19 19 100.00% 0.59 0.25 0.39 0.58 0.30 0.44 0.60 0.55 0.55 0.52 0.47 0.46
ACTIVATION OF ATR IN RESPONSE TO REPLICATION STRESS 38 38 100.00% 0.59 0.31 0.39 0.55 0.37 0.47 0.58 0.56 0.56 0.55 0.53 0.52
APC C CDC20 MEDIATED DEGRADATION OF CYCLIN B 26 26 100.00% 0.59 0.33 0.44 0.46 0.32 0.42 0.39 0.34 0.35 0.56 0.49 0.51
M G1 TRANSITION 81 81 100.00% 0.59 0.25 0.40 0.56 0.27 0.43 0.44 0.37 0.43 0.56 0.52 0.52
DNA REPAIR 112 29 25.89% 0.58 0.39 0.51 0.01 0.15 0.04 0.37 0.34 0.35 0.52 0.53 0.52
SLC MEDIATED TRANSMEMBRANE TRANSPORT 241 7 2.90% 0.58 0.20 0.36 0.23 0.30 0.23 -0.23 -0.17 -0.26 -0.01 -0.03 -0.10
ASSEMBLY OF THE PRE REPLICATIVE COMPLEX 65 65 100.00% 0.58 0.22 0.38 0.52 0.21 0.39 0.58 0.44 0.50 0.57 0.51 0.52
G2 M DNA DAMAGE CHECKPOINT 12 12 100.00% 0.57 0.38 0.47 0.57 0.43 0.54 0.54 0.50 0.52 0.51 0.50 0.49
G1 PHASE 38 38 100.00% 0.57 0.27 0.36 0.48 0.31 0.37 0.54 0.50 0.50 0.51 0.44 0.46
ASSOCIATION OF LICENSING FACTORS WITH THE PRE REPLICATIVE COMPLEX 14 14 100.00% 0.57 0.25 0.37 0.54 0.30 0.40 0.58 0.54 0.55 0.53 0.50 0.49
FANCONI ANEMIA PATHWAY 25 9 36.00% 0.56 0.46 0.48 0.53 0.42 0.50 0.43 0.47 0.45 0.48 0.50 0.49
RNA POL II TRANSCRIPTION 105 3 2.86% 0.56 0.37 0.49 0.47 0.31 0.43 0.40 0.36 0.40 0.56 0.54 0.56
APC C CDC20 MEDIATED DEGRADATION OF MITOTIC PROTEINS 73 73 100.00% 0.56 0.19 0.38 0.20 0.17 0.13 0.53 0.41 0.47 0.57 0.48 0.51
APOPTOSIS 148 53 35.81% 0.56 0.19 0.41 0.20 0.13 0.09 0.48 0.41 0.46 0.52 0.39 0.44
ACTIVATION OF THE PRE REPLICATIVE COMPLEX 31 31 100.00% 0.56 0.30 0.37 0.55 0.36 0.45 0.56 0.54 0.54 0.56 0.53 0.53
PHOSPHORYLATION OF THE APC C 23 23 100.00% 0.56 0.35 0.44 0.53 0.34 0.47 0.47 0.43 0.43 0.56 0.51 0.51
DEADENYLATION DEPENDENT MRNA DECAY 48 0 0.00% 0.56 0.33 0.49 0.53 0.40 0.49 0.38 0.36 0.37 0.42 0.33 0.33
LATE PHASE OF HIV LIFE CYCLE 104 15 14.42% 0.56 0.23 0.39 0.50 0.31 0.40 0.35 0.32 0.34 0.55 0.56 0.56
GLUCOSE TRANSPORT 38 7 18.42% 0.55 0.26 0.38 0.48 0.25 0.35 0.50 0.46 0.51 0.48 0.50 0.52
SIGNALLING BY NGF 217 19 8.76% 0.55 0.18 0.36 0.35 0.26 0.28 0.42 0.41 0.43 0.40 0.40 0.36
DNA STRAND ELONGATION 30 30 100.00% 0.55 0.32 0.39 0.52 0.36 0.45 0.56 0.56 0.55 0.52 0.56 0.54
EXTENSION OF TELOMERES 27 27 100.00% 0.55 0.36 0.45 0.47 0.35 0.48 0.52 0.55 0.54 0.45 0.52 0.49
CYCLIN E ASSOCIATED EVENTS DURING G1 S TRANSITION 65 65 100.00% 0.55 0.19 0.39 0.46 0.19 0.37 0.51 0.43 0.49 0.57 0.47 0.50
G1 S TRANSITION 112 112 100.00% 0.55 0.27 0.36 0.52 0.26 0.42 0.62 0.55 0.58 0.57 0.52 0.52
HEMOSTASIS 466 23 4.94% 0.54 0.22 0.33 0.39 0.10 0.22 0.26 0.34 0.26 0.57 0.50 0.53
E2F ENABLED INHIBITION OF PRE REPLICATION COMPLEX FORMATION 10 10 100.00% 0.54 0.32 0.39 0.51 0.36 0.45 0.57 0.55 0.55 0.49 0.49 0.49
PROTEIN FOLDING 53 4 7.55% 0.53 0.37 0.50 0.43 0.27 0.42 0.50 0.43 0.48 0.60 0.50 0.55
INTERACTIONS OF VPR WITH HOST CELLULAR PROTEINS 33 7 21.21% 0.53 0.17 0.36 0.46 0.21 0.34 0.49 0.44 0.47 0.48 0.49 0.51
LAGGING STRAND SYNTHESIS 19 19 100.00% 0.53 0.33 0.42 0.51 0.36 0.49 0.51 0.54 0.53 0.44 0.51 0.49
ANTIGEN PROCESSING UBIQUITINATION PROTEASOME DEGRADATION 212 71 33.49% 0.53 0.19 0.38 0.48 0.23 0.32 0.42 0.37 0.42 0.11 0.13 0.08
TRANSPORT OF RIBONUCLEOPROTEINS INTO THE HOST NUCLEUS 27 7 25.93% 0.52 0.21 0.37 0.48 0.23 0.38 0.38 0.28 0.32 0.47 0.50 0.51
GLOBAL GENOMIC NER GG NER 35 18 51.43% 0.52 0.38 0.48 0.40 0.29 0.42 0.42 0.43 0.44 0.44 0.54 0.49
APOPTOTIC CLEAVAGE OF CELLULAR PROTEINS 40 2 5.00% 0.52 0.16 0.33 0.46 0.20 0.36 0.00 0.04 -0.03 0.35 0.30 0.31
CHROMOSOME MAINTENANCE 122 122 100.00% 0.52 0.34 0.42 0.41 0.31 0.37 0.25 0.20 0.21 0.42 0.37 0.37
RECYCLING PATHWAY OF L1 27 0 0.00% 0.52 0.32 0.38 0.42 0.31 0.32 0.24 0.28 0.22 0.52 0.44 0.41
NUCLEOTIDE EXCISION REPAIR 51 18 35.29% 0.52 0.33 0.48 0.44 0.29 0.44 0.42 0.42 0.42 0.48 0.54 0.51
CDC6 ASSOCIATION WITH THE ORC ORIGIN COMPLEX 11 11 100.00% 0.52 0.18 0.31 0.25 0.14 0.24 0.58 0.56 0.57 0.53 0.50 0.49
MICRORNA MIRNA BIOGENESIS 23 0 0.00% 0.52 0.19 0.38 0.42 0.24 0.35 0.34 0.34 0.34 0.54 0.54 0.56
PREFOLDIN MEDIATED TRANSFER OF SUBSTRATE TO CCT TRIC 28 4 14.29% 0.52 0.29 0.43 0.47 0.22 0.40 0.63 0.53 0.57 0.55 0.48 0.51
TRANSPORT OF MATURE MRNA DERIVED FROM AN INTRONLESS TRANSCRIPT 33 7 21.21% 0.52 0.20 0.38 0.44 0.22 0.39 0.48 0.46 0.47 0.50 0.50 0.51
TRANSCRIPTIONAL REGULATION OF WHITE ADIPOCYTE DIFFERENTIATION 72 2 2.78% 0.52 0.24 0.36 0.03 0.20 0.06 0.29 0.28 0.31 0.22 0.19 0.17
REGULATION OF GLUCOKINASE BY GLUCOKINASE REGULATORY PROTEIN 27 7 25.93% 0.51 0.20 0.36 0.45 0.20 0.36 0.45 0.45 0.46 0.48 0.51 0.51
UNWINDING OF DNA 11 11 100.00% 0.51 0.27 0.32 0.52 0.34 0.41 0.55 0.53 0.52 0.52 0.53 0.52
MRNA SPLICING 111 1 0.90% 0.51 0.30 0.47 0.32 0.11 0.30 0.47 0.41 0.44 0.58 0.53 0.54
METABOLISM OF CARBOHYDRATES 247 14 5.67% 0.51 0.26 0.34 0.44 0.30 0.35 0.21 0.26 0.20 0.55 0.49 0.51
POL SWITCHING 13 13 100.00% 0.51 0.34 0.43 0.48 0.35 0.48 0.53 0.54 0.53 0.42 0.50 0.48
GLUCOSE METABOLISM 69 7 10.14% 0.51 0.24 0.36 -0.05 0.13 0.01 0.44 0.44 0.45 0.41 0.39 0.40
SYNTHESIS AND INTERCONVERSION OF NUCLEOTIDE DI AND TRIPHOSPHATES 19 1 5.26% 0.51 0.25 0.42 0.38 0.19 0.32 0.37 0.32 0.34 0.50 0.41 0.41
ORC1 REMOVAL FROM CHROMATIN 67 67 100.00% 0.51 0.13 0.34 0.17 0.16 0.10 0.51 0.41 0.47 0.56 0.45 0.48
REGULATION OF MRNA STABILITY BY PROTEINS THAT BIND AU RICH ELEMENTS 84 47 55.95% 0.51 0.17 0.35 0.32 0.26 0.24 0.46 0.37 0.42 0.45 0.36 0.39
METABRIC Validation Cohort TCGA RNA-seq Cohort TCGA Microarray Cohort
Correlations between the Pathifier score of each Reactome pathway and three CIN measurements in the four breast cancer cohorts
Note: 
1. Overlap = length of the overlap with the CELL CYCLE pathway in Reactome
2. Percentage = percentage of the overlap with the CELL CYCLE pathway in Reactome














SIGNALING BY FGFR MUTANTS 44 2 4.55% 0.51 0.11 0.29 0.40 0.13 0.24 0.37 0.35 0.32 0.32 0.28 0.22
SCFSKP2 MEDIATED DEGRADATION OF P27 P21 56 56 100.00% 0.51 0.15 0.37 0.00 0.10 -0.03 0.50 0.41 0.47 0.58 0.49 0.51
PYRUVATE METABOLISM AND CITRIC ACID TCA CYCLE 48 0 0.00% 0.50 0.15 0.33 0.15 0.11 0.07 0.31 0.31 0.34 0.38 0.31 0.35
INFLUENZA LIFE CYCLE 203 13 6.40% 0.50 0.15 0.35 0.06 0.00 0.11 0.13 0.16 0.14 0.34 0.36 0.32
TRANSPORT OF MATURE TRANSCRIPT TO CYTOPLASM 54 7 12.96% 0.50 0.23 0.38 0.41 0.20 0.36 0.55 0.51 0.54 0.50 0.52 0.52
TRANSCRIPTION COUPLED NER TC NER 45 18 40.00% 0.50 0.34 0.47 0.42 0.28 0.43 0.40 0.41 0.41 0.49 0.54 0.51
PROCESSIVE SYNTHESIS ON THE LAGGING STRAND 15 15 100.00% 0.50 0.33 0.40 0.47 0.34 0.43 0.47 0.49 0.48 0.40 0.48 0.47
CHOLESTEROL BIOSYNTHESIS 24 0 0.00% 0.50 0.21 0.35 0.44 0.28 0.35 0.31 0.30 0.32 0.48 0.39 0.39
CYTOSOLIC TRNA AMINOACYLATION 24 0 0.00% 0.50 0.13 0.31 0.47 0.16 0.32 0.54 0.44 0.49 0.42 0.33 0.38
REMOVAL OF THE FLAP INTERMEDIATE FROM THE C STRAND 10 10 100.00% 0.49 0.29 0.36 0.46 0.31 0.44 0.31 0.34 0.33 0.42 0.50 0.50
CLASS B 2 SECRETIN FAMILY RECEPTORS 88 0 0.00% 0.49 0.15 0.31 0.40 0.25 0.31 -0.08 -0.09 -0.09 0.06 0.04 0.02
IRON UPTAKE AND TRANSPORT 36 0 0.00% 0.49 0.29 0.41 0.34 0.23 0.27 0.35 0.35 0.29 0.48 0.47 0.45
TRANSMEMBRANE TRANSPORT OF SMALL MOLECULES 413 10 2.42% 0.49 0.35 0.39 0.42 0.19 0.30 0.29 0.32 0.27 0.48 0.43 0.42
HYALURONAN UPTAKE AND DEGRADATION 10 0 0.00% 0.49 0.33 0.41 0.43 0.31 0.40 0.32 0.33 0.29 0.43 0.39 0.39
PLATELET SENSITIZATION BY LDL 16 9 56.25% 0.49 0.17 0.25 0.42 0.16 0.26 -0.18 -0.11 -0.18 0.42 0.28 0.33
APOPTOTIC EXECUTION PHASE 54 2 3.70% 0.49 0.15 0.34 0.50 0.22 0.39 0.01 0.06 -0.01 -0.03 -0.05 -0.05
TRNA AMINOACYLATION 42 0 0.00% 0.49 0.15 0.32 0.49 0.23 0.37 0.52 0.46 0.49 0.40 0.40 0.45
FORMATION OF TUBULIN FOLDING INTERMEDIATES BY CCT TRIC 22 4 18.18% 0.49 0.26 0.37 0.49 0.27 0.42 0.62 0.52 0.56 0.54 0.47 0.51
METABOLISM OF AMINO ACIDS AND DERIVATIVES 200 43 21.50% 0.48 0.16 0.32 -0.01 0.16 0.06 0.51 0.42 0.48 0.57 0.42 0.49
MAP KINASE ACTIVATION IN TLR CASCADE 50 6 12.00% 0.48 0.20 0.32 0.37 0.16 0.22 0.33 0.33 0.33 0.41 0.31 0.35
PYRIMIDINE METABOLISM 24 2 8.33% 0.48 0.37 0.36 0.42 0.36 0.37 0.30 0.33 0.24 0.43 0.42 0.41
P53 DEPENDENT G1 DNA DAMAGE RESPONSE 57 57 100.00% 0.48 0.12 0.34 0.17 0.21 0.17 0.49 0.39 0.46 0.54 0.44 0.47
ANTIVIRAL MECHANISM BY IFN STIMULATED GENES 66 11 16.67% 0.48 0.10 0.28 0.48 0.19 0.32 0.06 0.05 0.10 0.54 0.47 0.51
NRAGE SIGNALS DEATH THROUGH JNK 43 0 0.00% 0.48 0.41 0.49 0.42 0.41 0.44 0.12 0.13 0.10 0.50 0.50 0.45
PROCESSING OF CAPPED INTRON CONTAINING PRE MRNA 140 8 5.71% 0.48 0.18 0.39 0.38 0.18 0.33 0.53 0.46 0.50 0.61 0.55 0.56
BASIGIN INTERACTIONS 30 0 0.00% 0.48 0.13 0.32 0.46 0.19 0.36 0.48 0.42 0.48 0.34 0.23 0.31
ELONGATION ARREST AND RECOVERY 32 0 0.00% 0.47 0.27 0.39 0.48 0.34 0.46 0.29 0.27 0.28 0.52 0.51 0.52
REGULATORY RNA PATHWAYS 26 0 0.00% 0.47 0.12 0.31 0.55 0.30 0.49 0.35 0.35 0.36 0.55 0.55 0.57
PLATELET HOMEOSTASIS 78 9 11.54% 0.47 0.23 0.28 0.43 0.24 0.30 0.31 0.36 0.29 0.46 0.42 0.43
REPAIR SYNTHESIS FOR GAP FILLING BY DNA POL IN TC NER 14 14 100.00% 0.47 0.30 0.40 0.44 0.32 0.46 0.50 0.52 0.51 0.42 0.49 0.46
HOST INTERACTIONS OF HIV FACTORS 132 59 44.70% 0.47 0.12 0.31 0.30 0.28 0.28 0.42 0.35 0.40 0.50 0.40 0.43
L1CAM INTERACTIONS 86 0 0.00% 0.47 0.42 0.39 0.40 0.30 0.32 0.26 0.31 0.25 0.25 0.30 0.21
BASE EXCISION REPAIR 19 7 36.84% 0.47 0.30 0.33 0.43 0.40 0.43 0.28 0.29 0.29 0.38 0.38 0.34
ABORTIVE ELONGATION OF HIV1 TRANSCRIPT IN THE ABSENCE OF TAT 23 0 0.00% 0.47 0.28 0.37 0.44 0.30 0.43 0.35 0.33 0.33 0.49 0.48 0.47
SCF BETA TRCP MEDIATED DEGRADATION OF EMI1 51 51 100.00% 0.46 0.08 0.30 0.22 0.14 0.12 0.53 0.38 0.45 0.51 0.37 0.44
NEP NS2 INTERACTS WITH THE CELLULAR EXPORT MACHINERY 27 8 29.63% 0.46 0.17 0.34 0.46 0.18 0.30 0.38 0.28 0.33 0.49 0.50 0.50
METABOLISM OF RNA 330 58 17.58% 0.46 0.16 0.37 0.19 0.06 0.21 0.40 0.34 0.38 0.50 0.47 0.46
HYALURONAN METABOLISM 14 0 0.00% 0.46 0.35 0.42 0.43 0.30 0.40 0.30 0.30 0.27 0.44 0.40 0.41
SIGNALING BY RHO GTPASES 113 0 0.00% 0.46 0.12 0.26 0.54 0.40 0.50 0.30 0.35 0.26 0.50 0.46 0.46
P53 INDEPENDENT G1 S DNA DAMAGE CHECKPOINT 51 51 100.00% 0.46 0.11 0.30 0.24 0.17 0.15 0.48 0.37 0.44 0.49 0.39 0.42
MRNA PROCESSING 161 11 6.83% 0.46 0.16 0.37 0.33 0.13 0.29 0.46 0.43 0.44 0.55 0.54 0.55
SIGNALING BY FGFR1 MUTANTS 30 2 6.67% 0.46 0.24 0.34 0.46 0.22 0.31 0.40 0.31 0.24 0.23 0.22 0.17
FORMATION OF RNA POL II ELONGATION COMPLEX 45 3 6.67% 0.46 0.25 0.38 0.41 0.32 0.44 0.34 0.34 0.34 0.49 0.52 0.51
EARLY PHASE OF HIV LIFE CYCLE 21 2 9.52% 0.46 0.16 0.26 0.49 0.23 0.38 0.41 0.37 0.40 0.34 0.40 0.37
ASSOCIATION OF TRIC CCT WITH TARGET PROTEINS DURING BIOSYNTHESIS 27 0 0.00% 0.46 0.29 0.40 0.31 0.17 0.31 0.62 0.54 0.58 0.52 0.51 0.53
MITOCHONDRIAL PROTEIN IMPORT 58 0 0.00% 0.46 0.25 0.32 0.23 0.25 0.30 0.41 0.37 0.39 0.43 0.40 0.39
METABOLISM OF POLYAMINES 15 0 0.00% 0.45 0.07 0.27 0.39 0.08 0.24 0.44 0.31 0.32 0.19 0.14 0.13
DOWNSTREAM SIGNALING EVENTS OF B CELL RECEPTOR BCR 97 52 53.61% 0.45 0.04 0.28 0.31 0.14 0.17 0.43 0.35 0.41 0.46 0.31 0.38
TRANSPORT OF GLUCOSE AND OTHER SUGARS BILE SALTS AND ORGANIC ACIDS METAL IONS AND AMINE COMPOUNDS 89 0 0.00% 0.45 0.16 0.29 0.39 0.19 0.30 -0.18 -0.15 -0.21 -0.16 -0.17 -0.17
S PHASE 109 109 100.00% 0.45 0.24 0.31 0.60 0.32 0.48 0.62 0.56 0.59 0.58 0.55 0.54
METABOLISM OF NON CODING RNA 49 7 14.29% 0.45 0.26 0.37 0.48 0.29 0.45 0.47 0.42 0.45 0.51 0.53 0.53
TRAF6 MEDIATED INDUCTION OF NFKB AND MAP KINASES UPON TLR7 8 OR 9 ACTIVATION 77 9 11.69% 0.45 0.14 0.27 0.34 0.15 0.21 0.39 0.37 0.37 0.08 0.12 0.06
SIGNALING BY GPCR 920 9 0.98% 0.45 0.10 0.23 0.29 -0.01 0.11 0.25 0.34 0.25 0.23 0.25 0.19
CDT1 ASSOCIATION WITH THE CDC6 ORC ORIGIN COMPLEX 56 56 100.00% 0.45 0.07 0.29 0.23 0.14 0.14 0.50 0.36 0.42 0.51 0.41 0.43
FORMATION OF THE HIV1 EARLY ELONGATION COMPLEX 34 3 8.82% 0.44 0.25 0.35 0.12 0.14 0.08 0.36 0.35 0.35 0.51 0.53 0.53
PURINE METABOLISM 33 0 0.00% 0.44 0.17 0.30 0.39 0.15 0.30 0.52 0.46 0.49 0.48 0.44 0.46
CLASS I MHC MEDIATED ANTIGEN PROCESSING PRESENTATION 251 72 28.69% 0.44 0.06 0.27 0.30 0.01 0.19 0.40 0.35 0.40 0.53 0.40 0.45
SULFUR AMINO ACID METABOLISM 24 0 0.00% 0.44 0.13 0.32 0.40 0.17 0.30 0.30 0.22 0.20 0.37 0.27 0.27
G ALPHA S SIGNALLING EVENTS 121 0 0.00% 0.44 0.40 0.40 0.46 0.30 0.36 0.48 0.52 0.48 0.12 0.17 0.10
DOUBLE STRAND BREAK REPAIR 24 8 33.33% 0.44 0.36 0.39 0.34 0.31 0.40 0.19 0.24 0.22 0.50 0.48 0.47
AUTODEGRADATION OF CDH1 BY CDH1 APC C 64 64 100.00% 0.44 0.08 0.29 0.24 0.17 0.15 0.45 0.35 0.41 0.52 0.40 0.44
HIV INFECTION 207 64 30.92% 0.43 0.03 0.24 0.29 0.05 0.22 0.42 0.35 0.40 0.59 0.49 0.53
DESTABILIZATION OF MRNA BY KSRP 17 0 0.00% 0.43 0.36 0.36 0.49 0.38 0.46 0.32 0.31 0.33 0.37 0.44 0.42
CASPASE MEDIATED CLEAVAGE OF CYTOSKELETAL PROTEINS 13 0 0.00% 0.43 0.05 0.25 0.44 0.17 0.33 0.33 0.26 0.32 0.23 0.12 0.16
CDK MEDIATED PHOSPHORYLATION AND REMOVAL OF CDC6 48 48 100.00% 0.42 0.06 0.27 0.21 0.15 0.12 0.49 0.36 0.42 0.50 0.40 0.41
RNA POL II PRE TRANSCRIPTION EVENTS 61 3 4.92% 0.42 0.25 0.35 0.41 0.33 0.39 0.34 0.34 0.35 0.52 0.52 0.53
TRANSPORT OF VITAMINS NUCLEOSIDES AND RELATED MOLECULES 31 0 0.00% 0.42 0.17 0.32 0.41 0.19 0.36 0.30 0.34 0.33 0.25 0.23 0.23
NFKB AND MAP KINASES ACTIVATION MEDIATED BY TLR4 SIGNALING REPERTOIRE 72 9 12.50% 0.42 0.16 0.23 0.32 0.12 0.19 0.36 0.34 0.35 0.13 0.16 0.11
DIABETES PATHWAYS 133 3 2.26% 0.42 0.06 0.29 0.42 0.25 0.32 0.39 0.34 0.38 0.39 0.28 0.35
REGULATION OF APOPTOSIS 58 46 79.31% 0.42 0.04 0.26 0.16 0.23 0.13 0.48 0.35 0.42 0.34 0.27 0.31
VIF MEDIATED DEGRADATION OF APOBEC3G 52 46 88.46% 0.42 0.05 0.26 0.24 0.23 0.20 0.44 0.34 0.40 0.35 0.27 0.31
INHIBITION OF REPLICATION INITIATION OF DAMAGED DNA BY RB1 E2F1 13 13 100.00% 0.42 0.27 0.30 0.28 0.20 0.19 0.49 0.49 0.49 0.44 0.38 0.40
TOLL RECEPTOR CASCADES 118 9 7.63% 0.42 0.08 0.21 0.22 -0.02 0.09 0.16 0.18 0.13 0.39 0.32 0.37
ALPHA LINOLENIC ACID ALA METABOLISM 12 0 0.00% 0.42 0.14 0.28 0.36 0.15 0.25 0.31 0.33 0.37 0.39 0.38 0.44
REGULATION OF ORNITHINE DECARBOXYLASE ODC 49 43 87.76% 0.42 0.05 0.26 0.36 0.08 0.25 0.49 0.35 0.42 0.31 0.22 0.27
AMINO ACID SYNTHESIS AND INTERCONVERSION TRANSAMINATION 17 0 0.00% 0.42 0.07 0.24 0.43 0.16 0.28 -0.34 -0.28 -0.36 0.40 0.44 0.43
PI3K EVENTS IN ERBB4 SIGNALING 38 3 7.89% 0.41 0.29 0.33 0.11 0.17 0.10 0.25 0.25 0.24 0.11 0.10 0.08
AUTODEGRADATION OF THE E3 UBIQUITIN LIGASE COP1 51 51 100.00% 0.41 0.05 0.26 0.20 0.19 0.15 0.50 0.36 0.43 0.30 0.21 0.26
SIGNALING BY FGFR1 FUSION MUTANTS 19 2 10.53% 0.41 0.21 0.30 0.49 0.34 0.39 0.44 0.30 0.26 0.09 0.09 0.05
JNK C JUN KINASES PHOSPHORYLATION AND ACTIVATION MEDIATED BY ACTIVATED HUMAN TAK1 16 0 0.00% 0.41 0.06 0.26 0.30 0.04 0.20 0.28 0.25 0.27 0.43 0.30 0.37
CROSS PRESENTATION OF SOLUBLE EXOGENOUS ANTIGENS ENDOSOMES 48 43 89.58% 0.41 0.03 0.26 0.20 0.15 0.13 0.49 0.35 0.41 0.29 0.20 0.25













DESTABILIZATION OF MRNA BY TRISTETRAPROLIN TTP 17 0 0.00% 0.41 0.37 0.42 0.42 0.34 0.40 0.22 0.22 0.25 0.29 0.35 0.38
ACTIVATION OF NF KAPPAB IN B CELLS 64 49 76.56% 0.41 0.03 0.25 0.35 0.08 0.26 0.44 0.35 0.41 0.32 0.20 0.28
HOMOLOGOUS RECOMBINATION REPAIR OF REPLICATION INDEPENDENT DOUBLE STRAND BREAKS 17 8 47.06% 0.41 0.36 0.40 0.30 0.25 0.35 0.28 0.27 0.28 0.50 0.47 0.45
PKB MEDIATED EVENTS 29 0 0.00% 0.41 0.22 0.36 0.50 0.32 0.44 0.31 0.32 0.34 0.45 0.27 0.28
P75 NTR RECEPTOR MEDIATED SIGNALLING 81 7 8.64% 0.41 0.28 0.36 0.44 0.16 0.35 0.44 0.39 0.42 0.21 0.31 0.25
FORMATION OF TRANSCRIPTION COUPLED NER TC NER REPAIR COMPLEX 30 3 10.00% 0.41 0.22 0.39 0.24 0.20 0.31 0.32 0.33 0.33 0.44 0.50 0.49
DESTABILIZATION OF MRNA BY AUF1 HNRNP D0 53 46 86.79% 0.41 0.04 0.26 0.35 0.07 0.24 0.49 0.35 0.42 0.31 0.21 0.26
MRNA CAPPING 30 3 10.00% 0.41 0.16 0.30 0.14 0.19 0.25 0.29 0.29 0.29 0.49 0.51 0.51
PI3K CASCADE 71 0 0.00% 0.41 0.22 0.26 0.33 0.26 0.25 0.43 0.39 0.41 0.52 0.39 0.40
SIGNALING BY INSULIN RECEPTOR 108 1 0.93% 0.41 0.42 0.33 0.28 0.27 0.24 0.37 0.36 0.36 0.35 0.26 0.24
GPCR LIGAND BINDING 408 0 0.00% 0.40 0.13 0.21 0.31 -0.03 0.12 0.17 0.24 0.14 0.51 0.44 0.47
PIP3 ACTIVATES AKT SIGNALING 29 3 10.34% 0.40 0.11 0.24 0.08 0.14 0.07 0.18 0.19 0.17 0.27 0.26 0.25
GASTRIN CREB SIGNALLING PATHWAY VIA PKC AND MAPK 205 1 0.49% 0.40 0.11 0.24 0.41 0.37 0.40 0.20 0.27 0.18 -0.26 -0.17 -0.27
REGULATION OF HYPOXIA INDUCIBLE FACTOR HIF BY OXYGEN 25 4 16.00% 0.40 0.19 0.36 0.36 0.14 0.33 0.36 0.33 0.37 0.38 0.32 0.37
PERK REGULATED GENE EXPRESSION 29 0 0.00% 0.40 0.39 0.43 0.45 0.40 0.45 0.32 0.31 0.33 0.24 0.32 0.31
ACTIVATION OF GENES BY ATF4 26 0 0.00% 0.40 0.34 0.34 0.45 0.41 0.45 0.24 0.28 0.30 0.25 0.35 0.33
SIGNALING BY WNT 65 58 89.23% 0.40 0.02 0.25 0.34 0.07 0.25 0.47 0.37 0.44 0.09 0.03 0.07
IL1 SIGNALING 39 3 7.69% 0.40 -0.04 0.22 0.36 0.04 0.22 0.24 0.26 0.21 -0.07 -0.02 -0.09
ADAPTIVE IMMUNE SYSTEM 539 99 18.37% 0.39 0.00 0.19 0.24 -0.04 0.08 0.31 0.24 0.30 0.49 0.39 0.45
IMMUNE SYSTEM 933 107 11.47% 0.39 -0.01 0.18 0.24 -0.04 0.08 0.42 0.39 0.38 0.50 0.36 0.42
GLYCOLYSIS 29 5 17.24% 0.39 0.17 0.25 0.39 0.20 0.30 0.47 0.41 0.44 0.44 0.34 0.38
TAK1 ACTIVATES NFKB BY PHOSPHORYLATION AND ACTIVATION OF IKKS COMPLEX 23 0 0.00% 0.39 0.05 0.24 0.34 0.07 0.23 -0.10 -0.03 -0.09 -0.07 -0.01 -0.11
G ALPHA Q SIGNALLING EVENTS 184 0 0.00% 0.39 0.10 0.24 0.43 0.37 0.40 0.31 0.38 0.29 0.50 0.50 0.48
MRNA 3 END PROCESSING 35 0 0.00% 0.38 0.19 0.29 0.46 0.26 0.42 0.41 0.39 0.41 0.43 0.41 0.40
PROCESSING OF CAPPED INTRONLESS PRE MRNA 23 0 0.00% 0.38 0.25 0.36 0.35 0.21 0.36 0.45 0.41 0.43 0.48 0.47 0.49
PYRUVATE METABOLISM 19 0 0.00% 0.38 0.17 0.26 0.41 0.17 0.34 -0.18 -0.16 -0.23 0.33 0.26 0.30
SHC MEDIATED CASCADE 28 0 0.00% 0.38 0.11 0.21 0.16 0.06 0.06 0.32 0.33 0.30 0.22 0.20 0.14
DESTABILIZATION OF MRNA BY BRF1 17 0 0.00% 0.38 0.33 0.35 0.40 0.31 0.38 0.28 0.27 0.29 0.39 0.44 0.45
SIGNALING BY CONSTITUTIVELY ACTIVE EGFR 18 4 22.22% 0.37 0.27 0.31 0.36 0.27 0.27 -0.02 -0.01 -0.04 -0.01 -0.03 -0.07
DEPOSITION OF NEW CENPA CONTAINING NUCLEOSOMES AT THE CENTROMERE 64 64 100.00% 0.37 0.27 0.33 0.38 0.30 0.34 0.36 0.32 0.31 0.48 0.44 0.42
CLEAVAGE OF GROWING TRANSCRIPT IN THE TERMINATION REGION 44 0 0.00% 0.37 0.23 0.37 0.38 0.20 0.37 0.44 0.41 0.43 0.50 0.48 0.50
APOPTOSIS INDUCED DNA FRAGMENTATION 13 0 0.00% 0.37 0.23 0.30 0.39 0.23 0.34 0.41 0.35 0.37 0.37 0.28 0.34
DEADENYLATION OF MRNA 22 0 0.00% 0.37 0.20 0.26 0.08 0.09 0.02 0.37 0.35 0.35 0.33 0.25 0.31
SIGNALING BY THE B CELL RECEPTOR BCR 126 52 41.27% 0.37 -0.06 0.18 0.22 0.13 0.13 0.38 0.31 0.37 0.28 0.17 0.23
ER PHAGOSOME PATHWAY 61 46 75.41% 0.37 -0.03 0.17 0.28 -0.04 0.14 0.41 0.30 0.39 0.22 0.14 0.20
MITOCHONDRIAL TRNA AMINOACYLATION 21 0 0.00% 0.37 0.32 0.36 0.43 0.37 0.45 0.45 0.44 0.46 0.05 0.20 0.20
MYD88 MAL CASCADE INITIATED ON PLASMA MEMBRANE 83 9 10.84% 0.36 0.20 0.21 0.32 0.15 0.21 0.20 0.22 0.17 0.02 0.06 -0.02
VIRAL MESSENGER RNA SYNTHESIS 14 0 0.00% 0.36 0.19 0.33 0.36 0.16 0.35 0.38 0.34 0.36 0.36 0.29 0.29
INNATE IMMUNE SYSTEM 279 10 3.58% 0.36 -0.02 0.15 0.19 -0.06 0.05 0.20 0.25 0.15 0.18 0.22 0.11
MRNA SPLICING MINOR PATHWAY 45 0 0.00% 0.36 0.22 0.33 0.29 0.10 0.27 0.42 0.37 0.41 0.50 0.50 0.50
SLBP DEPENDENT PROCESSING OF REPLICATION DEPENDENT HISTONE PRE MRNAS 11 0 0.00% 0.36 0.26 0.33 0.32 0.20 0.32 0.47 0.43 0.46 0.46 0.44 0.44
RNA POL III TRANSCRIPTION INITIATION FROM TYPE 2 PROMOTER 23 0 0.00% 0.35 0.33 0.40 0.40 0.38 0.42 0.24 0.28 0.29 0.38 0.44 0.41
PURINE RIBONUCLEOSIDE MONOPHOSPHATE BIOSYNTHESIS 11 0 0.00% 0.35 0.15 0.24 0.38 0.21 0.30 0.50 0.46 0.47 0.39 0.38 0.42
ACTIVATION OF BH3 ONLY PROTEINS 17 5 29.41% 0.35 -0.04 0.20 0.16 0.05 0.19 0.39 0.37 0.40 0.49 0.41 0.48
INTRINSIC PATHWAY FOR APOPTOSIS 30 5 16.67% 0.35 -0.10 0.17 0.28 -0.05 0.17 0.47 0.42 0.48 0.50 0.43 0.48
PURINE SALVAGE 13 0 0.00% 0.35 0.14 0.26 0.13 -0.01 0.10 0.39 0.32 0.37 0.38 0.28 0.29
ERK MAPK TARGETS 21 5 23.81% 0.35 0.26 0.23 0.36 0.27 0.30 0.27 0.31 0.29 0.28 0.27 0.25
LATENT INFECTION OF HOMO SAPIENS WITH MYCOBACTERIUM TUBERCULOSIS 33 0 0.00% 0.35 0.19 0.27 0.24 0.03 0.14 0.21 0.18 0.18 0.23 0.15 0.19
PROCESSING OF INTRONLESS PRE MRNAS 14 0 0.00% 0.35 0.24 0.32 0.37 0.25 0.35 0.41 0.38 0.37 0.41 0.40 0.40
MYOGENESIS 28 0 0.00% 0.35 0.11 0.24 0.37 0.20 0.28 0.25 0.28 0.25 0.16 0.24 0.16
DEVELOPMENTAL BIOLOGY 396 5 1.26% 0.35 0.39 0.32 0.17 0.31 0.20 0.41 0.39 0.40 -0.20 -0.21 -0.24
P75NTR SIGNALS VIA NFKB 14 3 21.43% 0.35 0.02 0.22 0.35 0.06 0.25 0.45 0.39 0.43 0.14 0.19 0.14
CTLA4 INHIBITORY SIGNALING 21 9 42.86% 0.35 0.01 0.10 0.28 0.07 0.11 0.01 0.01 -0.09 0.20 0.09 0.21
INTEGRATION OF PROVIRUS 16 0 0.00% 0.35 0.11 0.18 0.37 0.15 0.29 0.02 -0.05 -0.01 0.07 -0.02 0.03
CELL DEATH SIGNALLING VIA NRAGE NRIF AND NADE 60 6 10.00% 0.34 0.39 0.38 0.23 0.31 0.28 0.42 0.42 0.43 0.44 0.35 0.40
P75NTR RECRUITS SIGNALLING COMPLEXES 12 3 25.00% 0.34 0.01 0.22 0.35 0.07 0.26 0.31 0.30 0.32 0.14 0.19 0.13
DCC MEDIATED ATTRACTIVE SIGNALING 13 0 0.00% 0.34 0.23 0.32 0.48 0.26 0.39 0.38 0.39 0.41 0.19 0.24 0.24
NEGATIVE REGULATION OF FGFR SIGNALING 37 6 16.22% 0.34 0.15 0.17 0.30 0.19 0.18 0.34 0.35 0.33 0.26 0.23 0.19
SOS MEDIATED SIGNALLING 14 1 7.14% 0.34 0.04 0.14 0.26 0.12 0.15 0.35 0.30 0.32 0.34 0.29 0.31
TELOMERE MAINTENANCE 75 75 100.00% 0.34 0.29 0.34 0.35 0.31 0.35 0.34 0.32 0.31 0.08 0.07 0.08
GPCR DOWNSTREAM SIGNALING 805 0 0.00% 0.34 -0.07 0.13 0.28 -0.07 0.08 0.27 0.36 0.27 0.50 0.49 0.47
UNFOLDED PROTEIN RESPONSE 80 3 3.75% 0.34 0.04 0.29 0.31 0.09 0.27 0.32 0.28 0.31 0.18 0.17 0.21
RNA POL II TRANSCRIPTION PRE INITIATION AND PROMOTER OPENING 41 3 7.32% 0.33 0.11 0.29 0.36 0.30 0.39 0.36 0.34 0.36 0.49 0.48 0.49
SIGNALLING TO ERKS 36 1 2.78% 0.33 0.18 0.20 0.27 0.21 0.21 -0.22 -0.14 -0.14 0.25 0.23 0.28
MRNA DECAY BY 3 TO 5 EXORIBONUCLEASE 11 0 0.00% 0.33 0.28 0.32 0.40 0.33 0.41 -0.19 -0.08 -0.10 0.16 0.16 0.21
AMINO ACID TRANSPORT ACROSS THE PLASMA MEMBRANE 31 0 0.00% 0.33 0.01 0.17 0.38 0.11 0.25 0.30 0.25 0.32 0.40 0.35 0.42
TRANSCRIPTION 210 44 20.95% 0.33 0.28 0.36 0.32 0.29 0.34 0.40 0.35 0.36 0.11 0.10 0.11
RNA POL III CHAIN ELONGATION 17 0 0.00% 0.33 0.27 0.34 0.40 0.39 0.43 0.27 0.30 0.32 0.09 0.17 0.16
GAP JUNCTION DEGRADATION 10 0 0.00% 0.33 0.13 0.20 0.21 -0.01 0.04 0.36 0.21 0.23 0.23 0.08 0.10
ACTIVATED TAK1 MEDIATES P38 MAPK ACTIVATION 18 0 0.00% 0.33 0.07 0.21 0.32 0.09 0.21 0.03 0.05 0.05 0.15 0.21 0.18
INTERACTION BETWEEN L1 AND ANKYRINS 23 0 0.00% 0.33 0.20 0.23 0.20 0.19 0.14 0.30 0.36 0.29 0.32 0.33 0.33
MEIOSIS 116 80 68.97% 0.33 0.26 0.33 0.37 0.32 0.33 0.33 0.29 0.29 0.21 0.16 0.17
MRNA DECAY BY 5 TO 3 EXORIBONUCLEASE 15 0 0.00% 0.33 0.21 0.34 0.07 0.09 0.15 0.32 0.29 0.27 0.34 0.24 0.19
REGULATION OF PYRUVATE DEHYDROGENASE PDH COMPLEX 13 0 0.00% 0.33 0.09 0.27 0.31 0.17 0.29 0.04 0.05 0.00 0.39 0.37 0.38
ACTIVATION OF CHAPERONE GENES BY XBP1S 46 3 6.52% 0.32 0.01 0.25 0.34 0.22 0.27 0.46 0.41 0.43 0.22 0.24 0.22
INSULIN SYNTHESIS AND PROCESSING 21 0 0.00% 0.32 0.19 0.23 0.24 0.17 0.17 0.35 0.31 0.35 0.21 0.16 0.17
PEPTIDE LIGAND BINDING RECEPTORS 188 0 0.00% 0.32 -0.09 0.12 0.31 -0.01 0.15 0.21 0.26 0.19 0.37 0.32 0.36
PASSIVE TRANSPORT BY AQUAPORINS 11 0 0.00% 0.32 0.09 0.25 0.33 0.17 0.28 0.26 0.29 0.27 0.01 -0.01 -0.07
ACTIVATED TLR4 SIGNALLING 93 9 9.68% 0.32 0.16 0.17 0.28 0.10 0.15 0.26 0.26 0.23 0.44 0.35 0.43
NUCLEAR EVENTS KINASE AND TRANSCRIPTION FACTOR ACTIVATION 24 5 20.83% 0.32 0.23 0.20 0.31 0.29 0.28 0.23 0.27 0.25 0.31 0.26 0.27
SEMA4D INDUCED CELL MIGRATION AND GROWTH CONE COLLAPSE 27 0 0.00% 0.31 -0.04 0.14 0.37 0.37 0.39 0.13 0.04 0.08 0.08 -0.11 0.01













PI 3K CASCADE 56 3 5.36% 0.31 0.22 0.22 0.19 0.17 0.13 0.33 0.33 0.31 0.27 0.26 0.19
SIGNALLING TO RAS 27 1 3.70% 0.31 0.19 0.18 0.27 0.20 0.20 0.13 0.06 0.06 0.32 0.24 0.30
PROLONGED ERK ACTIVATION EVENTS 19 1 5.26% 0.31 0.10 0.15 0.25 0.17 0.19 0.02 0.08 0.07 0.24 0.29 0.25
INTEGRIN CELL SURFACE INTERACTIONS 79 0 0.00% 0.31 0.10 0.14 0.21 0.03 0.09 0.23 0.28 0.22 -0.09 -0.23 -0.12
FACILITATIVE NA INDEPENDENT GLUCOSE TRANSPORTERS 12 0 0.00% 0.31 -0.01 0.16 0.25 -0.02 0.11 -0.01 -0.01 -0.07 -0.01 -0.04 -0.15
SIGNALING BY ERBB4 90 10 11.11% 0.31 -0.08 0.18 -0.03 0.24 0.08 0.22 0.24 0.21 -0.16 -0.05 -0.11
TRYPTOPHAN CATABOLISM 11 0 0.00% 0.31 -0.02 0.14 0.18 -0.12 0.02 -0.36 -0.27 -0.36 0.29 0.13 0.21
RESOLUTION OF AP SITES VIA THE MULTIPLE NUCLEOTIDE PATCH REPLACEMENT PATHWAY 17 7 41.18% 0.31 0.26 0.30 0.44 0.39 0.42 0.25 0.27 0.26 0.37 0.36 0.32
CLASS A1 RHODOPSIN LIKE RECEPTORS 305 0 0.00% 0.31 -0.08 0.09 0.26 -0.08 0.07 0.29 0.35 0.25 0.37 0.32 0.37
GROWTH HORMONE RECEPTOR SIGNALING 24 0 0.00% 0.30 0.11 0.19 0.20 -0.01 0.06 0.34 0.31 0.31 0.29 0.24 0.30
ANTIGEN PROCESSING CROSS PRESENTATION 76 46 60.53% 0.30 -0.08 0.12 0.30 0.28 0.27 0.39 0.30 0.38 0.19 0.10 0.18
CELL SURFACE INTERACTIONS AT THE VASCULAR WALL 91 0 0.00% 0.30 -0.11 0.11 0.27 -0.03 0.14 0.22 0.28 0.19 0.30 0.21 0.29
CIRCADIAN REPRESSION OF EXPRESSION BY REV ERBA 23 0 0.00% 0.30 0.17 0.20 0.28 0.14 0.19 -0.01 0.00 0.00 0.12 0.03 0.04
POST CHAPERONIN TUBULIN FOLDING PATHWAY 19 4 21.05% 0.30 0.28 0.34 0.38 0.24 0.39 0.44 0.42 0.46 0.34 0.34 0.37
SHC RELATED EVENTS 17 1 5.88% 0.30 0.07 0.13 0.28 0.11 0.17 0.27 0.13 0.14 0.33 0.25 0.28
MEIOTIC RECOMBINATION 86 50 58.14% 0.30 0.24 0.31 0.31 0.28 0.31 0.29 0.26 0.25 0.11 0.11 0.11
FRS2 MEDIATED CASCADE 36 1 2.78% 0.30 0.15 0.17 0.15 0.13 0.09 0.22 0.27 0.25 0.20 0.19 0.14
POTASSIUM CHANNELS 98 0 0.00% 0.30 0.03 0.23 0.24 0.06 0.20 0.30 0.33 0.25 -0.15 -0.05 -0.12
TIE2 SIGNALING 17 0 0.00% 0.29 0.13 0.23 0.46 0.30 0.36 0.00 -0.04 -0.06 0.21 0.11 0.09
FORMATION OF INCISION COMPLEX IN GG NER 23 6 26.09% 0.29 0.25 0.34 0.09 0.12 0.20 0.27 0.25 0.27 0.47 0.39 0.45
SIGNALING BY PDGF 122 7 5.74% 0.29 0.32 0.25 0.33 0.31 0.28 0.31 0.35 0.29 -0.02 0.04 -0.05
GLUCAGON TYPE LIGAND RECEPTORS 33 0 0.00% 0.29 0.08 0.23 0.31 0.13 0.26 0.14 0.11 0.17 0.48 0.38 0.42
EGFR DOWNREGULATION 25 3 12.00% 0.29 0.27 0.25 0.24 0.28 0.23 0.15 0.20 0.14 -0.04 0.00 -0.05
ARMS MEDIATED ACTIVATION 17 1 5.88% 0.29 0.12 0.17 0.26 0.19 0.21 -0.01 0.07 0.06 0.23 0.28 0.24
SPRY REGULATION OF FGF SIGNALING 14 6 42.86% 0.29 0.24 0.17 0.30 0.19 0.17 0.21 0.21 0.17 0.28 0.20 0.23
PROSTACYCLIN SIGNALLING THROUGH PROSTACYCLIN RECEPTOR 19 0 0.00% 0.29 0.15 0.25 0.35 0.22 0.27 0.38 0.36 0.33 0.36 0.35 0.35
GABA B RECEPTOR ACTIVATION 38 0 0.00% 0.29 0.02 0.21 0.28 0.08 0.22 0.27 0.28 0.20 0.32 0.34 0.33
RAF MAP KINASE CASCADE 10 1 10.00% 0.29 -0.02 0.16 0.30 0.15 0.21 0.39 0.36 0.35 0.26 0.14 0.17
INFLAMMASOMES 17 0 0.00% 0.28 -0.09 0.11 0.22 -0.10 0.07 0.52 0.49 0.51 -0.20 -0.03 -0.09
PLATELET AGGREGATION PLUG FORMATION 36 0 0.00% 0.28 0.07 0.20 0.34 0.11 0.22 0.46 0.48 0.42 -0.01 -0.13 -0.04
GABA RECEPTOR ACTIVATION 52 0 0.00% 0.28 0.03 0.21 0.29 0.08 0.23 0.30 0.31 0.23 0.43 0.44 0.43
REGULATION OF INSULIN LIKE GROWTH FACTOR IGF ACTIVITY BY INSULIN LIKE GROWTH FACTOR BINDING PROTEINS IGFBPS 16 0 0.00% 0.28 0.21 0.25 0.37 0.21 0.28 0.38 0.39 0.35 0.31 0.21 0.29
G ALPHA Z SIGNALLING EVENTS 44 0 0.00% 0.28 -0.02 0.17 0.41 0.30 0.34 0.51 0.50 0.50 0.46 0.37 0.43
TRANS GOLGI NETWORK VESICLE BUDDING 60 0 0.00% 0.28 -0.08 0.13 0.40 0.11 0.30 0.20 0.22 0.26 0.21 0.19 0.16
ERKS ARE INACTIVATED 12 5 41.67% 0.28 0.17 0.15 0.31 0.19 0.21 0.28 0.29 0.28 0.29 0.19 0.24
SHC MEDIATED SIGNALLING 15 1 6.67% 0.28 0.07 0.13 0.28 0.12 0.17 0.24 0.12 0.11 0.26 0.15 0.19
PECAM1 INTERACTIONS 10 0 0.00% 0.28 -0.01 0.04 0.16 -0.08 -0.02 0.07 0.07 0.09 -0.10 -0.17 -0.13
RORA ACTIVATES CIRCADIAN EXPRESSION 24 0 0.00% 0.28 0.17 0.20 0.27 0.16 0.18 -0.07 -0.05 -0.05 0.11 0.03 0.04
IL 7 SIGNALING 11 0 0.00% 0.27 -0.05 0.05 0.11 -0.18 -0.07 0.18 0.24 0.13 0.16 0.18 0.06
ADENYLATE CYCLASE INHIBITORY PATHWAY 13 0 0.00% 0.27 -0.01 0.18 0.30 0.04 0.20 0.39 0.40 0.40 0.04 0.10 0.10
SIGNALING BY HIPPO 22 2 9.09% 0.27 -0.01 0.12 0.20 -0.01 0.06 0.11 0.11 0.06 0.04 0.04 -0.01
G ALPHA1213 SIGNALLING EVENTS 74 0 0.00% 0.27 -0.02 0.15 0.31 0.19 0.32 0.05 0.10 0.06 0.51 0.48 0.48
INTEGRIN ALPHAIIB BETA3 SIGNALING 27 0 0.00% 0.27 0.05 0.19 0.27 0.09 0.16 0.45 0.45 0.42 0.02 -0.13 -0.02
TRIF MEDIATED TLR3 SIGNALING 74 9 12.16% 0.27 0.16 0.16 0.31 0.11 0.17 0.36 0.34 0.35 0.17 0.20 0.15
NFKB ACTIVATION THROUGH FADD RIP1 PATHWAY MEDIATED BY CASPASE 8 AND10 12 0 0.00% 0.27 0.16 0.16 0.27 0.07 0.17 0.07 0.02 0.09 -0.21 -0.10 -0.14
EXTRINSIC PATHWAY FOR APOPTOSIS 13 0 0.00% 0.27 0.32 0.23 0.32 0.29 0.31 0.20 0.24 0.13 0.11 0.17 0.04
CRMPS IN SEMA3A SIGNALING 14 0 0.00% 0.27 0.31 0.25 0.33 0.39 0.33 0.19 0.26 0.18 0.19 0.29 0.18
RNA POL I TRANSCRIPTION 89 44 49.44% 0.27 0.23 0.29 0.24 0.26 0.26 0.29 0.26 0.25 0.13 0.11 0.12
AMYLOIDS 83 41 49.40% 0.27 0.23 0.28 0.27 0.29 0.29 0.28 0.26 0.24 0.13 0.11 0.12
INITIAL TRIGGERING OF COMPLEMENT 16 0 0.00% 0.27 0.34 0.29 0.27 0.37 0.34 0.31 0.32 0.23 -0.35 -0.23 -0.30
RNA POL I RNA POL III AND MITOCHONDRIAL TRANSCRIPTION 122 44 36.07% 0.27 0.26 0.30 0.24 0.26 0.28 0.28 0.26 0.24 0.12 0.10 0.11
IL 2 SIGNALING 41 1 2.44% 0.26 -0.11 0.03 0.16 -0.13 -0.03 0.13 0.17 0.09 0.04 -0.05 0.07
FGFR LIGAND BINDING AND ACTIVATION 22 0 0.00% 0.26 -0.06 0.11 0.17 -0.01 0.06 0.34 0.36 0.32 0.22 0.22 0.14
NFKB IS ACTIVATED AND SIGNALS SURVIVAL 11 3 27.27% 0.26 -0.04 0.14 0.23 0.11 0.18 0.28 0.28 0.26 0.14 0.20 0.14
NGF SIGNALLING VIA TRKA FROM THE PLASMA MEMBRANE 137 12 8.76% 0.26 0.25 0.16 0.27 0.25 0.23 0.38 0.39 0.38 0.38 0.36 0.38
ASPARAGINE N LINKED GLYCOSYLATION 81 1 1.23% 0.26 0.20 0.28 0.07 0.08 0.13 0.29 0.29 0.31 0.03 0.06 0.04
TRAF6 MEDIATED IRF7 ACTIVATION IN TLR7 8 OR 9 SIGNALING 10 0 0.00% 0.26 -0.11 0.09 0.15 -0.15 -0.01 0.04 -0.04 0.04 -0.08 -0.14 -0.02
A TETRASACCHARIDE LINKER SEQUENCE IS REQUIRED FOR GAG SYNTHESIS 25 0 0.00% 0.26 0.29 0.18 0.25 0.28 0.23 0.22 0.23 0.19 -0.01 -0.06 0.02
ADENYLATE CYCLASE ACTIVATING PATHWAY 10 0 0.00% 0.26 -0.03 0.18 0.31 0.06 0.21 0.38 0.40 0.41 -0.03 0.07 0.09
DIGESTION OF DIETARY CARBOHYDRATE 12 0 0.00% 0.26 0.09 0.26 0.25 0.10 0.25 0.06 0.04 0.04 0.08 0.05 0.07
LIGAND GATED ION CHANNEL TRANSPORT 21 0 0.00% 0.26 -0.07 0.10 0.22 -0.02 0.08 0.25 0.26 0.26 0.13 0.17 0.23
MEIOTIC SYNAPSIS 73 73 100.00% 0.25 0.23 0.28 0.25 0.28 0.27 0.33 0.29 0.28 0.08 0.07 0.08
SYNTHESIS OF SUBSTRATES IN N GLYCAN BIOSYTHESIS 14 0 0.00% 0.25 0.14 0.23 0.24 0.16 0.23 0.07 0.05 0.04 0.06 0.08 0.06
INTEGRATION OF ENERGY METABOLISM 120 8 6.67% 0.25 0.04 0.19 0.26 0.27 0.24 0.41 0.41 0.42 0.46 0.43 0.46
RNA POL I PROMOTER OPENING 62 41 66.13% 0.25 0.20 0.26 0.20 0.22 0.22 0.27 0.24 0.23 0.12 0.11 0.12
KERATAN SULFATE DEGRADATION 11 0 0.00% 0.25 0.14 0.16 0.29 0.27 0.22 0.38 0.43 0.37 0.37 0.40 0.33
PROTEOLYTIC CLEAVAGE OF SNARE COMPLEX PROTEINS 17 0 0.00% 0.25 0.14 0.23 0.20 0.15 0.19 0.49 0.39 0.41 0.35 0.29 0.30
CYTOKINE SIGNALING IN IMMUNE SYSTEM 270 16 5.93% 0.25 -0.10 0.07 0.28 0.38 0.33 0.17 0.15 0.19 0.45 0.29 0.37
REGULATION OF KIT SIGNALING 17 0 0.00% 0.25 -0.03 0.03 0.17 -0.03 0.01 -0.01 0.01 -0.10 -0.14 -0.04 -0.14
VEGF LIGAND RECEPTOR INTERACTIONS 10 0 0.00% 0.25 0.19 0.18 0.24 0.24 0.18 0.26 0.36 0.31 0.25 0.33 0.26
G ALPHA I SIGNALLING EVENTS 195 0 0.00% 0.25 -0.15 0.06 0.44 0.44 0.45 0.53 0.48 0.54 0.40 0.42 0.40
CS DS DEGRADATION 12 0 0.00% 0.25 0.34 0.20 0.28 0.33 0.26 0.21 0.20 0.15 0.06 -0.02 0.06
GAB1 SIGNALOSOME 38 3 7.89% 0.24 0.18 0.15 0.11 0.15 0.08 0.14 0.16 0.13 -0.12 -0.05 -0.11
PRE NOTCH TRANSCRIPTION AND TRANSLATION 29 6 20.69% 0.24 -0.12 0.16 0.33 0.07 0.15 0.28 0.30 0.30 0.53 0.48 0.49
AXON GUIDANCE 251 3 1.20% 0.24 0.41 0.22 0.19 0.32 0.24 0.25 0.30 0.23 0.35 0.45 0.34
RESPONSE TO ELEVATED PLATELET CYTOSOLIC CA2 89 1 1.12% 0.24 0.37 0.25 0.26 0.38 0.31 0.28 0.36 0.27 0.15 0.07 0.11
SYNTHESIS OF PC 18 0 0.00% 0.24 0.04 0.16 0.14 0.20 0.20 0.11 0.13 0.09 -0.17 -0.17 -0.17
SIGNALING BY FGFR IN DISEASE 127 15 11.81% 0.24 0.22 0.15 0.21 0.24 0.19 0.34 0.35 0.33 0.27 0.25 0.18
SHC1 EVENTS IN ERBB4 SIGNALING 20 1 5.00% 0.24 0.18 0.12 0.30 0.09 0.16 0.08 0.05 0.03 0.20 0.18 0.20
BILE SALT AND ORGANIC ANION SLC TRANSPORTERS 11 0 0.00% 0.24 0.05 0.15 0.29 0.12 0.22 0.00 0.04 -0.02 -0.09 -0.06 -0.03
REGULATION OF IFNG SIGNALING 14 0 0.00% 0.24 0.26 0.18 0.23 0.27 0.23 0.23 0.24 0.23 -0.04 -0.10 0.00













INWARDLY RECTIFYING K CHANNELS 31 0 0.00% 0.24 0.03 0.18 0.21 0.04 0.17 0.04 0.07 -0.04 0.40 0.39 0.39
G BETA GAMMA SIGNALLING THROUGH PI3KGAMMA 25 0 0.00% 0.24 0.16 0.11 0.28 0.17 0.20 0.23 0.27 0.17 0.35 0.36 0.33
ADP SIGNALLING THROUGH P2RY1 25 0 0.00% 0.23 0.07 0.19 0.22 0.06 0.17 0.18 0.23 0.17 0.26 0.26 0.24
YAP1 AND WWTR1 TAZ STIMULATED GENE EXPRESSION 24 0 0.00% 0.23 0.17 0.17 0.27 0.19 0.20 -0.03 -0.03 -0.08 0.39 0.30 0.34
MTORC1 MEDIATED SIGNALLING 11 0 0.00% 0.23 0.08 0.26 0.34 0.24 0.36 0.38 0.23 0.23 0.45 0.26 0.26
SIGNAL ATTENUATION 14 0 0.00% 0.23 0.13 0.10 0.17 0.08 0.17 0.31 0.23 0.28 0.32 0.26 0.28
DEGRADATION OF THE EXTRACELLULAR MATRIX 29 0 0.00% 0.23 0.06 0.17 0.14 0.24 0.16 0.01 -0.05 0.02 0.23 0.09 0.18
SEMA3A PAK DEPENDENT AXON REPULSION 15 1 6.67% 0.23 0.19 0.14 0.30 0.23 0.22 0.32 0.32 0.26 0.14 0.17 0.09
RETROGRADE NEUROTROPHIN SIGNALLING 13 0 0.00% 0.23 0.04 0.11 0.11 0.04 0.06 0.33 0.20 0.23 0.17 0.04 0.10
NEF MEDIATES DOWN MODULATION OF CELL SURFACE RECEPTORS BY RECRUITING THEM TO CLATHRIN ADAPTERS 21 0 0.00% 0.23 -0.06 0.08 0.09 0.28 0.18 0.14 0.21 0.15 0.16 0.18 0.13
IL RECEPTOR SHC SIGNALING 27 0 0.00% 0.23 -0.09 0.00 0.11 -0.17 -0.07 0.10 0.15 0.03 0.16 0.06 0.09
TRAF6 MEDIATED NFKB ACTIVATION 21 0 0.00% 0.23 0.10 0.12 0.24 0.11 0.11 0.13 0.13 0.13 -0.01 0.04 -0.02
INHIBITION OF VOLTAGE GATED CA2 CHANNELS VIA GBETA GAMMA SUBUNITS 25 0 0.00% 0.23 0.03 0.18 0.19 0.05 0.17 0.13 0.16 0.06 0.40 0.39 0.38
ACTIVATED AMPK STIMULATES FATTY ACID OXIDATION IN MUSCLE 19 0 0.00% 0.23 0.27 0.20 0.20 0.24 0.17 0.18 0.19 0.21 -0.08 -0.06 -0.11
GOLGI ASSOCIATED VESICLE BIOGENESIS 53 0 0.00% 0.22 0.02 0.25 0.04 0.23 0.08 0.19 0.21 0.24 0.09 0.10 0.03
NEUROTRANSMITTER RECEPTOR BINDING AND DOWNSTREAM TRANSMISSION IN THE POSTSYNAPTIC CELL 137 2 1.46% 0.22 -0.03 0.15 0.19 -0.01 0.14 0.31 0.33 0.29 -0.02 0.09 -0.02
ADHERENS JUNCTIONS INTERACTIONS 27 0 0.00% 0.22 0.04 0.14 0.32 0.19 0.22 0.39 0.39 0.39 -0.20 -0.14 -0.22
HS GAG BIOSYNTHESIS 31 0 0.00% 0.22 -0.03 0.17 0.30 0.06 0.19 0.38 0.32 0.38 0.11 -0.02 0.06
G PROTEIN ACTIVATION 27 0 0.00% 0.22 0.07 0.19 0.11 0.01 0.10 0.14 0.18 0.13 0.34 0.34 0.32
THROMBIN SIGNALLING THROUGH PROTEINASE ACTIVATED RECEPTORS PARS 32 0 0.00% 0.22 0.01 0.15 0.07 -0.08 0.03 0.25 0.32 0.33 0.41 0.28 0.33
PACKAGING OF TELOMERE ENDS 48 48 100.00% 0.22 0.20 0.25 0.17 0.22 0.20 0.29 0.24 0.23 0.10 0.09 0.10
MUSCLE CONTRACTION 48 0 0.00% 0.22 0.36 0.24 0.27 0.34 0.28 0.24 0.29 0.22 0.11 0.08 -0.01
CTNNB1 PHOSPHORYLATION CASCADE 16 9 56.25% 0.22 0.15 0.13 0.25 0.22 0.20 0.14 0.09 0.08 0.28 0.18 0.24
KERATAN SULFATE KERATIN METABOLISM 30 0 0.00% 0.22 0.21 0.10 0.25 0.25 0.21 0.36 0.41 0.36 0.34 0.40 0.36
LYSOSOME VESICLE BIOGENESIS 23 0 0.00% 0.22 0.02 0.20 0.09 -0.07 0.07 0.14 0.18 0.21 0.34 0.25 0.27
ADP SIGNALLING THROUGH P2RY12 21 0 0.00% 0.22 0.08 0.19 0.13 0.04 0.11 0.23 0.29 0.23 0.37 0.36 0.35
REGULATION OF RHEB GTPASE ACTIVITY BY AMPK 10 0 0.00% 0.22 0.06 0.20 0.21 0.00 0.19 -0.03 0.01 -0.09 -0.15 -0.06 -0.06
ACTIVATION OF KAINATE RECEPTORS UPON GLUTAMATE BINDING 31 0 0.00% 0.22 0.11 0.22 0.27 0.16 0.26 0.11 0.18 0.10 0.39 0.37 0.37
G BETA GAMMA SIGNALLING THROUGH PLC BETA 20 0 0.00% 0.22 0.09 0.20 0.12 0.04 0.11 0.08 0.15 0.07 0.40 0.38 0.39
TGF BETA RECEPTOR SIGNALING ACTIVATES SMADS 26 5 19.23% 0.22 0.14 0.27 0.24 0.32 0.24 -0.01 0.03 0.02 0.41 0.43 0.40
NITRIC OXIDE STIMULATES GUANYLATE CYCLASE 25 0 0.00% 0.22 0.29 0.26 0.29 0.31 0.33 0.24 0.31 0.26 -0.19 -0.10 -0.16
BIOSYNTHESIS OF THE N GLYCAN PRECURSOR DOLICHOL LIPID LINKED OLIGOSACCHARIDE LLO AND TRANSFER TO A NASCENT PROTEIN 29 0 0.00% 0.22 0.27 0.28 0.25 0.10 0.13 0.16 0.17 0.18 0.14 0.16 0.12
INHIBITION OF INSULIN SECRETION BY ADRENALINE NORADRENALINE 25 0 0.00% 0.21 0.04 0.17 0.23 0.06 0.18 0.37 0.42 0.41 0.41 0.36 0.38
G PROTEIN BETA GAMMA SIGNALLING 28 0 0.00% 0.21 0.14 0.09 0.28 0.16 0.19 0.16 0.20 0.11 0.35 0.37 0.34
INSULIN RECEPTOR RECYCLING 23 0 0.00% 0.21 0.24 0.23 0.31 0.24 0.28 0.01 0.03 0.01 -0.05 -0.06 -0.09
GLYCOSAMINOGLYCAN METABOLISM 111 0 0.00% 0.21 0.34 0.15 0.16 0.26 0.15 0.21 0.27 0.18 0.38 0.45 0.41
CELL JUNCTION ORGANIZATION 78 0 0.00% 0.21 0.35 0.25 0.36 0.24 0.31 0.23 0.30 0.23 0.22 0.19 0.21
RNA POL I TRANSCRIPTION TERMINATION 22 3 13.64% 0.21 0.34 0.29 0.19 0.26 0.27 0.34 0.34 0.35 0.37 0.43 0.44
THROMBOXANE SIGNALLING THROUGH TP RECEPTOR 23 0 0.00% 0.21 0.05 0.16 0.12 -0.02 0.10 0.31 0.34 0.33 0.43 0.38 0.39
GRB2 SOS PROVIDES LINKAGE TO MAPK SIGNALING FOR INTERGRINS 15 0 0.00% 0.21 0.06 0.20 0.41 0.26 0.34 0.36 0.35 0.34 0.00 -0.14 -0.03
SYNTHESIS OF PE 11 0 0.00% 0.21 0.29 0.29 0.10 0.23 0.27 -0.06 -0.06 -0.08 0.04 0.02 0.04
ABACAVIR TRANSPORT AND METABOLISM 10 0 0.00% 0.21 0.14 0.24 0.34 0.17 0.29 0.47 0.50 0.47 0.28 0.31 0.27
SIGNAL AMPLIFICATION 31 0 0.00% 0.21 0.06 0.16 0.19 0.03 0.16 0.16 0.21 0.15 0.26 0.29 0.27
ENDOSOMAL SORTING COMPLEX REQUIRED FOR TRANSPORT ESCRT 27 3 11.11% 0.21 0.25 0.21 -0.09 0.03 0.03 0.01 0.04 0.04 -0.05 0.00 -0.04
CREATION OF C4 AND C2 ACTIVATORS 10 0 0.00% 0.21 0.19 0.14 0.04 0.32 0.17 0.16 0.24 0.13 -0.05 0.02 -0.02
AMINE DERIVED HORMONES 15 0 0.00% 0.21 0.19 0.16 0.15 0.09 0.08 0.13 0.15 0.14 0.18 0.17 0.15
DOWNREGULATION OF TGF BETA RECEPTOR SIGNALING 23 5 21.74% 0.20 0.10 0.26 0.26 0.18 0.31 -0.01 0.06 0.02 0.33 0.39 0.40
SMOOTH MUSCLE CONTRACTION 25 0 0.00% 0.20 0.28 0.18 0.28 0.28 0.28 0.25 0.30 0.22 0.07 0.11 0.06
ANDROGEN BIOSYNTHESIS 10 0 0.00% 0.20 0.18 0.16 0.18 0.13 0.17 0.05 0.01 0.03 0.05 0.00 -0.02
INTERFERON SIGNALING 159 12 7.55% 0.20 -0.10 0.04 0.25 0.36 0.31 0.05 0.09 0.04 0.25 0.15 0.22
RAS ACTIVATION UOPN CA2 INFUX THROUGH NMDA RECEPTOR 17 1 5.88% 0.20 0.13 0.13 0.18 0.18 0.16 0.14 0.10 0.15 0.31 0.20 0.20
ETHANOL OXIDATION 10 0 0.00% 0.20 0.37 0.25 0.26 0.32 0.25 0.26 0.31 0.24 0.23 0.29 0.23
CHONDROITIN SULFATE DERMATAN SULFATE METABOLISM 49 0 0.00% 0.20 0.29 0.15 0.22 0.29 0.21 0.09 0.13 0.06 -0.10 -0.16 -0.09
P130CAS LINKAGE TO MAPK SIGNALING FOR INTEGRINS 15 0 0.00% 0.20 0.04 0.20 0.30 0.14 0.22 0.39 0.42 0.40 0.00 -0.14 -0.03
ACTIVATION OF THE AP1 FAMILY OF TRANSCRIPTION FACTORS 10 0 0.00% 0.20 0.27 0.16 0.18 0.25 0.19 -0.03 0.06 0.04 0.17 0.18 0.19
TRANSPORT TO THE GOLGI AND SUBSEQUENT MODIFICATION 33 1 3.03% 0.20 -0.10 0.07 -0.08 0.09 0.03 0.18 0.20 0.20 0.01 -0.03 0.04
P38MAPK EVENTS 13 0 0.00% 0.20 0.25 0.19 0.14 0.21 0.12 -0.18 -0.12 -0.08 0.19 0.08 0.10
KERATAN SULFATE BIOSYNTHESIS 26 0 0.00% 0.20 0.18 0.09 0.28 0.25 0.23 0.26 0.29 0.22 0.25 0.23 0.31
CHEMOKINE RECEPTORS BIND CHEMOKINES 57 0 0.00% 0.20 -0.20 -0.03 0.16 -0.18 -0.01 0.06 -0.04 0.08 0.31 0.20 0.28
SIGNALLING TO P38 VIA RIT AND RIN 15 1 6.67% 0.20 -0.06 0.16 0.25 0.07 0.20 0.30 0.25 0.26 0.26 0.13 0.10
RECYCLING OF BILE ACIDS AND SALTS 11 0 0.00% 0.20 0.14 0.18 0.19 0.10 0.19 0.06 0.14 0.12 0.25 0.25 0.30
AQUAPORIN MEDIATED TRANSPORT 51 3 5.88% 0.19 0.01 0.15 0.35 0.11 0.25 0.46 0.48 0.47 0.43 0.44 0.43
ACTIVATION OF CHAPERONE GENES BY ATF6 ALPHA 11 0 0.00% 0.19 0.01 0.07 0.20 0.19 0.27 0.11 0.11 0.11 0.16 0.23 0.26
ELEVATION OF CYTOSOLIC CA2 LEVELS 10 0 0.00% 0.19 -0.05 0.06 0.09 -0.10 -0.01 0.24 0.26 0.22 0.25 0.25 0.18
SIGNALING BY TGF BETA RECEPTOR COMPLEX 63 14 22.22% 0.19 0.04 0.22 0.42 0.31 0.43 0.14 0.16 0.18 0.33 0.38 0.43
TRANSCRIPTIONAL ACTIVITY OF SMAD2 SMAD3 SMAD4 HETEROTRIMER 38 12 31.58% 0.19 0.02 0.21 0.16 0.01 0.19 0.16 0.17 0.19 0.42 0.41 0.48
CHONDROITIN SULFATE BIOSYNTHESIS 21 0 0.00% 0.19 0.34 0.20 0.28 0.30 0.25 0.01 0.06 -0.02 -0.03 -0.10 0.03
NOREPINEPHRINE NEUROTRANSMITTER RELEASE CYCLE 10 0 0.00% 0.19 0.22 0.24 0.29 0.12 0.19 0.48 0.41 0.45 0.12 0.10 0.13
SHC1 EVENTS IN EGFR SIGNALING 15 1 6.67% 0.18 0.11 0.10 -0.11 0.09 -0.06 -0.01 -0.02 -0.05 -0.09 -0.07 -0.12
SIGNAL REGULATORY PROTEIN SIRP FAMILY INTERACTIONS 12 0 0.00% 0.18 0.35 0.26 0.15 0.02 0.02 0.13 0.14 0.07 -0.05 0.04 -0.09
THE NLRP3 INFLAMMASOME 12 0 0.00% 0.18 0.37 0.26 0.24 0.36 0.31 0.29 0.30 0.20 -0.16 -0.01 -0.13
REGULATION OF IFNA SIGNALING 24 0 0.00% 0.18 0.08 0.08 0.00 -0.16 -0.15 0.13 0.19 0.13 0.10 0.00 0.12
REGULATION OF WATER BALANCE BY RENAL AQUAPORINS 44 3 6.82% 0.18 0.02 0.14 0.29 0.28 0.29 0.45 0.48 0.47 0.37 0.42 0.41
TGF BETA RECEPTOR SIGNALING IN EMT EPITHELIAL TO MESENCHYMAL TRANSITION 16 3 18.75% 0.18 0.36 0.26 0.28 0.37 0.35 -0.03 0.02 -0.05 0.33 0.36 0.37
PLATELET ACTIVATION SIGNALING AND AGGREGATION 208 1 0.48% 0.18 0.42 0.28 0.25 0.40 0.33 0.20 0.29 0.20 0.13 0.13 0.09
CONVERSION FROM APC C CDC20 TO APC C CDH1 IN LATE ANAPHASE 22 22 100.00% 0.18 0.15 0.09 0.56 0.32 0.46 0.19 0.21 0.21 0.57 0.48 0.51
TRAFFICKING AND PROCESSING OF ENDOSOMAL TLR 14 0 0.00% 0.18 -0.12 -0.01 0.10 -0.14 -0.08 0.17 0.14 0.17 -0.09 -0.19 -0.04
REGULATION OF INSULIN SECRETION 93 3 3.23% 0.18 0.02 0.15 0.12 -0.07 0.06 0.33 0.34 0.33 0.49 0.47 0.48
NEGATIVE REGULATORS OF RIG I MDA5 SIGNALING 31 4 12.90% 0.18 0.03 0.14 0.18 -0.01 0.04 -0.17 -0.08 -0.11 0.04 -0.02 0.06
SMAD2 SMAD3 SMAD4 HETEROTRIMER REGULATES TRANSCRIPTION 27 11 40.74% 0.17 -0.01 0.19 0.15 0.02 0.18 -0.18 -0.12 -0.16 0.42 0.41 0.46
FGFR1 LIGAND BINDING AND ACTIVATION 14 0 0.00% 0.17 0.03 0.11 0.16 0.05 0.12 0.12 0.16 0.08 0.21 0.22 0.20













RESPIRATORY ELECTRON TRANSPORT ATP SYNTHESIS BY CHEMIOSMOTIC COUPLING AND HEAT PRODUCTION BY UNCOUPLING PROTEINS 98 0 0.00% 0.17 0.20 0.23 0.17 0.14 0.23 0.20 0.19 0.17 0.02 0.02 -0.05
PI METABOLISM 48 0 0.00% 0.17 0.05 0.10 0.23 0.25 0.21 0.20 0.21 0.21 0.11 0.12 0.04
OPIOID SIGNALLING 78 8 10.26% 0.17 0.07 0.17 0.31 0.31 0.29 0.36 0.41 0.38 -0.19 -0.08 -0.18
GRB2 EVENTS IN ERBB2 SIGNALING 22 1 4.55% 0.17 0.24 0.12 0.28 0.10 0.16 -0.06 -0.02 -0.07 0.05 -0.05 -0.06
CALNEXIN CALRETICULIN CYCLE 11 0 0.00% 0.17 0.00 0.11 0.18 0.07 0.13 0.29 0.26 0.28 -0.05 0.01 0.02
SIGNALING BY NODAL 18 0 0.00% 0.17 0.21 0.13 0.13 0.15 0.08 0.23 0.26 0.29 -0.04 -0.08 -0.01
INSULIN RECEPTOR SIGNALLING CASCADE 87 1 1.15% 0.17 0.33 0.18 0.29 0.23 0.21 0.37 0.36 0.37 0.45 0.35 0.35
METABOLISM OF MRNA 284 51 17.96% 0.17 0.10 0.12 0.07 -0.02 0.10 0.09 0.04 0.08 0.43 0.38 0.36
SEMA4D IN SEMAPHORIN SIGNALING 32 0 0.00% 0.17 -0.19 0.00 0.13 -0.14 0.00 0.04 0.06 0.01 -0.05 -0.14 -0.04
INTERFERON GAMMA SIGNALING 63 0 0.00% 0.17 -0.17 -0.01 0.12 -0.20 -0.04 0.22 0.24 0.20 0.00 -0.11 0.03
STRIATED MUSCLE CONTRACTION 27 0 0.00% 0.17 0.36 0.25 0.19 0.31 0.24 0.11 0.17 0.10 0.04 0.07 -0.02
ADVANCED GLYCOSYLATION ENDPRODUCT RECEPTOR SIGNALING 13 0 0.00% 0.17 -0.06 0.06 0.19 0.01 0.13 0.11 0.15 0.08 0.07 0.12 0.04
FGFR4 LIGAND BINDING AND ACTIVATION 12 0 0.00% 0.17 -0.02 0.06 0.14 0.00 0.04 0.33 0.35 0.31 0.21 0.22 0.18
HIGHLY CALCIUM PERMEABLE POSTSYNAPTIC NICOTINIC ACETYLCHOLINE RECEPTORS 13 0 0.00% 0.16 0.05 0.16 0.10 0.02 0.10 -0.28 -0.20 -0.25 -0.37 -0.29 -0.30
INTERFERON ALPHA BETA SIGNALING 64 1 1.56% 0.16 -0.05 0.04 0.15 -0.08 0.01 0.08 0.05 0.12 -0.02 -0.07 0.01
SIGNALING BY NOTCH2 12 0 0.00% 0.16 0.15 0.19 0.18 0.14 0.24 0.30 0.37 0.38 -0.03 0.12 0.09
COMMON PATHWAY 14 0 0.00% 0.16 0.26 0.18 0.23 0.22 0.22 0.16 0.20 0.14 0.28 0.32 0.27
HEPARAN SULFATE HEPARIN HS GAG METABOLISM 52 0 0.00% 0.16 0.30 0.10 0.12 0.24 0.12 0.11 0.17 0.10 -0.03 -0.15 -0.05
CELL EXTRACELLULAR MATRIX INTERACTIONS 14 0 0.00% 0.16 0.24 0.17 0.34 0.24 0.30 -0.01 0.08 0.00 0.01 0.06 -0.03
TCA CYCLE AND RESPIRATORY ELECTRON TRANSPORT 141 0 0.00% 0.16 0.18 0.23 0.17 0.13 0.23 0.20 0.18 0.17 -0.06 -0.07 -0.11
GLUCAGON SIGNALING IN METABOLIC REGULATION 34 3 8.82% 0.16 0.05 0.14 0.17 0.06 0.15 0.29 0.34 0.31 0.33 0.27 0.29
RNA POL III TRANSCRIPTION INITIATION FROM TYPE 3 PROMOTER 26 0 0.00% 0.16 0.35 0.20 0.21 0.34 0.28 0.20 0.21 0.20 -0.01 0.03 -0.02
PRESYNAPTIC NICOTINIC ACETYLCHOLINE RECEPTORS 12 0 0.00% 0.16 0.02 0.13 0.06 -0.03 0.05 0.08 0.04 0.08 -0.39 -0.34 -0.31
TRAF6 MEDIATED IRF7 ACTIVATION 30 0 0.00% 0.16 0.00 0.05 0.17 0.02 0.04 0.00 -0.03 0.01 -0.10 -0.12 -0.05
TRAF3 DEPENDENT IRF ACTIVATION PATHWAY 14 0 0.00% 0.15 0.04 0.07 0.14 0.00 0.03 0.08 0.05 0.10 -0.04 -0.07 0.01
RIG I MDA5 MEDIATED INDUCTION OF IFN ALPHA BETA PATHWAYS 73 4 5.48% 0.15 0.01 0.03 0.13 -0.01 0.01 -0.03 -0.05 0.00 -0.01 -0.05 0.00
CD28 DEPENDENT VAV1 PATHWAY 11 0 0.00% 0.15 0.01 0.01 0.12 -0.02 0.04 0.10 0.04 0.06 0.05 -0.03 0.06
N GLYCAN TRIMMING IN THE ER AND CALNEXIN CALRETICULIN CYCLE 13 0 0.00% 0.15 0.02 0.07 0.18 0.10 0.12 0.13 0.12 0.11 -0.05 0.01 0.02
ACETYLCHOLINE BINDING AND DOWNSTREAM EVENTS 16 0 0.00% 0.15 0.04 0.15 0.09 0.02 0.09 -0.26 -0.17 -0.22 -0.37 -0.29 -0.30
AMINE LIGAND BINDING RECEPTORS 38 0 0.00% 0.15 0.10 0.15 0.24 0.16 0.20 0.42 0.43 0.36 0.41 0.40 0.38
BINDING AND ENTRY OF HIV VIRION 10 0 0.00% 0.15 0.20 0.23 0.08 -0.04 0.07 0.29 0.22 0.25 0.26 0.21 0.24
REGULATION OF GENE EXPRESSION IN BETA CELLS 20 0 0.00% 0.15 0.10 0.09 0.20 0.11 0.08 0.06 0.08 0.02 0.30 0.26 0.22
N GLYCAN ANTENNAE ELONGATION IN THE MEDIAL TRANS GOLGI 18 0 0.00% 0.14 -0.14 0.03 -0.10 0.12 0.02 -0.19 -0.17 -0.24 -0.31 -0.22 -0.31
NOD1 2 SIGNALING PATHWAY 30 0 0.00% 0.14 -0.16 0.04 0.13 -0.15 0.03 0.11 0.15 0.05 0.13 0.17 0.05
PI3K AKT ACTIVATION 38 3 7.89% 0.14 0.20 0.09 0.13 0.15 0.10 0.29 0.28 0.28 0.41 0.36 0.35
ANTIGEN PRESENTATION FOLDING ASSEMBLY AND PEPTIDE LOADING OF CLASS I MHC 21 1 4.76% 0.14 -0.16 -0.03 0.11 -0.19 -0.04 0.13 0.08 0.16 0.00 -0.04 0.04
CHYLOMICRON MEDIATED LIPID TRANSPORT 16 0 0.00% 0.14 -0.06 0.05 0.08 -0.03 0.03 -0.01 -0.02 -0.02 0.06 0.00 0.07
HORMONE LIGAND BINDING RECEPTORS 10 0 0.00% 0.14 0.16 0.15 0.06 0.07 0.07 0.12 0.08 0.02 0.04 -0.09 -0.10
REGULATION OF COMPLEMENT CASCADE 14 0 0.00% 0.14 0.35 0.21 0.40 0.31 0.34 0.25 0.32 0.21 0.28 0.34 0.23
RESPIRATORY ELECTRON TRANSPORT 79 0 0.00% 0.14 0.18 0.21 0.17 0.17 0.23 0.18 0.17 0.15 0.30 0.26 0.30
COSTIMULATION BY THE CD28 FAMILY 63 9 14.29% 0.14 -0.24 -0.10 0.06 -0.28 -0.12 -0.01 -0.04 -0.04 0.16 0.01 0.13
SIGNALING BY NOTCH4 12 0 0.00% 0.14 0.10 0.16 0.18 0.15 0.25 0.39 0.42 0.44 0.15 0.14 0.13
SIGNALING BY FGFR 112 13 11.61% 0.14 0.17 0.09 0.17 0.22 0.16 0.34 0.35 0.33 0.27 0.23 0.18
REGULATION OF BETA CELL DEVELOPMENT 30 0 0.00% 0.14 0.18 0.13 0.19 0.15 0.10 0.10 0.13 0.07 0.33 0.28 0.31
SEMAPHORIN INTERACTIONS 68 1 1.47% 0.14 -0.11 0.03 0.30 0.02 0.17 0.23 0.28 0.21 0.29 0.30 0.27
IL 3 5 AND GM CSF SIGNALING 43 0 0.00% 0.14 -0.10 -0.04 0.11 -0.22 -0.08 0.13 0.21 0.10 0.03 -0.06 -0.03
CD28 CO STIMULATION 32 0 0.00% 0.14 -0.01 -0.04 0.07 0.32 0.17 0.04 0.09 -0.02 0.12 0.01 0.07
APOBEC3G MEDIATED RESISTANCE TO HIV1 INFECTION 12 0 0.00% 0.14 -0.15 -0.04 -0.10 -0.26 -0.22 0.39 0.35 0.36 0.08 0.03 0.04
ACTIVATION OF CHAPERONES BY ATF6 ALPHA 13 0 0.00% 0.14 0.14 0.27 0.21 0.19 0.29 0.15 0.14 0.13 0.11 0.15 0.18
ACETYLCHOLINE NEUROTRANSMITTER RELEASE CYCLE 10 0 0.00% 0.14 0.16 0.22 -0.19 -0.01 -0.06 0.27 0.19 0.17 0.08 0.10 0.11
APOPTOTIC CLEAVAGE OF CELL ADHESION PROTEINS 12 0 0.00% 0.13 -0.09 -0.02 0.24 -0.02 0.14 0.04 0.06 0.06 0.02 0.00 -0.05
INTRINSIC PATHWAY 17 0 0.00% 0.13 0.35 0.28 0.35 0.41 0.37 0.26 0.33 0.24 0.07 0.10 0.07
RNA POL I TRANSCRIPTION INITIATION 25 3 12.00% 0.13 0.25 0.23 0.22 0.29 0.33 0.28 0.29 0.30 0.45 0.45 0.45
REGULATION OF SIGNALING BY CBL 18 0 0.00% 0.13 0.24 0.13 -0.04 -0.33 -0.22 0.02 0.05 -0.05 -0.03 -0.01 -0.10
REGULATION OF INSULIN SECRETION BY GLUCAGON LIKE PEPTIDE1 43 3 6.98% 0.13 -0.01 0.10 0.30 0.08 0.20 0.22 0.26 0.27 0.37 0.39 0.40
GLYCOPROTEIN HORMONES 12 0 0.00% 0.13 0.20 0.16 0.12 0.12 0.13 0.20 0.23 0.18 -0.01 -0.15 -0.10
TANDEM PORE DOMAIN POTASSIUM CHANNELS 12 0 0.00% 0.13 -0.02 0.15 0.07 0.01 0.02 0.21 0.14 0.20 0.13 0.06 0.10
PI3K EVENTS IN ERBB2 SIGNALING 44 3 6.82% 0.12 0.33 0.19 0.07 0.15 0.06 0.17 0.21 0.16 0.07 0.00 0.00
METABOLISM OF PROTEINS 518 9 1.74% 0.12 0.18 0.20 0.20 0.12 0.24 0.44 0.38 0.41 0.27 0.33 0.25
PHOSPHOLIPASE C MEDIATED CASCADE 54 3 5.56% 0.12 -0.10 0.03 0.10 0.06 0.08 0.43 0.45 0.43 0.16 0.22 0.13
RECRUITMENT OF NUMA TO MITOTIC CENTROSOMES 10 10 100.00% 0.12 0.14 0.19 0.39 0.28 0.40 0.31 0.22 0.25 0.45 0.44 0.42
OTHER SEMAPHORIN INTERACTIONS 15 0 0.00% 0.12 0.00 0.09 0.04 -0.05 0.05 0.14 0.16 0.19 0.33 0.32 0.31
DOPAMINE NEUROTRANSMITTER RELEASE CYCLE 11 0 0.00% 0.12 0.17 0.18 0.13 0.13 0.16 0.41 0.38 0.39 0.07 0.09 0.08
PPARA ACTIVATES GENE EXPRESSION 104 0 0.00% 0.12 0.22 0.09 0.46 0.24 0.33 -0.11 -0.06 -0.09 0.49 0.37 0.41
PEPTIDE CHAIN ELONGATION 153 4 2.61% 0.12 0.09 0.15 0.39 0.22 0.36 0.09 0.13 0.10 0.20 0.25 0.21
CGMP EFFECTS 19 0 0.00% 0.12 0.26 0.20 0.23 0.30 0.28 0.25 0.32 0.26 0.10 0.16 0.12
CELL CELL COMMUNICATION 120 0 0.00% 0.12 0.37 0.20 0.08 0.31 0.18 0.10 0.16 0.07 0.38 0.27 0.37
HORMONE SENSITIVE LIPASE HSL MEDIATED TRIACYLGLYCEROL HYDROLYSIS 13 3 23.08% 0.11 0.08 0.08 0.09 -0.03 -0.01 0.17 0.27 0.22 0.12 0.17 0.15
HS GAG DEGRADATION 20 0 0.00% 0.11 0.09 0.17 0.27 0.05 0.21 -0.09 -0.01 -0.05 -0.04 -0.07 -0.02
TIGHT JUNCTION INTERACTIONS 29 0 0.00% 0.11 0.39 0.24 0.23 0.39 0.35 0.52 0.49 0.49 0.21 0.16 0.25
SIGNAL TRANSDUCTION BY L1 34 0 0.00% 0.11 0.24 0.10 0.03 0.23 0.09 0.07 0.14 0.09 -0.05 -0.01 -0.07
INFLUENZA VIRAL RNA TRANSCRIPTION AND REPLICATION 169 5 2.96% 0.11 0.07 0.11 0.34 0.20 0.34 0.08 0.12 0.08 0.23 0.27 0.24
FORMATION OF ATP BY CHEMIOSMOTIC COUPLING 16 0 0.00% 0.11 0.06 0.10 0.03 -0.05 0.05 0.28 0.21 0.23 0.04 0.07 0.07
TRANSLATION 222 4 1.80% 0.11 0.09 0.13 0.09 0.00 0.13 0.14 0.17 0.13 0.24 0.28 0.22
PEPTIDE HORMONE BIOSYNTHESIS 14 0 0.00% 0.11 0.21 0.13 0.08 0.08 0.10 0.11 0.15 0.14 -0.02 -0.11 -0.06
ANTIGEN ACTIVATES B CELL RECEPTOR LEADING TO GENERATION OF SECOND MESSENGERS 29 0 0.00% 0.10 -0.27 -0.10 0.03 -0.27 -0.12 0.00 0.05 -0.04 -0.06 -0.03 -0.09
HDL MEDIATED LIPID TRANSPORT 15 0 0.00% 0.10 -0.02 0.05 0.03 0.01 0.02 0.06 0.07 0.02 0.07 0.09 -0.02
COMPLEMENT CASCADE 32 0 0.00% 0.10 0.40 0.21 0.26 0.41 0.33 0.34 0.39 0.30 0.26 0.35 0.23
LIPOPROTEIN METABOLISM 28 0 0.00% 0.10 -0.01 0.05 0.03 0.00 0.01 0.09 0.10 0.05 0.11 0.07 0.09
GLUTAMATE NEUROTRANSMITTER RELEASE CYCLE 15 0 0.00% 0.10 0.17 0.17 -0.03 0.14 0.07 0.33 0.30 0.32 -0.34 -0.29 -0.31
NEF MEDIATED DOWNREGULATION OF MHC CLASS I COMPLEX CELL SURFACE EXPRESSION 10 0 0.00% 0.10 -0.09 0.01 0.02 0.24 0.13 -0.09 -0.04 -0.04 0.22 0.11 0.13













COPI MEDIATED TRANSPORT 10 0 0.00% 0.10 0.07 0.15 0.24 0.19 0.25 0.19 0.20 0.19 -0.04 0.04 0.01
RIP MEDIATED NFKB ACTIVATION VIA DAI 18 0 0.00% 0.10 -0.06 -0.02 0.03 0.00 -0.04 0.03 0.03 -0.02 0.01 0.06 0.00
ENERGY DEPENDENT REGULATION OF MTOR BY LKB1 AMPK 18 0 0.00% 0.10 0.24 0.14 0.05 0.18 0.09 0.28 0.30 0.31 -0.24 -0.14 -0.15
P2Y RECEPTORS 12 0 0.00% 0.10 -0.16 -0.03 0.25 0.15 0.22 0.38 0.40 0.31 0.07 -0.05 0.08
SIGNALING BY NOTCH3 12 0 0.00% 0.09 0.12 0.14 0.13 0.10 0.19 0.36 0.40 0.41 0.16 0.13 0.14
VOLTAGE GATED POTASSIUM CHANNELS 43 0 0.00% 0.09 0.09 0.15 -0.13 0.11 0.01 0.44 0.46 0.42 0.06 0.16 0.11
NEGATIVE REGULATION OF THE PI3K AKT NETWORK 9 0 0.00% 0.09 0.05 0.00 0.00 0.02 -0.08 0.06 0.09 0.03 0.17 0.13 0.14
METABOLISM OF VITAMINS AND COFACTORS 51 2 3.92% 0.09 0.36 0.15 0.33 0.20 0.23 0.45 0.43 0.46 0.31 0.38 0.38
SYNTHESIS OF PIPS AT THE GOLGI MEMBRANE 17 0 0.00% 0.09 0.19 0.17 0.16 0.23 0.19 0.20 0.21 0.25 -0.02 0.02 -0.02
N GLYCAN ANTENNAE ELONGATION 14 0 0.00% 0.09 -0.10 0.01 -0.04 0.14 0.03 -0.16 -0.16 -0.22 0.15 0.15 0.18
REGULATION OF AMPK ACTIVITY VIA LKB1 15 0 0.00% 0.09 0.27 0.15 0.08 0.19 0.11 0.14 0.13 0.14 -0.06 0.00 -0.03
ENDOSOMAL VACUOLAR PATHWAY 9 0 0.00% 0.09 -0.18 -0.06 0.07 -0.20 -0.07 0.01 -0.03 0.06 -0.06 -0.09 0.00
OXYGEN DEPENDENT PROLINE HYDROXYLATION OF HYPOXIA INDUCIBLE FACTOR ALPHA 18 4 22.22% 0.09 0.13 0.13 0.06 0.25 0.19 0.19 0.20 0.20 0.06 0.20 0.14
PROSTANOID LIGAND RECEPTORS 10 0 0.00% 0.08 0.35 0.25 0.18 0.25 0.22 0.23 0.29 0.19 0.11 0.23 0.12
SYNTHESIS OF PIPS AT THE PLASMA MEMBRANE 31 0 0.00% 0.08 -0.11 -0.05 0.12 -0.01 -0.01 0.22 0.26 0.22 0.10 0.02 -0.02
TETRAHYDROBIOPTERIN BH4 SYNTHESIS RECYCLING SALVAGE AND REGULATION 13 3 23.08% 0.08 0.11 0.01 0.26 0.15 0.21 0.18 0.13 0.13 0.02 0.04 -0.03
TRANSPORT OF ORGANIC ANIONS 11 0 0.00% 0.08 0.32 0.21 0.33 0.32 0.44 0.34 0.39 0.35 -0.01 0.05 0.02
CA DEPENDENT EVENTS 30 3 10.00% 0.08 -0.11 0.03 0.01 0.02 0.05 0.21 0.30 0.24 -0.14 -0.07 -0.12
EXTRACELLULAR MATRIX ORGANIZATION 87 0 0.00% 0.08 -0.05 0.07 0.15 0.04 0.13 0.17 0.12 0.18 0.12 -0.01 0.08
DOWNREGULATION OF ERBB2 ERBB3 SIGNALING 12 3 25.00% 0.08 0.04 0.02 -0.04 -0.03 -0.12 0.17 0.18 0.13 0.05 -0.03 -0.05
CREB PHOSPHORYLATION THROUGH THE ACTIVATION OF CAMKII 15 1 6.67% 0.08 -0.05 0.05 -0.03 -0.05 0.01 0.12 0.11 0.14 0.31 0.19 0.21
IMMUNOREGULATORY INTERACTIONS BETWEEN A LYMPHOID AND A NON LYMPHOID CELL 70 0 0.00% 0.07 -0.28 -0.13 0.01 -0.31 -0.16 -0.28 -0.19 -0.28 0.16 0.16 0.20
TCR SIGNALING 54 0 0.00% 0.07 -0.29 -0.13 0.00 -0.34 -0.17 -0.08 -0.07 -0.01 -0.03 0.08 -0.05
DOWNSTREAM TCR SIGNALING 37 0 0.00% 0.07 -0.29 -0.12 -0.01 -0.34 -0.18 -0.05 -0.08 -0.01 -0.22 -0.14 -0.22
LIPID DIGESTION MOBILIZATION AND TRANSPORT 46 3 6.52% 0.07 0.02 0.03 0.09 0.04 0.03 0.18 0.22 0.17 0.22 0.19 0.20
GLUTATHIONE CONJUGATION 23 0 0.00% 0.07 0.25 0.13 0.10 0.18 0.10 -0.01 -0.01 -0.08 -0.06 -0.06 -0.10
GLYCOGEN BREAKDOWN GLYCOGENOLYSIS 18 0 0.00% 0.07 -0.08 0.04 0.23 0.25 0.27 -0.06 0.01 -0.01 0.01 -0.07 -0.06
ACTIVATION OF IRF3 IRF7 MEDIATED BY TBK1 IKK EPSILON 14 3 21.43% 0.07 -0.12 -0.04 0.09 0.00 -0.01 0.15 0.13 0.11 0.30 0.33 0.27
BOTULINUM NEUROTOXICITY 19 0 0.00% 0.06 0.18 0.16 0.13 0.18 0.19 0.46 0.37 0.39 0.32 0.26 0.26
NEPHRIN INTERACTIONS 20 0 0.00% 0.06 0.29 0.22 0.22 0.26 0.30 0.19 0.15 0.18 0.11 0.06 0.01
DAG AND IP3 SIGNALING 32 3 9.38% 0.06 -0.08 0.06 -0.01 0.00 0.04 -0.12 -0.10 -0.12 0.04 0.13 0.09
PLC BETA MEDIATED EVENTS 43 3 6.98% 0.06 -0.14 0.00 0.04 0.05 0.08 0.11 0.20 0.12 -0.18 -0.09 -0.14
PKA MEDIATED PHOSPHORYLATION OF CREB 18 3 16.67% 0.06 -0.11 0.04 0.04 -0.08 0.01 0.33 0.37 0.38 -0.14 -0.01 0.03
SIGNALING BY ILS 107 4 3.74% 0.06 0.07 0.17 0.28 -0.07 0.10 0.12 0.17 0.08 0.04 0.15 0.01
CREB PHOSPHORYLATION THROUGH THE ACTIVATION OF RAS 27 1 3.70% 0.06 0.34 0.11 0.24 0.31 0.24 0.16 0.18 0.13 0.34 0.32 0.27
OPSINS 10 0 0.00% 0.06 -0.04 0.13 0.05 -0.08 0.05 -0.06 -0.02 -0.02 0.01 0.07 0.15
SEMA3A PLEXIN REPULSION SIGNALING BY INHIBITING INTEGRIN ADHESION 13 0 0.00% 0.06 0.27 0.17 0.19 0.21 0.17 0.17 0.22 0.19 0.04 0.11 0.02
3 UTR MEDIATED TRANSLATIONAL REGULATION 176 4 2.27% 0.06 0.04 0.08 0.42 0.29 0.39 0.07 0.12 0.08 0.22 0.26 0.22
CELL CELL JUNCTION ORGANIZATION 56 0 0.00% 0.06 0.37 0.20 0.34 0.41 0.37 0.32 0.36 0.32 0.18 0.13 0.20
GLUCONEOGENESIS 34 2 5.88% 0.06 -0.09 0.05 0.49 0.32 0.45 0.43 0.43 0.44 0.48 0.45 0.48
CYTOSOLIC SULFONATION OF SMALL MOLECULES 14 0 0.00% 0.05 0.11 0.19 0.08 0.03 0.11 0.20 0.21 0.21 0.16 0.22 0.23
TRIGLYCERIDE BIOSYNTHESIS 38 0 0.00% 0.05 0.31 0.17 0.29 0.33 0.29 0.01 0.06 -0.06 0.10 0.13 0.00
MEMBRANE TRAFFICKING 129 4 3.10% 0.05 -0.05 0.13 0.33 0.10 0.23 0.26 0.25 0.27 0.03 0.00 -0.02
GPVI MEDIATED ACTIVATION CASCADE 31 0 0.00% 0.05 -0.25 -0.14 -0.07 -0.34 -0.23 -0.03 -0.07 -0.05 -0.12 -0.10 -0.14
SYNTHESIS SECRETION AND DEACYLATION OF GHRELIN 16 0 0.00% 0.05 0.01 0.05 -0.01 -0.09 -0.01 0.10 0.03 0.02 0.04 0.09 0.01
FGFR2C LIGAND BINDING AND ACTIVATION 12 0 0.00% 0.05 0.07 0.08 0.09 0.07 0.10 0.33 0.35 0.30 0.21 0.13 0.12
RECEPTOR LIGAND BINDING INITIATES THE SECOND PROTEOLYTIC CLEAVAGE OF NOTCH RECEPTOR 12 3 25.00% 0.05 0.10 0.12 0.07 0.06 0.14 0.16 0.22 0.21 0.14 0.19 0.14
PLATELET CALCIUM HOMEOSTASIS 18 0 0.00% 0.04 0.03 -0.04 0.05 -0.03 -0.05 0.10 0.01 0.03 -0.04 -0.03 -0.06
SIGNALING BY NOTCH1 70 7 10.00% 0.04 0.18 0.15 0.07 0.04 0.12 -0.13 -0.06 -0.14 -0.17 -0.15 -0.25
SIGNALING BY FGFR3 MUTANTS 11 0 0.00% 0.04 0.15 0.08 0.12 0.23 0.14 0.31 0.32 0.28 0.13 0.16 0.08
NUCLEOTIDE LIKE PURINERGIC RECEPTORS 16 0 0.00% 0.04 -0.16 -0.09 0.14 0.00 0.09 0.26 0.26 0.20 -0.07 -0.10 -0.06
GENERATION OF SECOND MESSENGER MOLECULES 27 0 0.00% 0.04 -0.31 -0.16 -0.03 -0.36 -0.20 -0.05 -0.08 -0.04 -0.31 -0.19 -0.25
BILE ACID AND BILE SALT METABOLISM 27 0 0.00% 0.04 0.11 0.10 -0.05 0.02 -0.02 -0.19 -0.16 -0.19 0.04 0.05 0.07
TERMINATION OF O GLYCAN BIOSYNTHESIS 24 0 0.00% 0.04 0.03 0.04 0.01 0.05 0.00 0.08 0.08 -0.01 -0.03 -0.05 -0.05
SIGNALING BY ACTIVATED POINT MUTANTS OF FGFR1 11 0 0.00% 0.04 0.04 0.03 0.02 0.03 0.04 0.15 0.18 0.17 0.18 0.20 0.17
IL 6 SIGNALING 11 0 0.00% 0.04 0.14 0.13 -0.05 0.08 0.10 0.24 0.19 0.13 0.03 0.00 0.02
PD1 SIGNALING 18 0 0.00% 0.04 -0.31 -0.16 -0.04 -0.36 -0.21 -0.07 -0.13 -0.01 -0.02 -0.12 0.03
REGULATION OF THE FANCONI ANEMIA PATHWAY 11 8 72.73% 0.04 -0.11 -0.11 0.26 0.07 0.15 0.21 0.22 0.19 0.38 0.35 0.36
SYNTHESIS SECRETION AND INACTIVATION OF GIP 14 0 0.00% 0.03 0.02 0.05 -0.04 -0.09 -0.01 0.01 -0.03 -0.05 -0.12 -0.12 -0.12
INCRETIN SYNTHESIS SECRETION AND INACTIVATION 22 0 0.00% 0.03 0.02 0.05 -0.03 -0.09 -0.01 0.04 0.00 -0.02 -0.10 -0.02 -0.05
SYNTHESIS SECRETION AND INACTIVATION OF GLP1 19 0 0.00% 0.03 0.01 0.05 -0.03 -0.09 -0.01 0.04 0.00 -0.02 -0.10 -0.02 -0.05
GLUCURONIDATION 18 0 0.00% 0.03 0.14 0.08 0.05 0.15 0.05 -0.14 -0.17 -0.18 -0.10 -0.11 -0.14
DARPP 32 EVENTS 25 8 32.00% 0.03 0.09 0.03 0.14 0.24 0.16 0.20 0.23 0.20 0.23 0.15 0.13
SEROTONIN RECEPTORS 12 0 0.00% 0.03 0.04 0.06 -0.01 -0.04 -0.02 0.29 0.31 0.27 0.12 0.09 0.03
SYNTHESIS OF PIPS AT THE EARLY ENDOSOME MEMBRANE 12 0 0.00% 0.02 0.09 0.05 0.01 0.00 -0.04 -0.22 -0.26 -0.29 -0.12 -0.14 -0.18
TRANSFERRIN ENDOCYTOSIS AND RECYCLING 25 0 0.00% 0.02 0.23 0.11 0.34 0.21 0.26 0.04 0.05 0.02 0.00 -0.02 -0.06
FORMATION OF FIBRIN CLOT CLOTTING CASCADE 32 0 0.00% 0.02 0.29 0.15 0.13 0.30 0.21 0.30 0.37 0.29 0.07 0.12 0.08
PHOSPHORYLATION OF CD3 AND TCR ZETA CHAINS 16 0 0.00% 0.02 -0.32 -0.16 -0.05 -0.37 -0.21 -0.08 -0.14 -0.02 -0.06 -0.16 -0.01
SYNTHESIS OF PA 27 0 0.00% 0.02 0.25 0.12 0.02 0.25 0.15 0.00 0.05 -0.04 -0.13 -0.11 -0.15
ACYL CHAIN REMODELLING OF PG 16 0 0.00% 0.02 0.12 0.03 0.06 0.13 0.06 -0.06 -0.03 -0.11 -0.12 -0.13 -0.16
CD28 DEPENDENT PI3K AKT SIGNALING 22 0 0.00% 0.02 0.10 -0.03 0.25 -0.02 0.11 0.08 0.12 0.04 0.19 0.14 0.13
TRANSLOCATION OF ZAP 70 TO IMMUNOLOGICAL SYNAPSE 14 0 0.00% 0.02 -0.32 -0.17 -0.05 -0.37 -0.22 -0.09 -0.15 -0.03 0.22 0.24 0.17
DOWNSTREAM SIGNAL TRANSDUCTION 95 7 7.37% 0.02 0.27 0.08 0.13 0.25 0.15 0.33 0.34 0.30 0.23 0.22 0.17
DOWNREGULATION OF SMAD2 3 SMAD4 TRANSCRIPTIONAL ACTIVITY 20 5 25.00% 0.02 -0.05 0.12 0.01 -0.05 0.06 0.09 0.14 0.16 0.11 0.13 0.18
IONOTROPIC ACTIVITY OF KAINATE RECEPTORS 11 0 0.00% 0.02 0.03 0.00 0.20 0.27 0.28 0.16 0.19 0.15 -0.06 -0.13 -0.16
RAP1 SIGNALLING 17 2 11.76% 0.01 -0.03 -0.04 0.02 -0.07 -0.03 0.37 0.43 0.39 0.00 0.09 0.02
OLFACTORY SIGNALING PATHWAY 328 0 0.00% 0.01 -0.01 0.06 -0.06 -0.04 -0.03 0.32 0.27 0.26 0.39 0.32 0.35
ACYL CHAIN REMODELLING OF PI 15 0 0.00% 0.01 0.13 0.03 0.02 0.10 0.03 -0.07 -0.05 -0.12 -0.12 -0.12 -0.15
PROLACTIN RECEPTOR SIGNALING 14 3 21.43% 0.01 0.08 0.09 0.12 0.08 0.15 0.50 0.39 0.40 -0.37 -0.23 -0.30
METABOLISM OF PORPHYRINS 14 0 0.00% 0.01 0.03 0.05 0.06 0.04 0.06 -0.10 -0.07 -0.05 -0.07 0.04 0.08
SRP DEPENDENT COTRANSLATIONAL PROTEIN TARGETING TO MEMBRANE 179 4 2.23% 0.01 0.02 0.02 0.02 -0.04 0.07 0.09 0.13 0.09 0.24 0.28 0.24













SYNTHESIS OF BILE ACIDS AND BILE SALTS VIA 7ALPHA HYDROXYCHOLESTEROL 15 0 0.00% 0.00 0.17 0.12 0.24 0.13 0.25 0.30 0.28 0.30 -0.22 -0.21 -0.21
POST NMDA RECEPTOR ACTIVATION EVENTS 33 1 3.03% 0.00 -0.08 0.01 -0.03 -0.10 -0.04 0.17 0.23 0.17 0.15 0.14 0.08
NCAM SIGNALING FOR NEURITE OUT GROWTH 64 1 1.56% 0.00 0.34 0.13 0.29 0.37 0.31 -0.08 -0.04 -0.10 -0.23 -0.33 -0.26
ACTIVATION OF THE MRNA UPON BINDING OF THE CAP BINDING COMPLEX AND EIFS AND SUBSEQUENT BINDING TO 43S 84 3 3.57% 0.00 0.01 0.00 0.39 0.29 0.39 0.03 0.07 0.03 0.24 0.24 0.22
SIGNALING BY ROBO RECEPTOR 30 1 3.33% -0.01 0.01 0.07 0.07 0.05 0.11 -0.20 -0.11 -0.19 -0.31 -0.26 -0.30
AMINE COMPOUND SLC TRANSPORTERS 27 0 0.00% -0.01 -0.04 -0.04 -0.05 -0.05 -0.04 0.15 0.11 0.07 -0.34 -0.28 -0.32
PRE NOTCH EXPRESSION AND PROCESSING 44 6 13.64% -0.01 0.00 0.02 0.23 0.05 0.22 0.51 0.48 0.49 0.37 0.35 0.32
NOTCH HLH TRANSCRIPTION PATHWAY 13 0 0.00% -0.01 -0.10 -0.01 0.01 -0.07 0.05 0.07 0.12 0.07 0.06 0.08 0.07
PURINE CATABOLISM 10 0 0.00% -0.01 0.23 0.07 0.25 0.21 0.20 -0.08 -0.06 -0.09 0.27 0.26 0.23
NONSENSE MEDIATED DECAY ENHANCED BY THE EXON JUNCTION COMPLEX 176 7 3.98% -0.01 0.00 0.00 0.28 0.19 0.30 0.08 0.13 0.09 0.22 0.27 0.22
FATTY ACYL COA BIOSYNTHESIS 18 0 0.00% -0.01 0.22 0.06 0.08 0.26 0.16 0.04 0.07 -0.05 0.04 0.05 -0.05
BMAL1 CLOCK NPAS2 ACTIVATES CIRCADIAN EXPRESSION 36 0 0.00% -0.01 0.19 0.05 0.09 0.16 0.11 0.10 0.11 0.09 0.35 0.28 0.29
FATTY ACID TRIACYLGLYCEROL AND KETONE BODY METABOLISM 168 0 0.00% -0.02 0.30 0.06 0.34 0.14 0.31 -0.07 -0.02 -0.07 0.18 0.17 0.11
DEFENSINS 51 0 0.00% -0.02 -0.26 -0.15 -0.04 -0.27 -0.14 0.01 0.03 -0.05 0.11 0.19 0.06
CITRIC ACID CYCLE TCA CYCLE 26 0 0.00% -0.02 0.09 0.15 0.23 0.11 0.16 0.29 0.32 0.34 0.28 0.19 0.23
TRAFFICKING OF AMPA RECEPTORS 28 1 3.57% -0.02 0.24 0.09 0.00 0.25 0.10 0.01 0.10 0.01 -0.07 -0.01 -0.02
RNA POL III TRANSCRIPTION 33 0 0.00% -0.02 0.28 0.09 0.09 0.27 0.15 -0.11 -0.10 -0.11 -0.08 -0.05 -0.12
SYNTHESIS OF BILE ACIDS AND BILE SALTS VIA 24 HYDROXYCHOLESTEROL 10 0 0.00% -0.02 0.16 0.08 -0.06 0.08 0.02 -0.02 -0.05 -0.10 -0.08 -0.10 -0.18
ACYL CHAIN REMODELLING OF PS 15 0 0.00% -0.02 0.12 0.01 0.00 0.09 0.02 -0.05 -0.03 -0.11 -0.12 -0.12 -0.15
NOTCH1 INTRACELLULAR DOMAIN REGULATES TRANSCRIPTION 46 7 15.22% -0.02 0.16 0.06 -0.03 0.17 0.02 -0.15 -0.07 -0.17 -0.28 -0.22 -0.33
ACYL CHAIN REMODELLING OF PC 22 0 0.00% -0.02 0.12 0.01 0.00 0.10 0.01 -0.05 -0.03 -0.09 -0.14 -0.14 -0.17
ACYL CHAIN REMODELLING OF PE 21 0 0.00% -0.02 0.12 0.01 0.00 0.03 0.04 -0.08 -0.06 -0.12 -0.14 -0.13 -0.17
DSCAM INTERACTIONS 11 0 0.00% -0.02 0.03 -0.01 -0.01 0.04 0.00 0.03 0.02 -0.03 0.13 0.12 0.09
CIRCADIAN CLOCK 53 8 15.09% -0.03 0.18 0.07 0.07 0.19 0.10 0.03 0.05 0.01 0.25 0.19 0.15
SIGNALING BY EGFR IN CANCER 109 11 10.09% -0.03 0.33 0.11 0.23 0.26 0.22 0.30 0.32 0.30 0.09 0.06 0.02
ENOS ACTIVATION AND REGULATION 20 3 15.00% -0.03 0.17 -0.02 0.32 0.14 0.18 0.59 0.56 0.58 0.05 0.10 0.04
TRAFFICKING OF GLUR2 CONTAINING AMPA RECEPTORS 16 0 0.00% -0.03 0.19 0.05 -0.09 0.19 0.05 -0.09 0.00 -0.07 -0.07 0.03 0.00
POST TRANSLATIONAL MODIFICATION SYNTHESIS OF GPI ANCHORED PROTEINS 26 0 0.00% -0.03 0.24 0.17 0.00 0.07 0.11 0.08 0.16 0.14 -0.09 0.08 0.00
ACTIVATION OF RAC 14 0 0.00% -0.04 0.23 0.03 0.01 0.20 0.06 -0.07 -0.02 -0.09 0.05 0.08 -0.01
NETRIN1 SIGNALING 41 0 0.00% -0.04 0.29 0.15 -0.01 0.23 0.16 0.00 0.05 -0.01 -0.16 -0.05 -0.10
GAP JUNCTION ASSEMBLY 18 0 0.00% -0.04 -0.01 0.07 0.16 0.09 0.18 0.19 0.13 0.19 -0.09 -0.11 -0.07
GAP JUNCTION TRAFFICKING 27 0 0.00% -0.04 -0.01 0.07 0.17 0.10 0.18 0.35 0.31 0.31 -0.08 -0.10 -0.05
GABA A RECEPTOR ACTIVATION 12 0 0.00% -0.04 -0.03 -0.02 -0.02 0.00 -0.04 0.00 0.02 -0.01 0.10 0.19 0.22
EFFECTS OF PIP2 HYDROLYSIS 25 0 0.00% -0.04 0.00 -0.09 0.26 0.32 0.36 0.37 0.39 0.35 0.24 0.24 0.24
ROLE OF SECOND MESSENGERS IN NETRIN1 SIGNALING 11 0 0.00% -0.04 -0.06 -0.04 -0.09 -0.12 -0.10 0.21 0.17 0.14 0.14 0.18 0.22
SIGNALING BY BMP 23 1 4.35% -0.04 0.14 -0.01 0.04 0.18 0.06 0.20 0.27 0.23 -0.12 -0.04 -0.12
PHASE II CONJUGATION 70 0 0.00% -0.04 0.23 0.11 -0.07 0.16 0.03 -0.06 -0.01 -0.10 -0.02 -0.03 -0.09
ABC FAMILY PROTEINS MEDIATED TRANSPORT 34 0 0.00% -0.04 0.31 0.08 0.06 0.24 0.11 0.34 0.37 0.35 0.09 0.05 0.05
EICOSANOID LIGAND BINDING RECEPTORS 16 0 0.00% -0.04 0.04 0.09 0.12 0.19 0.14 0.25 0.31 0.21 0.19 0.28 0.17
ACTIVATED NOTCH1 TRANSMITS SIGNAL TO THE NUCLEUS 27 3 11.11% -0.05 -0.02 0.04 0.19 0.17 0.26 0.30 0.34 0.34 -0.04 -0.07 -0.12
AKT PHOSPHORYLATES TARGETS IN THE CYTOSOL 12 3 25.00% -0.05 0.04 0.04 -0.04 0.02 -0.06 -0.07 -0.05 -0.09 0.06 0.12 0.05
RNA POL III TRANSCRIPTION TERMINATION 19 0 0.00% -0.05 0.25 0.06 0.30 0.24 0.27 -0.05 -0.02 -0.08 -0.10 -0.05 -0.10
ACTIVATION OF NMDA RECEPTOR UPON GLUTAMATE BINDING AND POSTSYNAPTIC EVENTS 37 1 2.70% -0.05 0.21 0.08 0.05 0.26 0.15 0.19 0.25 0.19 0.12 0.13 0.07
SIGNALING BY ERBB2 101 11 10.89% -0.06 0.30 0.10 0.12 0.22 0.14 0.29 0.30 0.30 0.10 0.02 0.03
TRAF6 MEDIATED INDUCTION OF TAK1 COMPLEX 14 3 21.43% -0.06 0.07 0.01 -0.09 -0.02 -0.05 0.09 0.10 0.06 -0.06 -0.08 -0.06
BASE FREE SUGAR PHOSPHATE REMOVAL VIA THE SINGLE NUCLEOTIDE REPLACEMENT PATHWAY 10 0 0.00% -0.06 0.15 0.11 0.12 0.11 0.14 0.19 0.19 0.19 -0.14 -0.02 0.02
CLASS C 3 METABOTROPIC GLUTAMATE PHEROMONE RECEPTORS 15 0 0.00% -0.06 0.00 0.00 0.30 0.09 0.23 -0.15 -0.12 -0.13 0.01 0.02 -0.02
ABCA TRANSPORTERS IN LIPID HOMEOSTASIS 18 0 0.00% -0.06 0.28 0.05 -0.02 0.18 0.05 0.15 0.19 0.15 -0.11 -0.08 -0.09
GABA SYNTHESIS RELEASE REUPTAKE AND DEGRADATION 17 0 0.00% -0.06 0.11 0.10 -0.02 0.15 0.07 0.54 0.43 0.48 -0.20 -0.14 -0.17
VITAMIN B5 PANTOTHENATE METABOLISM 11 0 0.00% -0.06 0.19 0.01 0.14 0.14 0.20 -0.11 -0.12 -0.16 -0.20 -0.08 -0.11
AMINO ACID AND OLIGOPEPTIDE SLC TRANSPORTERS 49 0 0.00% -0.07 -0.06 -0.02 0.26 0.23 0.23 0.44 0.41 0.41 -0.12 -0.10 -0.07
IRAK2 MEDIATED ACTIVATION OF TAK1 COMPLEX UPON TLR7 8 OR 9 STIMULATION 9 3 33.33% -0.07 0.02 -0.01 -0.13 0.01 -0.09 0.00 -0.01 -0.03 0.07 0.03 0.01
SIGNALING BY NOTCH 103 13 12.62% -0.07 0.12 0.10 0.11 -0.01 0.12 -0.13 -0.06 -0.13 -0.21 -0.14 -0.25
MEMBRANE BINDING AND TARGETTING OF GAG PROTEINS 10 3 30.00% -0.07 0.22 0.07 0.00 0.16 0.12 -0.12 -0.05 -0.10 -0.13 -0.09 -0.14
DOWNSTREAM SIGNALING OF ACTIVATED FGFR 100 7 7.00% -0.07 0.27 0.09 0.11 0.22 0.14 0.32 0.35 0.32 0.22 0.20 0.16
MITOCHONDRIAL FATTY ACID BETA OXIDATION 14 0 0.00% -0.07 0.05 -0.02 0.24 0.16 0.27 0.30 0.28 0.30 0.20 0.12 0.13
ACTIVATED POINT MUTANTS OF FGFR2 16 0 0.00% -0.07 0.05 0.00 0.20 0.07 0.16 0.13 0.21 0.12 0.16 0.19 0.13
O LINKED GLYCOSYLATION OF MUCINS 59 0 0.00% -0.08 -0.11 -0.06 -0.14 -0.09 -0.11 -0.17 -0.12 -0.21 -0.27 -0.25 -0.29
GLYCEROPHOSPHOLIPID BIOSYNTHESIS 82 0 0.00% -0.08 0.21 0.03 -0.07 0.16 0.10 -0.14 -0.06 -0.17 -0.14 -0.12 -0.15
GAMMA CARBOXYLATION TRANSPORT AND AMINO TERMINAL CLEAVAGE OF PROTEINS 11 0 0.00% -0.08 0.16 0.04 0.03 0.20 0.10 0.09 0.15 0.11 0.11 0.17 0.09
TRANSPORT OF INORGANIC CATIONS ANIONS AND AMINO ACIDS OLIGOPEPTIDES 94 0 0.00% -0.08 0.24 0.04 0.04 0.22 0.07 -0.14 -0.09 -0.19 -0.37 -0.31 -0.36
PRE NOTCH PROCESSING IN GOLGI 16 0 0.00% -0.08 0.04 -0.09 -0.03 0.05 -0.04 0.26 0.20 0.19 -0.16 -0.15 -0.17
ZINC TRANSPORTERS 15 0 0.00% -0.08 0.18 0.10 0.14 0.24 0.22 0.22 0.21 0.26 0.16 0.17 0.22
PHOSPHOLIPID METABOLISM 198 0 0.00% -0.09 0.26 0.04 -0.02 0.26 0.11 0.23 0.26 0.22 -0.15 -0.07 -0.16
UNBLOCKING OF NMDA RECEPTOR GLUTAMATE BINDING AND ACTIVATION 15 1 6.67% -0.09 -0.01 -0.06 -0.08 -0.05 -0.06 0.08 0.14 0.08 0.32 0.17 0.23
PYRIMIDINE CATABOLISM 12 0 0.00% -0.09 0.28 0.06 0.00 0.29 0.08 0.02 0.08 0.00 -0.07 0.02 -0.04
METABOLISM OF LIPIDS AND LIPOPROTEINS 478 3 0.63% -0.09 0.31 0.04 0.00 0.22 0.06 0.16 0.21 0.16 0.54 0.45 0.47
RESOLUTION OF AP SITES VIA THE SINGLE NUCLEOTIDE REPLACEMENT PATHWAY 12 0 0.00% -0.09 0.14 0.09 0.03 0.19 0.12 -0.12 -0.04 -0.05 -0.13 -0.01 -0.02
NA CL DEPENDENT NEUROTRANSMITTER TRANSPORTERS 17 0 0.00% -0.10 -0.05 -0.08 -0.02 -0.01 -0.07 0.11 0.09 0.13 -0.12 -0.17 -0.17
NRIF SIGNALS CELL DEATH FROM THE NUCLEUS 15 4 26.67% -0.10 0.19 0.11 0.11 0.12 0.18 0.21 0.26 0.27 0.05 0.15 0.13
ROLE OF DCC IN REGULATING APOPTOSIS 10 0 0.00% -0.10 -0.02 -0.07 -0.03 0.09 -0.05 0.26 0.21 0.24 -0.18 -0.21 -0.16
STEROID HORMONES 29 0 0.00% -0.11 0.20 -0.01 -0.03 0.19 0.03 -0.12 -0.16 -0.15 0.10 0.11 0.09
SPHINGOLIPID DE NOVO BIOSYNTHESIS 31 0 0.00% -0.11 0.24 0.03 -0.04 0.23 0.07 0.18 0.26 0.21 0.15 0.21 0.13
BETA DEFENSINS 42 0 0.00% -0.11 -0.26 -0.17 -0.14 -0.31 -0.19 0.01 0.04 -0.03 0.15 0.20 0.09
METABOLISM OF STEROID HORMONES AND VITAMINS A AND D 35 0 0.00% -0.11 0.19 -0.01 -0.03 0.18 0.01 0.32 0.33 0.29 0.15 0.13 0.12
COLLAGEN FORMATION 58 0 0.00% -0.11 -0.10 -0.03 -0.01 -0.02 0.01 -0.09 -0.12 -0.06 -0.03 -0.11 -0.07
REGULATED PROTEOLYSIS OF P75NTR 10 0 0.00% -0.11 0.16 0.10 -0.05 0.13 0.05 0.23 0.29 0.28 0.04 0.15 0.12
IKK COMPLEX RECRUITMENT MEDIATED BY RIP1 10 0 0.00% -0.11 -0.07 -0.09 -0.02 0.25 0.06 0.01 0.08 0.00 0.13 0.19 0.10
BIOLOGICAL OXIDATIONS 139 0 0.00% -0.12 0.27 0.06 -0.01 0.24 0.10 0.20 0.22 0.14 0.07 0.08 0.01
PHASE1 FUNCTIONALIZATION OF COMPOUNDS 70 0 0.00% -0.13 0.20 0.00 0.05 0.26 0.12 0.31 0.32 0.25 0.28 0.28 0.23
XENOBIOTICS 16 0 0.00% -0.13 0.04 -0.04 -0.04 -0.03 0.05 0.23 0.14 0.18 0.10 0.03 0.05













SYNTHESIS OF GLYCOSYLPHOSPHATIDYLINOSITOL GPI 17 0 0.00% -0.14 0.13 -0.02 -0.05 0.05 0.06 -0.26 -0.12 -0.19 -0.16 0.03 -0.05
REGULATION OF INSULIN SECRETION BY ACETYLCHOLINE 11 0 0.00% -0.14 0.20 0.02 -0.09 0.15 -0.01 -0.16 -0.08 -0.15 -0.24 -0.15 -0.24
SPHINGOLIPID METABOLISM 69 0 0.00% -0.15 0.26 0.08 -0.09 0.22 0.04 0.26 0.28 0.25 0.04 0.14 0.05
REVERSIBLE HYDRATION OF CARBON DIOXIDE 12 0 0.00% -0.15 0.17 0.01 0.18 0.14 0.18 0.11 0.17 0.15 -0.22 -0.18 -0.23
GENERIC TRANSCRIPTION PATHWAY 352 12 3.41% -0.15 0.15 -0.05 -0.11 0.14 0.07 0.32 0.27 0.30 0.12 0.07 0.05
PTM GAMMA CARBOXYLATION HYPUSINE FORMATION AND ARYLSULFATASE ACTIVATION 27 0 0.00% -0.16 0.20 0.01 -0.05 0.20 0.07 0.07 0.13 0.07 -0.12 -0.08 -0.17
ION TRANSPORT BY P TYPE ATPASES 34 0 0.00% -0.17 0.09 -0.14 -0.06 0.09 -0.04 0.17 0.19 0.17 -0.24 -0.23 -0.24
ENDOGENOUS STEROLS 15 0 0.00% -0.17 0.07 -0.08 -0.07 0.14 0.00 0.04 0.03 -0.03 -0.03 0.02 -0.08
NUCLEAR SIGNALING BY ERBB4 38 3 7.89% -0.18 0.25 0.02 -0.05 0.25 0.10 0.54 0.48 0.51 -0.22 -0.11 -0.17
GLYCOSPHINGOLIPID METABOLISM 38 0 0.00% -0.20 0.05 -0.03 0.18 0.06 0.07 0.37 0.34 0.38 0.17 0.22 0.25
NEUROTRANSMITTER RELEASE CYCLE 34 0 0.00% -0.20 0.11 0.02 -0.13 0.12 0.01 0.35 0.31 0.33 -0.34 -0.28 -0.30
ORGANIC CATION ANION ZWITTERION TRANSPORT 13 0 0.00% -0.22 0.18 -0.04 -0.17 0.16 -0.05 0.03 0.10 0.07 -0.19 -0.14 -0.22
CYTOCHROME P450 ARRANGED BY SUBSTRATE TYPE 51 0 0.00% -0.22 0.09 -0.09 -0.07 0.17 0.01 0.06 0.08 -0.01 -0.03 -0.02 -0.07
METAL ION SLC TRANSPORTERS 22 0 0.00% -0.22 0.11 -0.08 0.14 0.22 0.18 -0.16 -0.12 -0.21 0.11 0.16 0.09
SYNTHESIS OF VERY LONG CHAIN FATTY ACYL COAS 14 0 0.00% -0.22 -0.09 -0.14 0.11 0.29 0.20 0.04 0.07 -0.05 0.02 0.05 -0.05
NCAM1 INTERACTIONS 39 0 0.00% -0.23 -0.26 -0.20 0.23 0.27 0.26 0.01 0.03 -0.02 -0.19 -0.25 -0.21
SYNTHESIS OF PIPS AT THE LATE ENDOSOME MEMBRANE 10 0 0.00% -0.24 -0.07 -0.16 -0.19 -0.01 -0.08 0.13 0.12 0.15 -0.16 -0.19 -0.22
TRANSMISSION ACROSS CHEMICAL SYNAPSES 186 2 1.08% -0.24 0.16 -0.01 0.03 0.28 0.15 0.28 0.34 0.25 0.41 0.41 0.34
BRANCHED CHAIN AMINO ACID CATABOLISM 17 0 0.00% -0.25 0.10 -0.06 0.13 0.23 0.12 0.42 0.37 0.44 0.34 0.25 0.27
PEROXISOMAL LIPID METABOLISM 21 0 0.00% -0.26 -0.08 -0.10 0.08 -0.04 0.09 0.31 0.30 0.32 0.20 0.22 0.25
ION CHANNEL TRANSPORT 55 0 0.00% -0.26 0.07 -0.17 0.04 0.10 -0.01 0.19 0.22 0.20 -0.25 -0.25 -0.27
POST TRANSLATIONAL PROTEIN MODIFICATION 188 1 0.53% -0.27 0.19 -0.08 0.29 0.07 0.13 0.36 0.37 0.38 -0.03 0.01 -0.05
NEURONAL SYSTEM 279 2 0.72% -0.27 0.17 -0.04 0.38 0.39 0.38 0.22 0.26 0.17 0.43 0.45 0.39
THE ACTIVATION OF ARYLSULFATASES 12 0 0.00% -0.28 0.03 -0.11 -0.14 -0.02 -0.09 -0.24 -0.19 -0.28 -0.27 -0.21 -0.29
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Correlation with number of amplified/deleted gene 
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